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In recent years, much progress 
has been made in application of 
pharmacotherapy for different 
paediatric conditions. The aim 
of this study was to investigate 
medicine use, associated factors 
and drug-related problems among 
children in a general population. 
Furthermore, to study the 
prescribing of medicines for off-label 
use and unauthorised medicines 
in paediatric tertiary care and to 
analyse whether there had been any 
change in this kind of prescribing 
over a 10-year period, before and 
four years after the European Union 
Paediatric Regulation entered into 
force in 2007.
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ABSTRACT 
 
Every sixth child aged 0–14 years used a prescribed medicine in Finland in 1996. There is need to ascertain more 
recent information on medicine use and possible factors linked to it. In addition, there is very limited popula-
tion-based information on drug-related problems (DRPs) in children, especially from the caretakers’ perspec-
tive. Some of the reasons for DRPs are related to the fact that there are few medicinal products authorised for 
children and lack of appropriate paediatric formulations. The use of medicines without approved directions 
(off-label) and the use of unauthorised medicines are common in paediatric pharmacotherapy. The Paediatric 
Regulation in the European Union since 2007 aims to reduce this kind of use of medicines.   
In the present study, the factors associated with medicine use were determined in children aged 0–11 years 
living in Finland. Furthermore the lifetime prevalence of DRPs, their type and medicines associated with DRPs 
were investigated. A cross-sectional population survey of a random sample of 6 000 children was carried out in 
spring 2007. The final response rate was 67% with a study population of 4 032. A questionnaire was sent to the 
parent(s) of the child. To investigate the use of medicines off-label and that of unauthorised medicines in hos-
pitalised children in Finland, a prospective study was conducted in three paediatric wards in the Kuopio Uni-
versity Hospital (KUH); neonatal intensive care unit, general paediatric ward and paediatric surgical ward in 
April and May 2001 and 2011. The prescriptions for patients aged less than 18 years were reviewed during a 2-
week period in each of the three wards.  
The results of the present study indicate that the proportion of children using prescribed medicines in 2007 
had remained at the same level (17%) as in the year 1996. The present study provides support to the earlier 
evidence that morbidity, health status, young age and parental medicine use are associated with medicine use 
in children. Socioeconomic factors did not appear to influence medicine use. In addition, every fifth child aged 
0–11 years had experienced DRPs, predominantly adverse drug events (ADEs). The lifetime prevalence of ADEs 
was 17% (95% CI 16–19%), that of other DRPs 5.2% (95% CI 4.5–5.9%). The prevalence of serious ADEs was 
0.4% and that of unexpected ADEs was 0.8%. The most common of the other DRPs were problems in admin-
istration and dosing of medicine. Altogether 64% of all DRPs were related to anti-infective agents. 
The vast majority of the paediatric inpatients in KUH received some medication for off-label use or unau-
thorised medicines. This kind of use of medicines was more prevalent in 2011 than in 2001 (79% vs. 58%, 
p<0.001). The frequency of off-label prescriptions increased from 36% to 42% during that ten year period 
whereas that of unauthorised medicines remained at the same level (13%).  
The use of medicines in children is common and factors associated with it are mainly health related. The 
results of this study also reveal that drug-related problems in paediatric pharmacotherapy are common. Ac-
cording to this study and other European studies, there has been no decrease in trends of the off-label use of 
medicines commonly used in paediatric inpatients at least until 2011. In this study, the prescribing for off-label 
use had increased. The development of paediatric pharmacotherapy should be a priority for the pharmaceutical 
industry, regulatory agencies and for health professionals. 
 
National Library of Medicine Classification: QV 55, QV 56, WB 330, WS 366 
Medical Subject Headings: Pharmaceutical Preparations; Drug Therapy; Prescription Drugs; Drug-Related Side Effects and 
Adverse Reactions; Off-Label Use; Drug Prescriptions; Hospitals, Pediatric; Child; Child, Preschool; Infant; Infant, New-
born; Prevalence; Morbidity; Health Status; Parents; Cross-Sectional Studies; Finland  
VI 
 
 
 
  
VII 
 
 
Lindell-Osuagwu, Leena 
Lasten lääkkeiden käyttö - näkökulmana lääkkeisiin liittyvät ongelmat 
Itä-Suomen yliopisto, terveystieteiden tiedekunta 
Publications of the University of Eastern Finland. Dissertations in Health Sciences 232. 2014. 114 s. 
 
ISBN (print): 978-952-61-1463-7 
ISBN (pdf): 978-952-61-1464-4 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706 
 
TIIVISTELMÄ 
Lasten lääkkeiden käytön yleisyyttä on Suomessa viimeksi tutkittu vuonna 1996. Tuolloin joka kuudes 0–14-
vuotias käytti lääkärin määräämää lääkettä. Lääkkeiden käytöstä on tarve saada ajankohtaisempaa tietoa sekä 
tutkia siihen yhteydessä olevia tekijöitä. Lääkehoidon toteuttajina ja seuraajina vanhempien rooli on olennai-
nen, mutta heiltä saatua tietoa lasten lääkehoitoon liittyvistä ongelmista on vain vähän. Väestötasolla asiaa ei 
tiettävästi ole tutkittu lainkaan. Lisäksi usein ongelmana on viranomaisten arvioiman tiedon puute myyntilu-
vallisten lääkkeiden käytöstä lapsille, mikä hankaloittaa lääkkeen määräämistä. Myöskään lapsille sopivia lää-
kemuotoja ei ole riittävästi. Näihin ongelmiin on pyritty vaikuttamaan Euroopan komission tammikuussa 2007 
voimaan tulleella lastenlääkeasetuksella.  
Tämän tutkimuksen tavoitteena oli selvittää lasten lääkkeiden käytön yleisyyttä, siihen yhteydessä olevia 
tekijöitä ja ongelmia. Lisäksi tavoitteena oli selvittää, kuinka yleisesti sairaalassa määrätään lääkkeitä myynti-
luvan ohjeista poiketen (off-label) tai lääkkeitä, joilla ei ole Suomessa myyntilupaa (unauthorised), sekä verrata 
tilannetta ennen ja jälkeen lastenlääkeasetuksen voimaantulon.  
Lasten lääkkeiden käyttöä tutkittiin valtakunnallisella kyselyllä, joka lähetettiin 0–11-vuotiaiden lasten 
(n=6000) vanhemmille keväällä 2007. Vastausprosentti oli 67 % (n=4032). Lääkkeiden määräämistä sairaalassa 
tutkittiin Kuopion yliopistollisen sairaalan (KYS) kolmella lastenosastolla huhti–toukokuussa vuosina 2001 ja 
2011. Tiedot alle 18-vuotiaiden lääkemääräyksistä kerättiin kullakin tutkimusosastolla kahden viikon tutkimus-
jakson aikana.   
Lasten vanhempien mukaan 17 % lapsista oli käyttänyt lääkärin määräämää lääkettä kyselyhetkellä ja sa-
mansuuruinen osuus oli käyttänyt itsehoitolääkettä kyselyä edeltävän kahden päivän aikana. Tämän tutkimuk-
sen tulokset tukevat aikaisempaa tietoa siitä, että lapsen sairastavuus, terveydentila, ikä ja vanhemman oma 
lääkkeenkäyttö ovat tekijöitä, joilla on yhteys lapsen lääkkeenkäytön todennäköisyyteen. Sen sijaan vanhem-
man koulutustaso ja perheen tulot eivät olleet yhteydessä lääkkeiden käyttöön tässä tutkimuksessa. Joka viides 
lapsi oli kokenut elämänsä aikana lääkkeeseen liittyvän ongelman, yleisimmin lääkehaittatapahtuman. Haittoja 
oli 17 %:lla (95 % CI 16–19 %) ja muita lääkkeistä aiheutuneita, yleisimmin lääkkeen ottamiseen liittyviä ongel-
mia 5,2 %:lla (95 % CI 4,5–5,9 %) lapsista. Vakavia haittoja oli ollut 0,4 %:lla ja odottamattomia haittoja 0,8 %:lla 
lapsista. Yleisimmin (64 %) ongelmia aiheuttivat infektiolääkkeet. 
Valtaosa KYSin kolmen lastenosaston potilaista sai lääkemääräyksen, joka poikkesi lääkkeelle hyväksytyistä 
virallisista ohjeista, tai sai määräyksen lääkkeestä, jolla ei ollut myyntilupaa Suomessa. Tällainen määrääminen 
oli yleisempää vuonna 2011 kuin 2001 (79 % vs. 58 %, p<0,001). Ohjeista poikkeavien määräysten suhteellinen 
osuus lisääntyi 36 %:ta 42 %:iin kymmenen vuoden aikana, kun taas lääkkeiden osuus, joilla ei ollut myyntilu-
paa, pysyi samana (13 %).  
Tämän tutkimuksen tulosten perusteella lasten lääkkeiden käyttö on yleistä ja siihen yhteydessä olevat te-
kijät liittyvät pääasiassa terveydentilaan. Vanhempien näkökulmasta lasten lääkehoitoon liittyy yleisesti ongel-
mia, eniten haittoja. Tämän tutkimuksen tulosten mukaan ohjeista poikkeava lääkkeenkäyttö ei ollut vähenty-
nyt vuoteen 2011 mennessä sairaalan lapsipotilailla, vaan jopa lisääntynyt. Lääketeollisuuden, viranomaisten 
ja terveydenhuollon ammattilaisten on edelleen syytä jatkaa lasten lääkehoidon kehittämistä. 
 
Luokitus: QV 55, QV 56, WB 330, WS 366 
Yleinen suomalainen asiasanasto: lääkkeet; lääkehoito; lääkemääräykset; haitat; ongelmat; sairaalaosastot; lastensairaalat; 
lapset; alaikäiset; esikouluikäiset; kouluikäiset; leikki-ikäiset; taaperoikäiset; vauvat; vastasyntyneet; poikittaistutkimus; 
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Abbreviations 
 
ADE Adverse drug event 
ADR Adverse drug reaction 
ATC Anatomical Therapeutic Chemical  
CI Confidence interval 
DRP Drug-related problem 
EMA European Medicines Agency, former EMEA, European Agency for the Evalua-
tion of Medicinal Products  
EU European Union 
FDA  Food and Drug Administration  
Fimea Finnish Medicines Agency 
ICH International Conference on Harmonisation 
IQR Interquartile range 
KUH  Kuopio University Hospital  
LLT Low level terms in MedDRA® 
MA  Marketing authorisation  
MedDRA®  Medical Dictionary for Regulatory Activities 
MCU Medium-care unit 
MeSH Medical Subject Headings 
NICU Neonatal intensive care unit  
NSAID Nonsteroidal anti-inflammatory drug 
OL Off-label 
OTC Over-the-counter 
PDCO Paediatric Committee 
PICU Paediatric intensive care unit 
PIP Paediatric investigation plan 
PUMA Paediatric Use Marketing Authorisation 
SICU Surgical intensive care unit 
SmPC  Summary of product characteristics, former SPC  
SOC System organ class in MedDRA®  
UA Unauthorised 
UL Unlicensed (unauthorised) 
WHO  World Health Organization  
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Terminology 
 
Adolescent 
From 12 years to less than 18 years. 
 
Adverse drug event 
An adverse outcome that occurs while a person is taking a medicinal product, but may not 
necessarily be attributable to the medicine (Uppsala Monitoring Centre 2013a). When it is not 
possible to ascribe causality to the medicine, adverse outcomes are described as events (Ed-
wards and Aronson 2000). For example, a patient can perceive tiredness as an adverse event 
but this can be either due to the medicine or to the underlying disease. 
 
Adverse drug reaction 
A response which is noxious and unintended, and which occurs at doses normally used in 
humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of phys-
iological function (WHO 1972, Uppsala Monitoring Centre 2013a). An adverse drug reaction, 
in contrast to an adverse event, is characterised by the suspicion of a causal relationship be-
tween the drug and the occurrence, i.e. judged as being at least possibly related to treatment 
by the reporting or a reviewing health professional. For example, sodium valproate is known 
to increase the risk for hepatotoxicity, especially in children less than 3 years old, and this 
can be detected with laboratory tests. 
 
ATC classification of medicines 
Anatomical Therapeutic Chemical system is WHO’s tool and gold standard for international 
drug utilisation research and statistics (World Health Organization 2014). 
 
Child 
Aged less than 18 years if the age is not defined otherwise in the content of the sentence or 
chapter. 
 
Cross-sectional study  
This is a type of observational and descriptive study, which aims to describe a certain feature 
in the entire population under study at a specific point in time. For example, the feature can 
be the prevalence of an illness or the use of medicines and the data is collected from a popu-
lation or its representative subset. In addition, a cross-sectional study can support deduction 
of cause and effect.  
 
  
XX 
 
 
 
Drug-related problem 
An undesirable event or circumstance involving drug therapy that actually or potentially 
interferes with desired health outcome (Strand et al. 1990, Pharmaceutical Care Network Eu-
rope Foundation 2010). Drug-related problems encompass conditions of the patient result-
ing, for example from the harmful effects of medicine, problems in treatment effectiveness 
due to a variety of causes, under- and overdosing problems, inappropriate choice of medi-
cine, and interactions. The cause of a drug-related problem can be linked to the individual or 
to the medicine or to its selection.  
 
Infant 
From 1 month to 23 months. 
 
Interquartile range 
This is a measure of variability that is based on dividing the data into quartiles. The values 
that divide the data are called the first, second, and third quartiles. The second is the median 
value; the first quartile includes 25% of the data set and the third quartile 75% of the data. 
The interquartile range is equal to third quartile value minus first quartile value. However, 
in study reports, the subtracted value may not be presented but instead the values of the 
quartiles are provided. 
 
Marketing authorisation 
A medicinal product can only be on the market when marketing authorisation has been 
granted by the competent authority. The competent authority in European Economic Area 
(EEA), a Member State’s regulatory body (or EEA country) for its own territory (national 
authorisation) or European Community for the entire Community (a centralised authorisa-
tion). 
  
Medicinal product 
A medicine released for consumption in the manufacturer’s package. It may contain one or 
more active substances.  
 
Neonate, new-born 
From birth to 27 completed days. 
 
Off-label use of medicine  
All uses of an authorised medicine not described in the approved summary of product char-
acteristics. 
  
Off-patent medicine 
Medicinal product that is no longer covered by a patent or a supplementary protection cer-
tificate; the patent protections of the original developer have expired. 
 
Paediatric Regulation 
Regulation (EC) No 1901/2006 of the European Parliament and of the Council on Medicinal 
Products for Paediatric Use. 
XXI 
 
 
Paediatric investigation plan  
The paediatric investigation plan includes details of the timing and the measures proposed 
to demonstrate the quality, safety and efficacy of the medicinal product in the paediatric 
population (Regulation (EC) No 1901/2006). The document upon which the development and 
authorisation of medicinal products for the paediatric population is based in the European 
Union.  
 
Point prevalence 
This is usually expressed as a fraction, percentage, or number per 1 000 of the population that 
has the particular condition, e.g. disease or who is using some particular medicine, at a spe-
cific point in time. 
 
Preterm neonate 
Born earlier than 37th week of gestation. The preterm is a neonate until s/he has reached 37th 
week of gestation plus 27 days. 
 
Term neonate 
Born earliest on 37th week of gestation. From birth to 27 days. 
 
Unauthorised, unlicensed medicine  
A medicine that has not received a marketing authorisation as medicinal for human use in 
either adults or children in a particular country where the medicine is used. This includes 
modifications of authorised medicines, i.e. medicines prepared extemporaneously, medi-
cines prepared by the hospital pharmacy or any other pharmacy, use of chemicals, medicines 
used prior to the approval of an authorisation, medicines with expired authorisation, im-
ported medicinal products with special license but with no authorisation in that particular 
country (Turner et al. 1997). 
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1 Introduction  
Drug-related problems are of major clinical relevance and a significant public health concern 
in paediatric populations in terms of mortality, morbidity and healthcare costs (Impicciatore 
et al. 2001, Moore et al. 2002, Easton-Carter et al. 2003, Temple et al. 2004, Johann-Liang et al. 
2009). They are reasons for hospitalisations but also significant concerns that confront chil-
dren and guardians at home. Most of them are adverse drug events, administration and dos-
ing problems, for example these can result in the child not receiving the intended medication 
(Sepponen et al. 2002, 2003).  
Guardians have an important role and responsibility in taking care of their child’s medi-
cation and noticing the possible harmful reactions, especially in infants who cannot verbally 
describe their experiences. However, the parents’ perspective has rarely been used, especially 
at a population level when studying medicine utilisation and unwanted outcomes of medi-
cation. In general, information on drug-related problems has been collected from the records 
of hospitals or outpatient clinics and national databases (Easton et al. 1998, Impicciatore et al. 
2001, Easton-Carter et al. 2003, Easton et al. 2004, Le et al. 2006, Moore et al. 2007, Clavenna 
and Bonati 2009a, Johann-Liang et al. 2009, Aagaard et al. 2010a). In order to improve health 
care policies and education, it is essential to collect information from guardians.  
Another aspect of the problems encountered in paediatric pharmacotherapy originates 
from the lack of authorisations in relevant paediatric age groups and conditions. The younger 
the child or the rarer the disease, the more probable the medicine needs to be used in a man-
ner deviating from the authorised directions, i.e. off-label (Kimland and Odlind 2012). This 
has long been more of a concern for health professionals, regulatory authorities, and academ-
ics (Turner et al. 1997, Lenk et al. 2009, Hoppu et al. 2012). Weighing the benefits against the 
potential unknown risks and extrapolating dosing from adult clinical trials have been the 
routine, but nonetheless they remain a challenge in paediatric pharmacotherapy. In paediat-
ric patients, medicines can behave differently, causing increased effects or they can have de-
creased efficacy both of which are safety concerns (Kearns et al. 2003). The immaturity of 
drug metabolising and elimination pathways represents challenges quite distinct from those 
encountered in adults. 
The lack of suitable dosage forms and strengths in paediatric pharmacotherapy is also a 
common challenge (Nunn 2003, Helin-Tanninen 2013). Commercial dosage forms may be 
authorised for adult use only and may well be unsuitable for children. This often leads either 
to off-label use or to modifications of an authorised product that makes it unauthorised. For 
example, solid oral medicines may be dispensed as powders, capsules or oral suspensions. 
Extemporaneous compounding is known to be prone to errors, and the stability and compat-
ibility of such products may also constitute problems (Conroy 2011, Helin-Tanninen 2013). 
In addition, many excipients in adult formulations may be inappropriate, even harmful, to 
small children (Lass et al. 2012).  
Of those medicinal products that were authorised in the European Union under the cen-
tralised procedure during a ten year period between 1995 and 2005, only 33% were author-
ised for use in children, 23% for infants and a mere 9% for use in newborns (Ceci et al. 2006). 
The European regulation aims to improve children’s access to authorised medicines in age-
appropriate dosage forms by demanding that a clinical trial for new medicinal products 
should be done also in the paediatric population, especially if it is estimated that children 
could benefit from this new therapy. It also provides the investigative industry with incen-
tives to encourage it to study medicines in the paediatric population.  
The Regulation (1901/2006/EC) of the European Parliament and Council on medicinal 
products for paediatric use came into force in January 2007. After five years since its imple-
mentation, the proportion of paediatric trials had increased (10%), 31 new medicines were 
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authorised initially with a paediatric indication, 72 new paediatric uses were authorised for 
existing medicines and 26 new pharmaceutical forms were adapted for children (European 
Medicines Agency 2012). In addition to this information, there is a need for studies that de-
scribe the actual use of medicines; off-label and unauthorised medicines. This is important in 
order to gather information on medicines that lack official dosing directions or appropriate 
dosage forms.  
The purposes of this study were first to investigate medicine use and associated factors 
among children in a general population in Finland, and then to investigate drug-related prob-
lems in this same population. The third aim was to study the prescribing of medicines for 
off-label use and unauthorised medicines in paediatric tertiary care in Finland, to compare 
the situation with other countries and to analyse whether there had been any change in this 
kind of prescribing over a 10-year period, and after the European Union Paediatric Regula-
tion entered into force in 2007. 
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2 Review of the Literature 
The purpose of this literature review is to provide an overview of the context where the drug-
related problems in paediatric pharmacotherapy arise and to examine those problems in de-
tail. 
For this review a wide range of keywords and MeSH terms (Medical Subject Headings) 
were used representing children, guardians, pharmaceutical preparations, medicine utilisa-
tion in various settings, marketing authorisation, prescribing and drug-related problems, in-
cluding off-label use of medicines and adverse drug events. The study reports were searched 
using the electronic databases Scopus, PubMed and International Pharmaceutical Abstracts 
(IPA). The references listed in the published articles were also reviewed in order to identify 
additional studies. Each relevant article identified from the title or abstract was reviewed 
according to the year of publication, study design, study sample, main outcome measures 
and main findings.  
An information specialist assisted in building systematic search strategies for the two main 
topics of this thesis; drug-related problems perceived by guardians (Appendix 1) and off-
label and unauthorised medicine use in hospitalised children (Appendix 2).  
In addition, searches were made in Google Scholar, national and international web pages 
of different institutions (e.g. European Medicines Agency, Finnish National Agency of Med-
icines, UK Medicines and Healthcare Products Regulatory Agency and U.S. Food and Drug 
Administration), legislation databases (EudraLex and Finlex) and personal contacts were 
used to retrieve data from Social Insurance Institution’s prescription database.  
2.1 CHILDREN  
According to the Oxford Dictionary, a child is a young human being below the age of puberty or 
below the legal age of majority. In Article 2 of the Regulation (EC) No 1901/2006 of the European 
Parliament and of the Council on Medicinal Products for Paediatric Use (subsequently short-
ened to Paediatric Regulation) children are defined as aged between birth and 18 years.  
Scientific research aims to gain information which can be generalised. In clinical investi-
gations of medicines, the growth and developmental stage of children imposes some limits 
to attempts at generalisation. In children, the response to a medicine depends on the physical, 
cognitive, and psychosocial phase of development (ICH 2000, Sinha and Cranswick 2007). 
There is extensive inter-individual variation; children of the same age may vary according to 
weight, height, body surface area and maturity (Kearns et al. 2003). In addition, boys and 
girls of the same age are different. The developmental age-related differences in absorption, 
distribution, metabolism, and excretion are better known than differences in pharmacody-
namics in children. Some well-known special characteristics in metabolism have been found 
through adverse drug reactions (ADRs) i.e. effects which have not been identified in the adult 
population. A classic example was the grey baby syndrome due to impaired metabolism of 
chloramphenicol in newborn infants (Choonara et al. 1996).  
 Apart from the physical phase of child’s development, the cognitive phase has a major 
influence on how successful the medication will be (Sanz 2003, Costello et al. 2004). Thus, it 
is obvious that it is important to conduct clinical investigations in different age categories of 
children as this is the only route to devise individualised treatment regimens for the dosing 
of medicines.  
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For research purposes, it is possible to classify children into different age categories. How-
ever, there will always be an overlap in developmental stages (Kearns et al. 2003). In the 
international guidelines for clinical investigations, the following subsets are defined: preterm 
and term neonates 0–27 days, infants 1 month–23 months, children 2–11 years and adoles-
cents from 12 up to 16–18 years, depending on region (ICH 2000). In addition and as an ex-
ception in Finland, the statistics on medicine consumption and reimbursements are provided 
in age classes subdivided into five year sections (0–4, 5–9, 10–14, 15–19) by the Social Insur-
ance Institution and the Finnish Medicines Agency, Fimea.  
2.2 MORBIDITY IN CHILDREN  
In childhood, the dynamic process of maturation and characteristics of morbidity, which are 
different than in adult population are reflected in medicine use.  
The majority of Finnish children are healthier than before, however some chronic diseases 
and health problems are becoming more common among children, such as asthma and aller-
gies, diabetes, obesity and psychosocial problems (Mäki et al. 2010). According to one of the 
basic indicators: under-5 mortality rate, the Finnish children are privileged in global terms. 
In Finland, the probability of dying between birth and 5 years of age is one of the lowest in 
the world (UNICEF 2013). The life expectancy is also high; a Finnish child born in 2011 can 
expect to live another 80 years.  
The immunisation coverage is also high, 96% of the children born in 2007 had been vac-
cinated (National Institute for Health and Welfare 2013a). The recent benefits of the national 
immunisation program have been the reduced numbers of rotavirus and pneumococcal in-
fections in children. The rotavirus vaccination has been a part of the national vaccination 
program since the autumn 2009 and pneumococcal vaccination since 2010. The incidence of 
severe rotavirus diarrhoea has declined by 50% in children <1 year of age and the hospitali-
sation decreased by 80%. This has a remarkable impact on the conditions needed to treat 
subjects in paediatric hospital wards. The serious pneumococcal infections have also been 
reduced in young children after the vaccine was included into the national program.  
Access to primary health care is free for children in Finland (Act 734/1992 Asiakasmak-
sulaki, Regulation 912/1992 Asiakasmaksuasetus). The public primary health care is pro-
vided in municipal health centers, child health clinics and schools. There is also private sector 
that is subject to a charge, but this sector is very small compared to its public counterpart in 
the extent to which it provides health care to children. The 21 hospital districts provide spe-
cialised medical care in central hospitals and other specialised units (Statistics Finland 2013). 
Tertiary care services are provided in the university hospitals of which there are a total of 
five in Finland. 
For outpatients including children, the medicines are sold in privately owned and licensed 
pharmacies in Finland. The National Health Insurance Scheme reimburses much of the ex-
penses incurred in treating an illness (Health Insurance Act 1224/2004), i.e. part of the costs 
of most prescription-only medicines used for the treatment of an illness. In addition, some 
over-the-counter (OTC) medicines are reimbursable if a physician writes a prescription.  
2.2.1 Morbidity in the general child population 
Entitlement for the special medicine refunds by the Social Insurance Institution of Finland 
provides some kind of overall picture of the morbidity in the population. Individuals with 
serious or chronic diseases are entitled to special refunds. There are a total of about 50 of 
these kinds of diseases or conditions. However, some common diseases and conditions in the 
paediatric population demanding medication are not entitled to receive these special re-
funds. In children aged 0–4 years, the most common conditions for special refunds were 
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asthma, cow’s milk allergy and epilepsy in 2012; in the older age group of 5–14 years the top 
three conditions were asthma, diabetes and epilepsy (Social Insurance Institution 2013).  
In Finland, the prevalence of chronic diseases has been estimated in cross-sectional stud-
ies. The overall morbidity among children less than 15 years of age almost doubled in the 
period from 1987 to 1995–1996 (Klaukka et al. 1990, Arinen et al. 1998). By the late 1990’s, 24% 
of boys and 19% of girls had at least one chronic disease. In a population of children aged 
less than 12 years, 11% had a chronic disease in 2007; more boys than girls (Siponen et al. 
2011). Allergy (4% of children), asthma (4%), atopy (3%), migraine (0.6%), attention deficit 
hyperactivity disorder (ADHD) (0.5%), heart defect (0.5%), diabetes (0.4%), epilepsy (0.3%), 
and rheumatoid arthritis (0.1%) were the most frequent of the physician diagnosed chronic 
diseases reported by the parents. In addition, some kind of impairment (e.g. visual impair-
ment/heterotropia, dysphasia, mental disability, hearing impairment, autism) was reported 
in another 2% of the children. Similar results have been found in a Finnish national health 
pilot survey, the Child Health Monitoring Development project (LATE-project; Mäki et al. 
2010). That survey was carried out in child and school health care units in 10 different mu-
nicipalities in Finland in 2007. Every tenth child had either atopic eczema or different types 
of allergies, and 6% of the children had asthma. The chronic diseases and impairments were 
more common among older children (>7 years) than younger children. The overweight was 
found to be common (27%) among adolescents. However, as many as 11% of the 3 year old 
children were overweight. 
The most frequent acute diseases suffered by children are infections, especially in the 
youngest children (0–2 years); this is the case in Finland (Siponen et al. 2011) and also in other 
European countries (<14 years of age) (Sanz et al. 2004, von Linstow et al. 2008, Stam et al. 
2012). They are also the commonest reasons for health care visits and emergency admissions 
to hospitals (Sands et al. 2012, Gill et al. 2013). In Finland in 2007, patients seen by a physician 
in an outpatient primary health care per 1000 persons of same age were 1056 in the age group 
of <1 year, 851 in the age group of 1–6 years and 594 in the age group of 7–14 years according 
to statistics (National Institute for Health and Welfare 2014).  
The average annual rate of influenza has been found to be highest among children <3 years 
of age in Finland (Silvennoinen 2012). In almost every other child (40%) in this age group, 
acute otitis media was diagnosed as a complication of influenza. In addition, nearly half of 
the children in the LATE-project below 4 years of age had suffered otitis media at least once 
during a one year period, and then the rate decreased in older children (>5 years) (Mäki et al. 
2010). In another Finnish study in a one year period, recurrent acute respiratory illness (44%) 
and otitis media (15%) were identified more often in children aged 1–3 years than in children 
aged 4–6 years (23% and 2.5%, respectively) among children attending day care centres in 
Helsinki in 1998 (Hatakka et al. 2010).  
2.2.2 Morbidity in hospitalised children 
In Finland, the prevalence of hospitalised children in specialist medical care is closer to that 
of the entire population but lower than that in elderly population. About 8% of the paediatric 
population below 15 years of age had been hospitalised, the corresponding figures were 12% 
for the entire population and 28% of the elderly (≥75 years) in 2011 (National Institute for 
Health and Welfare 2012, Official Statistics of Finland). Pain, infections, prematurity, nutri-
tion difficulties and surgery or anaesthesia have been reported to be commonest treatment 
indications in the prescriptions written for paediatric inpatients in Sweden (Kimland et al. 
2012). No such similar, national level information on hospitalised children could be found in 
Finland. It is likely that the conditions treated in hospitalised children in Finland are quite 
similar with those in Sweden. 
Annually in Finland, 6% of the new-borns are born as preterm (<37 week of gestation) 
needing hospital care (National Institute for Health and Welfare 2013b). These patients re-
quire intensive care because of the immaturity of their organs and difficulties in adapting to 
6 
 
 
 
extra-maternal life. Especially very preterm infants suffer often multiple ailments. Respira-
tory distress syndrome, bronchopulmonary dysplasia, brain injuries, severe retinopathy of 
prematurity and perinatal infections such as neonatal sepsis are common reasons for hospi-
talisation (Bassler et al. 2009). In a Swedish nationwide study, more than one-third of the 
hospitalised children (<18 years of age) were neonates and infants (Kimland et al. 2012). 
In paediatric general medical wards, the main focus of treatment is often on infectious 
diseases (Oehme et al. 2012, Rashed et al. 2012a). Infections and diseases of the respiratory 
system are among most common diagnoses in the children being treated in these wards. In 
UK among children 0–15 years of age, the most common problems requiring attention in a 
paediatric emergency department were breathing difficulties and febrile illnesses (upper and 
lower respiratory tract infections) and diarrhoea and/or vomiting (gastroenteritis) (Gill et al. 
2013, Sands et al. 2012). Out of the chronic conditions, asthma was the leading cause of all 
admissions (64–73%) (Gill et al. 2013).  
2.3 MEDICINE USE IN CHILDREN 
The utilisation of medicines in children has been increasingly investigated in Europe and 
North America, predominately using national or regional prescription databases (Bonati 
1994, Clavenna and Bonati 2009b). In 1994 in his review Bonati stated that drug use in the 
children is a 'hidden' reality in the literature. At that time there were very few studies in paedi-
atric outpatients published and in his review he was able to only sketch outlines on the med-
icines most commonly used and for which diseases. In Europe, one reason for the increased 
investigation in recent years has been the Paediatric Regulation’s requirements which de-
mands that the member states must collect relevant data on paediatric medicine use and 
communicate the data to the European Medicines Agency in 2009.  
A particular mention of the inventory demand of the Paediatric Regulation can be found 
in the introductory part or the aims of at least three recent study reports. The Swedish studies 
focused on off-label prescriptions in hospitals (Kimland et al. 2012) and on OTC medicine 
use in children (Nydert et al. 2011). A report from Slovak Republic by Slažneva et al. (2012) 
focused on off-label medicine use among hospitalised children. No such study reports were 
identified from Finland; apart the inventory published as a part of the European Medicines 
Agency’s report on the survey of all paediatric uses of medicinal products in Europe (Euro-
pean Medicines Agency 2009).  
2.3.1 Prevalence of medicine use 
For children the majority of medicines are prescribed in primary care and used at home for 
common paediatric acute or chronic diseases. One common outcome measure in paediatric 
medicine utilisation studies has been 1-year prevalence or the prescription rate in children 
treated (Clavenna and Bonati 2009b). Cross-sectional studies, especially at a population level, 
have been scarce especially if they used the outcome measure of point prevalence. Two stud-
ies conducted in Finland in 1987 and 1995–1996 found that the point prevalence of prescrip-
tion medicine use was 13% and 17%, respectively, in children below 15 years of age (Klaukka 
et al. 1990, Arinen et al. 1998).  Furthermore, it is important to acknowledge parents as a 
source of information in medicine utilisation research because they are most often responsi-
ble for the implementation of their child’s medication, its follow-up and they know the actual 
use. The actual use cannot be detected from databases. 
In Finland, the statistics of medicine consumption, sales and reimbursement of medicines 
are gathered and provided by the Social Insurance Institution and the Finnish Medicines 
Agency Fimea. The advantage of this register based information is that it monitors the dis-
pensed prescriptions in the entire population. However, the majority of the OTC medicines 
7 
 
 
and the prescription medicines provided outside the reimbursed system are not included. In 
addition, the reimbursed products also include clinical nutritional preparations and basic 
topical ointments, which are not classified as medicinal products. Furthermore, changes in 
the reimbursement system have altered the number of recipients receiving reimbursements. 
Thus the reduction in proportions of children receiving reimbursements (Figure 1) in years 
2004 and 2005 are attributable to changes in the system (Social Insurance Institution, un-
published).  
Approximately half of the paediatric population receives at least one prescribed and reim-
bursed medicinal product annually in Finland (Figure 1). In the whole population, the pro-
portion of recipients with a reimbursed prescription has increased from 64% in 2000 to 71% 
in 2012 (Social Insurance Institution 2013). In European countries, and in North and South 
America, the prevalence rate of prescription medicines in the paediatric population has been 
reported to vary from 51% in Denmark to 70% in Greenland (Clavenna and Bonati 2009b, 
Oliveira et al. 2012, Carnovale et al. 2013, Zhang et al. 2013). An average estimate of 60% was 
reported from Denmark, the Netherlands, Greenland and Italy (Clavenna and Bonati 2009b). 
The annual average number of prescriptions per child in primary care in Denmark, Green-
land and Italy has varied in the range from 1.6 to 2.2 prescriptions in the entire paediatric 
population and from 3.2 to 3.4 in treated children. However, most of the data are more than 
a decade old. More up to date information would be needed since the new medicinal prod-
ucts become available and new information available on the paediatric pharmacotherapy will 
affect the prescribing practices. A few more current population-based reports on prescribed 
medicines in children have been published, for example one from Italy and one from Western 
Canada (Carnovale et al. 2013, Zhang et al 2013). The 1-year prevalence of prescription med-
icines in paediatric populations in British Columbia in 2007 and in Italy in 2011 were similar 
(55% and 52%, respectively) to those reported earlier in European countries. 
 
 
  % 
 
Figure 1. Medicine reimbursement according to age of insured children in Finland, proportion of 
the population (National Board of Health, National Agency for Welfare and Health, National 
Agency for Medicines, Finnish Medicines Agency and Social Insurance Institution 1987–2012). 
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The anti-infective agents are the most commonly prescribed medicines in the youngest pae-
diatric age group both in Finland (Figure 2) and in other nations (Sturkenboom et al. 2008, 
Clavenna and Bonati 2009b, Zhang et al. 2013). In Finland, the other most commonly pre-
scribed and reimbursed medicines in the youngest age group are musculoskeletal (mainly 
anti-inflammatory and antirheumatic products), respiratory and dermatological medicines. 
This differs to some extent from the prescribing patterns in UK, Italy and the Netherlands. In 
these countries, medicines acting on the alimentary (e.g. antidiarrhoeals, medicines for acid 
disorders, laxatives) and sensory organs (mostly ophthalmological preparations) were more 
commonly prescribed for children <2 years of age than in Finland in the youngest age group, 
and medicines affecting the musculoskeletal system were prescribed less than in Finland. 
However, the age groups are not fully comparable; in the Finnish statistics, the youngest age 
group includes children up to 4 years and the age group examined in Sturkenboom and col-
leagues study was <2 years of age. There may also be variation in the treatment regimens and 
morbidity between the countries both of which may change with time. For example, Italian 
children have had a greater chance to receive anti-infectives or antiasthmatic medicines than 
Dutch children (Rossignoli et al. 2007, Clavenna and Bonati 2009b). The authors who have 
studied the medicine utilisation in the Italian paediatric population postulated that there was 
a need to pay more attention to the rational use of these medicines and prescribing habits 
(Gagliotti et al. 2005, Clavenna et al. 2009). Antibiotic use has been claimed to be overuse and 
often second-line antibiotics (cephalosporins or macrolides) have been used due to their bet-
ter palatability and shorter duration of therapy. It has also been speculated that the wide use 
of steroids (inhaled or systemic) in children less than one year of age has not always been 
rational (Clavenna et al. 2009).  
 
 
A Alimentary tract and metabolism; B Blood and blood forming organs; C Cardiovascular system; D Dermato-
logicals; G Genitourinary system and sex hormones; H Systemic hormonal preparations, excl. sex hormones 
and insulins; J Anti-infectives for systemic use; L Antineoplastic and immunomodulating agents; M Musculo-
skeletal system; N Nervous system; P Antiparasitic products; R Respiratory system; S Sensory organs 
* A person receiving recurrent prescriptions is counted only once. 
 
Figure 2. One-year prevalence of recipients (number per 1 000 children) with reimbursed pre-
scription according to age and the ATC system in 2012 (Social Insurance Institution, Prescrip-
tion Register, unpublished).  
 
0
50
100
150
200
250
300
350
400
450
J M R D A H S C N L B G P
0–4 years of age 5–9 years of age 10–14 years of age 15–19 years of age
R
ec
ip
ie
nt
s*
 p
er
 1
 0
00
 c
hi
ld
re
n 
9 
 
 
In Finland, since 2005 there has been an increase in the proportion of recipients in the age 
group of adolescents and young adults (15–19 years of age) (Figure 1).  This could partly be 
explained by the high number of reimbursed medicinal products affecting the nervous sys-
tem (Figure 2). The number of recipients in this group with reimbursed medicinal product 
affecting the nervous system had increased by one third from the year 2008 to 2012, and in 
2012 it was higher than in the younger age groups (Social Insurance Institution, Prescription 
Register, unpublished). More than half of the nervous system medicines were analgesics and 
the remaining percentage were psychoanaleptics (i.e. antidepressants and psychostimulants) 
in this age group. Internationally, the percentages of European children receiving antidepres-
sants and stimulants are markedly lower than that reported in British Columbia and espe-
cially lower than in the USA (Zhang et al. 2013) where the rates have been found to be three 
times higher than in European countries. 
 
Use of over-the-counter medicines 
The OTC medicines are used mostly for minor ailments in childhood that can be managed 
without seeking a physician’s advice (McIntyre et al. 2003). In Finland, in 1996 according to 
a cross-sectional study, the prevalence of OTC medicine use among children was 13% among 
children aged 0–6 years and 8% among older children aged 7–14 years (Arinen et al. 1998). 
In Germany, a higher prevalence, 17%, was found in children aged 0–17 years in 2003–2006 
(Du and Knopf 2009). The higher prevalence is most likely because vitamins and homeo-
pathic preparations were included unlike in Finnish figures.  
Analgesics and antipyretics, cough and cold preparations are the most commonly used 
medicines both in Finland and in many European and non-European countries (McIntyre et 
al. 2003, Wong et al. 2007, Carrasco-Garrido et al. 2009, Trajanovska et al. 2010, Ylinen et al. 
2010).  For example, in Sweden paracetamol, ibuprofen, nasal decongestants, and mucolytics 
were estimated to be the most commonly used OTC medicines in the child population (Ny-
dert et al. 2011). In Finland, paracetamol was estimated to be the most commonly used sub-
stance (5% of children) (Ylinen et al. 2010). 
2.3.2 Factors related to medicine use 
A higher rate of medicine use in children is associated with poor health (Carrasco-Garrido et 
al. 2009, Du and Knopf 2009, Knopf et al. 2013). Hospitalised children receive on average a 
higher number of medicines than paediatric outpatients. There is also an association between 
the number of visits to the physician and the amount of medicines used (Louhi-Pirkanniemi 
et al. 2004, Carrasco-Garrido et al. 2009). However, the ease of access and availability of health 
care services is known to display an association with greater medicine use.  
A young age of the child has been shown to predict the child’s medicine use (Thrane and 
Sørensen 1999, Madsen et al. 2001, Knopf et al. 2013). In Finland, the proportion of children 
receiving reimbursed medicines has been highest in the youngest age group of children (0–4 
years of age) since 1987 to the present day (Figure 1). Similarly, in the United Kingdom, Italy 
and the Netherlands, it is the youngest group of children (<2 years of age) who receive the 
highest rate of prescriptions as assessed from the population based databases in years 2000–
2005 (Sturkenboom et al. 2008).  
Gender is one of the factors known to be related to medicine use. More boys in the young-
est age group (0–14 years) receive reimbursed prescriptions than girls, whereas, in adoles-
cents (above 15 years), it is the girls that receive more prescriptions (Figure 3). This pattern is 
evident in Finland and it has been reported also from other European countries as well as 
from Western Canada (Straand et al. 1998, Thrane and Sørensen 1999, Holstein et al. 2003, 
Tobi et al. 2003, Sturkenboom et al. 2008, Clavenna et al. 2009, Zhang et al. 2013).  
In Finland, in 2012 more boys than girls aged 0–9 years received reimbursed prescriptions 
for anti-infectives, medicinal products affecting musculoskeletal and respiratory systems 
(Table 1). Conversely, more girls aged above 15 years received reimbursed prescriptions for 
10 
 
 
 
these aforementioned groups of medicines, but also for medicinal products affecting the 
nervous system, dermatologicals, and products affecting the genitourinary tract including 
oral contraceptives (46/1 000 girls vs. 2/1 000 boys, p<0.001) than boys in the same year.  
 
  %                  % 
 
  %                   %
 
Figure 3. Medicine reimbursements according to age and gender of insured children in Finland 
as a proportion of the population (National Board of Health, National Agency for Welfare and 
Health, National Agency for Medicines, Finnish Medicines Agency and Social Insurance Institu-
tion 1987–2012).     
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Table 1. Boy and girl recipients (number per 1 000 children) with the top five most commonly 
reimbursed medicinal products in each age group in Finland in 2012 (Social Insurance Institu-
tion, Prescription Register, unpublished). 
 
Medicine group Boys  
n/1 000 
Girls  
n/1 000 
Recipients aged 0–4 years 587* 538 
Anti-infectives for systemic use 470 431 
Musculoskeletal system 165 140 
Respiratory system 164** 119 
Dermatologicals 79 69 
Alimentary tract and metabolism 19 18 
Recipients aged 5–9 years 498 464 
Anti-infectives for systemic use 341 339 
Respiratory system 180** 130 
Musculoskeletal system 91 86 
Dermatologicals 48 49 
Sensory organs 33 21 
Recipients aged 10–14 years 412 382 
Anti-infectives for systemic use 225 229 
Respiratory system 169* 130 
Musculoskeletal system 51 59 
Nervous system 59* 35 
Dermatologicals 40 43 
Recipients aged 15–19 years 454 570*** 
Anti-infectives for systemic use 260 351*** 
Respiratory system 148 158 
Musculoskeletal system 112 166*** 
Nervous system 90 129** 
Dermatologicals 59 79 
*p<0.05, ** p<0.01, ***p<0.001, 2-sample test for equality of proportions with continuity correction to 
compare differences between boys and girls. 
 
The use of antibiotics is more prevalent than any other group of medicines among children. 
The factor that should dominate prescribing of antibiotics is the prevalence of micro-organ-
ism infections (Melander et al. 2003). However, it has been suggested that other factors such 
as educational level, behaviour and attitudes of the parent as well as prescriber’s attitudes 
and, especially parental pressure can all affect the prescribing of these kinds of medicines to 
children (Stam et al. 2012, Teixeira Rodrigues et al. 2013).   
Other factors, such as, mother’s own medicines use have been shown to be related to the 
medicine use by her child/children (de Jong et al. 2012). Furthermore, in Germany and also 
in the USA, it was claimed that the mother’s educational level and household incomes were 
linked to the medicine use by the child(ren) (Kogan et al. 1994, Du and Knopf 2009, Knopf et 
al. 2013). The higher education of the mother and income, the more children were likely to 
be taking medicines. However, this is not straightforward or valid in all countries and health 
care systems. For example, in England the income and level of deprivation of a parent were 
not associated with the treatment of minor childhood ailments with the OTC medicines 
(McIntyre et al. 2003). 
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Previous experience and received advice are important in self-medication and OTC medicine 
use in children (McIntyre et al. 2003, Trajanovska et al. 2010). When seeking advice, the symp-
toms may determine the source from where the parent first seeks help. In England, for cough 
symptoms the majority of parents had consulted a pharmacist; whereas, for rash and earache 
they lended to consult a physician (McIntyre et al. 2003). This difference is reflected in the 
use of prescribed and OTC medicines. In addition, parents with lower incomes in Australia 
(Trajanovska et al. 2010) and fewer children in England (McIntyre et al. 2003) tend to seek 
advice more often from a physician.  
In Finland, it is not known if the guardians’ educational level or incomes have any effect 
on the use of medicines in children. Inequalities in health care provision have been a central 
issue in health public policy for more than two decades (Ministry of Social Affairs and Health 
2008). Inequality has increased in both health and in the use of health services, and this may 
also have an impact on use of medicines in children. 
2.3.3 Medicine utilisation in hospitalised children   
The population of hospitalised children is small but they are prescribed a larger number of 
medicines to treat their more serious and less common conditions than children in primary 
care.  
There are very few up-to-date studies investigating medicine utilisation in hospitalised 
children. The utilisation of medicines is sometimes described in studies examining drug-re-
lated problems (DRPs) or on off-label use of medicines or on some other subject; rarely do 
they focus solely on medicine utilisation. Therefore, it is challenging to summarise the med-
icine utilisation patterns in different paediatric wards and countries.  
The following paragraphs aim to provide an overview of the situation, especially in the 
similar units studied in this thesis, i.e. neonatal units, general paediatric wards and surgical 
units. No individual studies were found from surgical units but there are descriptions of 
analgesics, anaesthetics and sedatives used in hospitalised children. 
In 41 hospitals in Sweden, paediatric patients received a median of 3 prescriptions per 
patient issued in two separate four days period in 2008 (Kimland et al. 2012). Neonates and 
infants received half of all the prescriptions for use lasting more than 1 week. Older children 
and adolescents received medicines mainly for use as a single dose or as on demand. The 
most frequently prescribed medicines were medicines affecting the nervous system, followed 
by medicines affecting blood and blood-forming organs, anti-infectives for systemic use, 
medicines affecting the alimentary tract and metabolism, and respiratory system. Paraceta-
mol was the most common (11%) medicine prescribed. 
In Neonatal Intensive Care Units (NICUs) patients are exposed to a high number of med-
icines. For example, the median number of 8 medicines administered per neonate was re-
ported in German (Table 2; Neubert et al. 2010). A similar average number of 8 prescriptions 
was reported in a Malaysian NICU (Lee et al. 2013) and 8.5 in the USA in 2304 admissions 
(Kumar et al. 2008). If one considers the preterm infants, then the highest medicine use has 
been in the group of extreme preterm i.e. below 28 week of gestational age and with a birth 
weight less than 1000 grams found in studies from the USA, Germany and Estonia (Warrier 
et al. 2006, Neubert et al. 2010, Lass et al. 2011).  
In the NICUs anti-infectives for systemic use are the most commonly prescribed medicines 
in the USA, Germany and Estonia (Clark et al. 2006, Warrier et al. 2006, Neubert et al. 2010, 
Lass et al. 2011). The individual anti-infective substances used in neonates tend to vary de-
pending on national prescribing habits. After anti-infectives, medicines affecting the blood 
and blood forming organs, cardiovascular medicines, medicines affecting the nervous sys-
tem, respiratory and alimentary system were the five commonest medicine groups pre-
scribed. In general, the most widely used individual substances were surfactant and caffeine 
citrate in the different NICUs.  
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In paediatric general wards, children receive less medication compared to those in the neo-
natal units. In Germany, the median number of medicines was 3 per patient during the hos-
pitalisation in the general paediatric ward in a university hospital (Table 2; Oehme et al. 
2012). In five European and non-European general paediatric wards (Germany, UK, Aus-
tralia, Hong Kong and Malaysia) the median number of medicines per patient ranged from 
2 in Hong Kong to 5 in the UK (Rashed et al. 2012b). In these countries, the most commonly 
prescribed medicines in paediatric general wards were anti-infectives for systemic use, fol-
lowed by analgesics, anti-inflammatory and antirheumatic medicines, and medicines to treat 
obstructive airway diseases (Oehme et al. 2012, Rashed et al. 2012a). When comparing the 
two study years, 1999 and 2008, researchers from Germany found that among medicated 
children, the exposure rate, i.e. number of children receiving at least one analgesic or anti-
inflammatory or antirheumatic product during their hospitalisation, had increased signifi-
cantly, from 23% to 63%, during the nine year time period (Oehme et al. 2012).  
In hospitalised children, there is a clear need for analgesia, anaesthesia and sedation but 
this varies with the different medical conditions and procedures and settings, not only in 
surgical wards, emergency units and intensive care units, but also in everyday occurrences 
in all paediatric units. In the USA in 2008 the medicines for analgesia, anaesthesia and seda-
tion were found to be the medicines most frequently provided to hospitalised children (Lasky 
et al. 2011). Lasky and colleagues used a large dataset containing records for 877 201 paedi-
atric hospitalisations. Nonsteroidal anti-inflammatory medicines, local and regional anaes-
thetics, opioids, benzodiazepines, sedative hypnotics, and barbiturates were being used to 
treat children (Lasky et al. 2012). Within these medicine groups, some medicines were more 
widely used than others: paracetamol and ibuprofen; lidocaine; fentanyl and morphine; mid-
azolam; propofol and phenobarbital. No similar studies on medicine utilisation in a large 
population were found from European countries.  
 
Table 2. Summary of medicine utilisation in hospitalised paediatric patients in two types of units 
in three European and one non-European country. 
 
 Estonia1 Germany2,3,4 UK4 Malaysia5 
 
Estimator for number of medicines per patient during hospitalisation  
 
NICUs Median 4  
(IQR 2–7) 
Median  8 (range 0–45)2 - Average 8 
General wards - Median 3 (IQR 2–5)3 
Median 2 (IQR 1–4)4 
Median 5  
(IQR 3–8) 
Median 3  
(IQR 2–3) 
 
Most commonly prescribed medicines according to ATC system in decreasing order 
NICUs J, C, N, A, R  J, B, N, R, A, C - NR 
General wards - J, N, R J, N, R J, N, R 
 
Most common active substances  
  
NICUs J; gentamicin, 
ampicillin  
B; heparin 
J; tobramycin 
N; diazepam and midazolam 
R; theophylline, caffeine cit-
rate, surfactant 
C; dobutamine 
 
- NR 
General wards - J; cefotaxime 
N; metamizole sodium 
R; salbutamol 
 
J; amoxicillin 
and enzyme in-
hibitor 
N; paracetamol 
R; salbutamol 
J; cefuroxime 
N; paraceta-
mol 
R; salbutamol 
IQR, interquartile range; NICU, neonatal intensive care unit; NR, not reported 
A Alimentary tract and metabolism; B Blood and blood forming organs; C Cardiovascular system; J Anti-
infectives for systemic use; N Nervous system; R Respiratory system 
1Lass et al. 2011, 2Neubert et al. 2010, 3Oehme et al. 2012, 4Rashed et al. 2012b, 5Lee et al. 2013 
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2.4 PAEDIATRIC DRUG-RELATED PROBLEMS 
Epidemiological studies on DRPs in children are scarce; fewer studies have assessed various 
DRPs, but numerous studies have assessed solely adverse drug events (ADEs) or adverse 
drug reactions (ADRs) related to hospital admissions or their occurrence in hospitalised chil-
dren and outpatients. The relationships between DRPs, ADEs and ADRs are presented in 
Figure 4.  
 
 
 
Figure 4. Context of drug-related problem, adverse drug event and adverse drug reaction 
(Strand et al. 1990, Directive 2010/84/EU, Uppsala Monitoring Centre 2013a). 
 
Drug-related problems encompass a wide range of conditions of patient that are related to a 
medication.  ADRs have been defined, described and quantified more extensively than the 
other DRPs (Strand et al. 1990). ADRs need to be distinguished from the ADEs. If the causal 
relationship between the used medicine and the harmful reactions is unclear and cannot be 
determined then the preferable term to be used is ADE rather than ADR (Edwards and Ar-
onson 2000). The causality assessment is normally done by healthcare professionals who es-
timate whether the suspected ADR is definite, probable, possible or unlikely (doubtful) (Na-
ranjo et al. 1981, Gallagher et al. 2011). Though, researchers do not always acknowledge the 
difference in these terms; many reports tend to use the term ADR even though the causality 
has remained unclear, e.g. in the studies where parents are reporting harmful effects of med-
icines.  
2.4.1 Drug-related problems in paediatric outpatients  
The majority of the DRP studies in paediatric outpatients have focused on ADRs and detected 
by health care professionals. Less attention has been paid to a guardian’s perceptions on 
DRPs and on other DRPs than ADRs.  
The guardians’ perspectives were inquired in a survey that focused solely on antibiotic 
use in children aged 0–12 years living in Eastern Finland in 1995 (Sepponen et al. 2002). The 
most common problems parents faced were ADEs in 17% of children followed by admin-
istration and dosing problems in 11% of children. However, there are very few reports on 
ADEs perceived by guardians in paediatric outpatients (Table 3). In these reports the study 
designs and settings vary which means that the rates of experienced ADEs detected by the 
parents are not comparable. A high rate of ADEs (61%) was detected among children with 
medication for Attention-Deficit Hyperactivity Disorder in the UK. According to a German 
study, 1% of the general child population were assessed to experience ADEs over a one-week 
Drug 
related 
problem
Adverse 
drug 
event
Adverse 
drug 
reaction
DRP: Any event involving medicine that in-
terferes with desired health outcomes  
ADE: Any adverse outcome that occurs 
while a person is using a medicine  
ADR: An adverse drug reaction is a re-
sponse to a medicine which is noxious and 
unintended  
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time period. In Germany, most ADEs were mild and affected on gastrointestinal system and 
skin. ADEs were mostly associated with medicines affecting nervous system, anti-infectives 
and medicines for respiratory system.  
The logic and reasoning that the parents used to assess the likelihood of ADEs has been 
found to be similar than physicians had used (Arnott et al. 2012). The parents simply noted 
the temporal associations between the occurrences of symptoms and taking the medicine, the 
fading of symptoms between doses and the possibility of other reasons for symptoms.   
The review of the studies on ADEs perceived by guardians and their conclusions suggest 
that the following can be recommended: Parents are in an ideal position to detect ADEs and 
could take a more active role in reporting if they feel empowered after having received ap-
propriate information and counselling. 
 
Table 3. Results of studies on adverse drug events in paediatric outpatients perceived by guard-
ians. 
 
Country 
and  
refer-
ence 
Study pe-
riod 
Design, data source Number 
of  
children 
Age  Main out-
come 
Proportion 
of children 
with an 
ADE 
UK 
Tobaiqy 
et al. 
2011 
 
2 months 
in 2010 
Questionnaire 
to the parents of chil-
dren with a diagnosis of 
ADHD and whose child is 
currently prescribed 
ADHD medications 
 
200 3–16 
years 
ADEs per-
ceived by 
the parents 
61 %  
Germany 
Knopf 
and Du 
2010 
 
Recall of 7 
days 
in 2006 
Medical interview/ques-
tionnaire. Non-institu-
tionalised children 
17 450  0–17 
years 
ADEs per-
ceived by 
the parents 
or children 
themselves 
 
1 %  
 
Nigeria 
Oshikoya 
et al. 
2009  
 
3 months  
in 2007 
Questionnaire given 
to the parents fetching 
medication (antibiotics, 
antimalarials, analge-
sics) for their child, 15 
different pharmacies 
 
2 868 1 
month
–12 
years 
ADEs per-
ceived by 
the parents 
18 %  
UK 
Stewart 
et al. 
2005 
4 weeks 
in 2003 
Questionnaire supplied 
to the parent/guardian 
purchasing medicines for 
the child (amoxicillin, 
salbutamol, paracetamol 
or ibuprofen), 7 pharma-
cies 
106 0–11 
years 
Feasibility of 
parental re-
porting sys-
tem 
NR 
ADHD, Attention-Deficit Hyperactivity Disorder; ADE, adverse drug event; NR, not reported 
 
In paediatric outpatients, the overall incidence of ADRs detected by health professionals has 
been reported to be low; only one child out of every hundred experiences ADRs (Impicciatore 
et al. 2001, Clavenna and Bonati 2009a). The commonest medicines related to ADRs are anti-
infectives for systemic use followed by medicines affecting central nervous system and hor-
mones (Bourgeois et al. 2009, Clavenna and Bonati 2009a, Smyth et al. 2012).  The most com-
mon problems have been dermatological and gastrointestinal symptoms found in a large na-
tional retrospective patient record study conducted in the USA (Bourgeois et al. 2009). Anti-
infectives were found to be associated with ADEs most commonly among children 0–4 years 
of age and they then decreased in frequency in older children. This same age group had the 
highest proportion (43%) of the all ADE-related visits to clinics. The ADEs related to medi-
cines affecting central nervous system and hormones increased in frequency in older children 
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up to 18 years of age. The ADE-related visits according to age and associated with these par-
ticular groups of medicines probably reflect the common use of these medicines in each age 
group. With respect to the actual pharmacological groups the highest rate of ADE-related 
visits was associated with antineoplastic and immunosuppressive agents, followed by hor-
mones and antimicrobials.  
2.4.2 Drug-related problems in hospital settings 
Recently, a few observational studies have assessed paediatric DRPs in hospitalised children 
in the UK and Saudi Arabia (Rashed et al. 2012c), and in France, Quebec, Switzerland and 
Belgium (Prot-Labarthe et al. 2013). In a cohort of paediatric inpatients, in the UK and Saudi 
Arabia almost half (45%) had experienced a DRP in the medical ward, paediatric intensive 
care unit (PICU) or NICU during the 3-month follow-up period. The most common DRPs 
were: dosing problems, e.g. too low or high dose, too short or long dosing interval; medicine 
choice problems, e.g. inappropriate dosage forms, untreated indications; improper admin-
istration techniques, mainly reported from PICUs; and ADRs (Rashed et al. 2012c, Prot-Lab-
arthe et al. 2013).  
 
Adverse drug reactions in hospitalised children 
One in ten of the hospitalised children experience an ADR according to systematic reviews 
and meta-analysis estimations (Clavenna and Bonati 2009a, Aagaard et al. 2010a, Smyth et 
al. 2012). There is a wide variation in the prevalences described due to different study popu-
lations and units, treatment schemes and methods used to detect ADRs. A recent report of 
the multicentre study (ADVISE) of 1 278 patients conducted in paediatric general medical 
wards provides also variable rates of children with ADRs (Rashed et al. 2012a). The overall 
proportion of patients with an ADR was 16.5%; 8.4% in Hong Kong, 7.5% in Australia, 7.2% 
in Germany, 18.3% in Malaysia and 33.8% in the UK. Another recent and large study of 5 118 
children was conducted in paediatric medical and surgical secondary and tertiary referral 
center in UK (Thiesen et al. 2013). The proportion of patients with an ADR assessed as either 
probable or definite was 18%. If the possible ADRs were included, the proportion of children 
with an ADR would have been higher.  In the aforementioned ADVISE study conducted by 
Rashed et al. (2012b), the possible ADRs were also included and a different causality assess-
ment tool was used (Naranjo algorithm) than in UK study (Liverpool causality assessment 
tool). The authors who developed the latter tool postulated that by using the Naranjo tool in 
children, the likelihood of ADRs may be underestimated (Gallagher et al. 2011).  
The higher rate in the UK compared to other countries as found in the ADVISE study was 
postulated by the authors to be related to the high number of medicines prescribed per pa-
tient and differences in medicines being used, e.g. morphine was prescribed only in UK and 
Australia and i.v. salbutamol only in UK i.e. out of the ADRs in UK almost half, 43.5%, were 
associated with either morphine or salbutamol. In addition, possible reasons for variation in 
results can be that the study populations were not large, and fewer patients were from Aus-
tralia and Hong Kong than from other countries. 
In the overall study population of the above five countries, the most common site for ADRs 
was gastrointestinal tract followed by skin and appendages (Rashed et al. 2012a). The most 
frequently associated medicines with ADRs were antibacterials, analgesics and medicines for 
obstructive airway diseases, which were also most often prescribed. This is consistent with 
some other studies from the UK and Germany, even though conducted in different paediatric 
wards (Turner et al. 1999, Neubert et al. 2006). 
In the UK, over half (56%) of the children had undergone general anaesthesia and 2% were 
oncology patients (Thiesen et al. 2013). Nausea or vomiting, pruritus and constipation were 
among the commonest types of ADRs. Out of all of medicines, opioid analgesics and anaes-
thetic agents were those most commonly (54%) associated with ADRs.  
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According to the most recent studies, ADRs in hospitalised children can be more common 
than indicated in the earlier meta-analysis estimations and reviews. More studies would be 
needed to clarify the current situation in hospitalised children in different European coun-
tries. 
2.4.3 Adverse drug reactions reported to the spontaneous reporting systems 
The World Health Organization’s (WHO) spontaneous ADR reporting system is to acquire 
information of new and possibly unknown ADRs that have not been reported prior to au-
thorising and marketing of the medicinal product (Uppsala Monitoring Centre 2013b). It is 
mainly intended for detecting rare and serious ADRs. This system is particularly important 
in children, since major part of the clinical trials have been conducted in  adults and therefore 
the safety profile of many medicines has been unknown in the paediatric population.  
In Finland, physicians, pharmacists and nowadays also consumers are encouraged to re-
port all suspected serious ADRs; unexpected ADRs, i.e. those not mentioned in the SmPC; 
ADRs related to the use of a new medicine (<2 years on the market); ADRs that seem to in-
crease in frequency; ADRs concerning interactions; ADRs concerning medication errors and 
overdosing; and ADRs related to off-label use of medicine including medicine abuse, and 
work-related ADRs (Finnish Medicines Agency normative guideline 2/2013). The reporting 
of suspected ADRs is voluntary; except for vaccines for which it is obligatory. In addition, if 
the suspected ADR is related to a vaccine, even an individual batch and ADRs in new or 
expanded target populations are encouraged to be reported (Communicable Diseases Act 
1986/583, National Institute for Health and Welfare 2013a). 
The spontaneous reporting system is very important; however, there are some issues that 
are known to restrict its usage for research purposes. First, the spontaneous ADR reports 
cannot be used to determine prevalence or incidence (Aagaard et al. 2012). Secondly, un-
derreporting of ADRs both in children and in adults is widespread (Hazell and Shakir 2006). 
The WHO Programme for International Drug Monitoring has listed some ideal characteris-
tics for the national pharmacovigilance centres (Uppsala Monitoring Centre 2013b). One of 
them is the optimal ADR reporting rate of over 200 reports per million inhabitants per year. 
The overall reporting rate of Finland has remained low (121) as compared with many other 
high-income countries in Scandinavia, Europe and Asia (Aagaard et al. 2012). The Swedes 
are the most active of the Scandinavians in reporting; their rate has been 333 compared to 216 
in Norway, 92 in Denmark, and 43 in Iceland. The highest reporting rate (613) across nations 
has been in New Zealand and the lowest (3) originates from low-income countries.  The low 
reporting rate (<28) in middle- and low income countries is alarming because the majority of 
the world’s paediatric population lives in those countries.  
During the last decade, the majority (85%) of the all ADR reports submitted to the WHO-
ADR database, VigiBaseTM, have come from high-income countries. In addition, 16% of the 
all reports were for serious ADRs (Aagaard et al. 2012). The reporting rate in high-income 
countries by age group was highest (25%) in individuals more than 65 years of age, followed 
by children aged 0–4 years (24%) and lowest (8%) in children and youths aged 5–19 years. 
In Finland, between 2007 and 2011 the reporting rate per 950 000–960 000 (roughly one 
million) children below 16 years of age has been annually in a range of 57–77, excluding vac-
cine reports (Kalliokoski 2012, Official Statistics of Finland 2013). These are low numbers 
compared to the optimal ADR reporting rate of 200 reports per million inhabitants per year.  
More reports were for children aged 14 years followed by children aged 10 years, 15 years 
and <1 year than for other children. There were more (56%) reports related to boys than girls. 
Psychoanaleptics; methylphenidate, atomoxetine; immunosuppressants, e.g. infliximab, 
etanercept; psycholeptics like risperidone; antiepileptics; medicines for obstructive airway 
diseases and antibacterials for systemic use were the most frequently reported medicines. 
With respect to the reported medicines, more than half (64%) belonged in these aforemen-
tioned groups. The most common ADRs were psychiatric disorders; aggressiveness, optical 
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illusions, and restlessness, skin and subcutaneous tissue disorders; urticaria, itching, and 
rashes and general and administration site disorders; fever. The most frequently reported 
medicines and ADRs differ from those used in earlier years of 1973–2006. At the later time 
point, the most frequently reported medicines were antibacterials for systemic use; cefaclor, 
amoxicillin, sulfamethoxazole-trimethoprim combination, benzylpenicillin, and the com-
monest site for ADRs was skin and subcutaneous tissue (Kalliokoski et al. 2007). Of all reports 
in children from the year 1990 to 2005, 18% to 63% included a serious ADR. 
2.4.4 Outcomes of the drug-related problems 
Adverse drug reactions are a notable reason for morbidity and also mortality in children. The 
occurrence of ADRs in children has been reported in numerous observational studies, and 
four systematic reviews provide information on estimates of ADR rates (Impicciatore et al. 
2001, Clavenna and Bonati 2009a, Aagaard et al. 2010a, Smyth et al. 2012).  
Polypharmacotherapy has been claimed as an evident risk factor for ADEs or ADRs in 
several studies across nations in inpatients but also in non-hospitalised children in one large 
German study (Turner et al. 1999, Knopf and Du 2010, Rashed et al. 2012a, Smyth et al. 2012, 
Du et al. 2013, Bellis et al. 2013a, b, Thiesen et al. 2013). Paediatric patients with five or more 
medicines had a three times higher risk for ADRs compared to children with fewer medicines 
in paediatric general wards in a multicentre study in five countries; Germany, UK, Hong 
Kong, Malaysia and Australia (Rashed et al. 2012a). In addition, young age (<1 year) has been 
noted as a risk factor in outpatients (Menniti-Ippolito et al. 2000); whereas, in hospitalised 
children, risk for ADRs seem to increase with age (Rashed et al. 2012a, Thiesen et al. 2013). 
However, it has also been proposed that in the younger children, the symptoms that need to 
be communicated by patient (e.g. pain, nausea, hallucinations, and pruritus) may be un-
derrepresented in settings with children of different-aged (Thiesen et al. 2013). Children with 
severe illnesses or requiring general anaesthesia are at a high risk of experiencing ADRs 
(Turner et al. 1999, Du et al. 2013, Thiesen et al. 2013).  
With respect to the medicines causing ADRs, a higher risk has been associated with the 
use of opiate analgesics, antiepileptics, antibacterials and antimycotics for systemic use, cor-
ticosteroids for systemic use, and antineoplastic and immunomodulating agents than with 
the use of other medicines (Neubert et al. 2006, Bourgeois et al. 2009, Rashed et al. 2012a, 
Thiesen et al. 2013).  
 
Hospital admissions due to drug-related problems 
It has been estimated that between 2–3% of all the emergency department visits by children 
were attributable to DRPs (Easton-Carter et al. 2003, Rashed et al. 2013). The following were 
the most common DRPs as a cause of hospital admissions: child not receiving the prescribed 
medication, ADRs and accidental or intentional poisonings in Australian studies; whereas 
dosing and medicine choice problems were noted in Saudi Arabia; and ADRs were the major 
cause in the UK (Easton et al. 1998, Easton-Carter et al. 2003, Easton et al. 2004, Rashed et al. 
2013).  
Two to three out of every hundred hospital admissions in children were estimated to be 
due to ADRs according to systematic reviews and meta-analysis (Clavenna and Bonati 2009a, 
Aagaard et al. 2010a, Smyth et al. 2012). In a more recent review, evaluating 17 studies from 
the last decade (2002–2012), the reported incidence rate of ADRs requiring hospital admis-
sion varied from 0.14% to 21.5% across nations (Khan 2013). The frequency of the ADR-re-
lated admissions tends to vary for example depending on the studied paediatric patient 
group. Children with cancer treatment had numerous (42%) admissions due to ADEs or 
ADRs in Norway and in the UK (Buajordet et al. 2002, Bellis et al. 2013a).   
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2.5 OFF-LABEL AND UNAUTHORISED MEDICINE USE IN CHILDREN 
In the EU, the authorised information for healthcare professionals on how to use medicines 
safely and effectively is provided in the summaries of product characteristics (SmPCs). 
SmPCs are updated whenever new efficacy or safety data emerge (European Commission 
2009). Off-label prescribing is defined as prescribing an authorised medicine for use or in 
some way that is not described or is disclaimed in the approved SmPC (Table 4) (Turner et 
al. 1997, Neubert et al. 2008). The classification presented by Turner et al. has been most often 
used in European studies. The term “off-label” originates from the USA and it is intended to 
describe the use of licensed (authorised) medicines outside the terms of their labelling (mar-
keting authorisation) (Turner et al. 1997). 
Unauthorised (unlicensed) use of medicine means all uses of a medicine which has not 
been granted a marketing authorisation in the particular country where used (Table 5).  
 
Table 4. Classification of off-label use of medicines (Turner et al. 1997) 
 
Off-label class Description 
Dose  Dose deviates from the one recommended in the SmPC.  
Indication Medicine prescribed for another indication than stated in the SmPC.  
Age Medicine used outside authorised age range. 
Route  Medicinal product administered by deviant route than that recommended in the 
SmPC. 
Contraindication Medicine is contraindicated for use in children. 
SmPC, summary of product characteristics 
 
Table 5. Description of unauthorised medicines (Turner et al. 1997) 
 
Unauthorised  Description 
Modification of an 
authorised medicine 
The form, appearance and packaging are specified in the SmPC. Any change in 
advance of need made to these characteristics alters the original medicinal prod-
uct and it then becomes unauthorised. This includes extemporaneous dispensing, 
for example tablets intended for adults being crushed and turned into a powder 
or suspension. 
 
Special manufactur-
ing licence 
Authorised medicines but the particular formulation manufactured under a ‘spe-
cials’ manufacturing licence or unauthorised medicines when manufacturer con-
siders them not viable for authorising process. The Medicines and Healthcare 
Products Regulatory Agency grants this licence to a manufacturer in the UK. 
 
Use of chemicals Use of chemicals as medicines. 
 
Prior licence  Medicines used prior to the granting of a licence. 
 
Imported medicines Medicinal product not authorised in the country where used but may be author-
ised in another country. 
SmPC, summary of product characteristics 
2.5.1 Prevalence of off-label and unauthorised medicine use  
 
The extent of prescribing for off-label use and unauthorised medicines in paediatric popula-
tion has been studied in different settings, e.g. paediatric intensive care units, general paedi-
atric hospital wards, emergency departments and in general practice in paediatric outpa-
tients. In the EU, of the evaluated total number of prescriptions between 45–60% were for off-
label use and unauthorised medicines in children according to the “Report on the survey of 
all paediatric uses of medicinal products in Europe” (European Medicines Agency 2009).  
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In Finland, it has been estimated that about 57% of medicines used off-label occurred in the 
paediatric population in 2007 (European Medicines Agency 2009). This data was collected on 
the basis of legal requirements of the Paediatric Regulation and it was obtained from a uni-
versity hospital pharmacy and the Finnish Social Insurance Institute databases.  
The prevalence of off-label use and use of unauthorised medicines have been reported to 
vary between 16% and 64% in paediatric outpatients (Pandolfini and Bonati 2005, Kimland 
and Odlind 2012, Ribeiro et al. 2013, Knopf et al. 2013). In hospitalised children, higher rates, 
especially in preterm neonates and also in other paediatric age groups with serious condi-
tions in intensive care units, have been reported ranging from 70% up to 100% (European 
Medicines Agency 2009, Doherty et al. 2010, Neubert et al. 2010, Lass et al. 2011, Kimland 
and Odlind 2012).  
2.5.2 Risks of drug-related problems associated in off-label and unauthorised medicine 
use  
Some of the DRPs or reasons leading to DRPs identified in hospitalised children overlap and 
are similar with different types of off-label use of medicines. These kind of DRPs are non-
conformity to guidelines, contraindication, sub- and supratherapeutic doses or dosing inter-
vals, inappropriate dosage form, and improper administration (Prot-Labarthe et al. 2013, 
Rashed et al. 2013) and they accounted for 54% of all of the identified DRPs in three paediatric 
intensive care units and two cardiology units in France, Quebec, Switzerland and Belgium 
(Prot-Labarthe et al. 2013).  
The higher risk of ADRs has been associated with the use of off-label and unauthorised 
medicines than that attributable with the authorised use, both in hospitalised children and 
outpatient settings (Turner et al. 1999, Horen et al. 2002, Santos et al. 2008, Mason et al. 2012). 
However, there are also study results which have not found any significant association be-
tween off-label use and the use of unauthorised medicines, and increased ADR occurrence 
(Neubert et al. 2004, Phan et al. 2010, Tramontina et al. 2013). The uncertainty of the associa-
tion and variation in results may be due to the rather small sizes in some of the study popu-
lations, varying methodologies and settings and definitions of the terms used, and also na-
tional differences in medicine use and differences in paediatric authorising status of medi-
cines.  
Recently, in hospital settings it has been found that it is the number of medicines admin-
istered; either number of authorised or number of off-label/unauthorised medicines, rather 
than only the use of medicines off-label or unauthorised medicines that is a more evident risk 
factor for ADRs (Bellis et al. 2013a, b). These studies were conducted in the UK with a sound 
methodology and an adequate number of patients and medicines. It was also found that the 
off-label prescribing below the minimum age or weight can be a risk factor for ADRs in some 
medicine groups (Bellis et al. 2013b). Further studies are needed to confirm the pharmacoki-
netics of these high risk medicines. 
The risk for serious ADRs in association with the off-label use and use of unauthorised 
medicines has been claimed to be higher than that encountered with their authorised use 
(Choonara and Conroy 2002). These kinds of results were found in a register based ADR 
study in Denmark. Overall, of the spontaneous reports of ADRs in children over one decade, 
17% were for medicines prescribed off-label according to the child’s age (Aagaard and Han-
sen 2011). The majority of these, 60%, were serious ADRs, whereas only 35% of ADRs with 
authorised medicines use were classified as serious. Most of the serious off-label ADRs were 
associated with medicines affecting the nervous system, sex hormones and allergens. There 
were 13 fatal cases; 4 due to pulmonary embolism and thrombosis with hormonal contracep-
tives in 17-year-old girls and 2 were necrotising colitis in 2 male infants linked with ibuprofen 
used for treating patent ductus arteriosus.  
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A similar result of a higher rate in ADR reports for medicines used off-label than for those 
authorised for children, was found also in Sweden over a shorter period of time, i.e. a two 
year retrospective study (Wallerstedt et al. 2011). These researchers compared the overall 
reporting rates between children and adults for medicines used off-label and noted that the 
rate was higher for children. However, both of these findings from Denmark and Sweden 
need to be interpreted cautiously. The results may not directly reflect a higher occurrence of 
ADRs in off-label use of medicines; they may also be due to a higher reporting rate when the 
medicine is used off-label.  
2.5.3 Legislation concerning medicines for paediatric use 
In the EU and USA, there are legislations and initiatives to encourage the development and 
regulatory assessment of paediatric medicines. They use the carrot and stick approach i.e. 
requirements and incentives (Figure 5). Canada and Japan also have legislation to provide 
incentives for research and development of medicines in children but without requirements 
(Hoppu et al. 2012). In the EU, the legislation has been in force since 2007, in the USA it was 
commenced a decade earlier, since 1997. The Paediatric Regulation created in the EU was 
able to benefit from the experience gained in the USA.  
In the EU, the Paediatric Regulation aims to increase number of medicinal products that 
are investigated, developed and authorised for use in paediatric population. It also aims to 
increase the information available on the use of medicinal products in children, and to reduce 
off-label and unauthorised medicine use in children. It requires companies to study medi-
cines in paediatric populations and to develop age-appropriate formulations for all new med-
icines seeking marketing authorisation in the EU, including also line extensions for patent-
protected medicines. This has to be done without subjecting children to unnecessary trials 
and without it causing any delay in gaining authorisation for medicines for adults. As an 
incentive for performing paediatric studies, companies are eligible for extensions to patent 
protection and market exclusivity (Figure 5).  
For the medicines applying for authorisation in the EU it is obligatory to submit a paedi-
atric investigation plan (PIP), a development plan of studies in children or to seek a waiver 
(European Medicines Agency 2013b, Paediatric Regulation (EC) No 1901/2006). This also ap-
plies to the authorised patent-protected products in the case the company seeks authorisation 
for a new indication, route of administration or pharmaceutical form. The PIP should include 
details of planned studies, their efficacy, safety and quality, age-appropriate formulation to 
cover the needs of all age groups of children, from birth to 18 years, and timelines for studies. 
The Paediatric Committee (PDCO) is responsible for assessing the content of paediatric in-
vestigation plans and for providing opinions on them at the European Medicines Agency.  
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* Orphan medicinal products are granted market exclusivity for 10 years. If the paediatric investigation plan is com-
pleted then the orphan market exclusivity can be extended for an additional two years.  
 
Figure 5. Obligations, rewards and incentives of the Paediatric Regulation (EC) No 1901/2006 
for marketing authorisation applicants in the European Union.  
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For some medicines it is possible to apply for a waiver or a deferral and then the specific 
reasons will be assessed by the PDCO (European Medicines Agency 2013b, Paediatric Regu-
lation). The reasons for waivers includes; the medicinal product is likely to be ineffective or 
unsafe in the paediatric population, or the target disease or condition occurs only in adults, 
or the new therapy would not result in a significant benefit over existing therapies for paedi-
atric patients. A deferral can be granted for example if the PDCO assesses that it will be better 
to perform trials in children only after adult data have been gathered. 
There are rewards for developing off-patent medicines; those not covered by a basic patent 
or supplementary protection certificate; one incentive is a 6-month extension of patent pro-
tection another is as much as 10 years of market protection in the case of paediatric-use mar-
keting authorisation (PUMA). PUMA covers the indication and appropriate formulation for 
the paediatric population and the PIP must examine all paediatric subsets. The PUMA appli-
cations are automatically handled with a centralised procedure. Research and development 
of off-patent medicine is also benefited by funding through EU Framework Programmes. EU 
funding of 80 million euro has been granted to 16 projects with at least 20 off-patent active 
substances (European Commission 2013). However, the Paediatric Regulation does not set 
any requirement on need to develop off-patent medicines even though the off-label use of 
such medicines has been shown to be widespread in paediatric population.  
The PDCO has created a priority list for the off-patent medicinal products for which pae-
diatric studies are needed (European Medicines Agency 2013a). The list was updated last in 
August 2013. The following areas have been claimed to be always as high priorities: (i) de-
velopment of age-appropriate formulations and strengths; (ii) data in neonates for all condi-
tions; (iii) data in infants for oncological conditions and for refractory paediatric epilepsy 
syndromes. 
 
Experiences obtained of the impact of the EU’s Paediatric Regulation  
The Paediatric Regulation includes also requirements for the European Commission. Accord-
ingly, a 5-year report was published in 2012 to describe the experiences, and the next report 
will be published by January 2017, 10 years after its implementation. Initial marketing au-
thorisations with paediatric indication were granted for 13 new medicines, 11 products were 
granted the 6-months incentive whereas only one PUMA was granted (midazolam, oromuco-
sal use) (Figure 6). In addition, 30 new paediatric indications and 9 new formulations had 
been approved for already authorised medicines.  
The PDCO had agreed on 476 PIPs and demanded studies with neonates in 30% of these 
PIPs (European Medicines Agency 2012). Most (75%) of the PIPs were for medicines not yet 
authorised at the time of evaluation, i.e. for new medicines. It has been claimed that the num-
ber of paediatric trials has been lower than expected (Saint Raymond 2010). For example, 
only 29 of the PIPs had been completed by the end of 2011. According to the 5-year report, 
the submission of PIP proposals was delayed and the implementation of paediatric trials may 
also be postponed for 3–5 years after submission of the PIP, especially if the deferral permis-
sion is granted (Olski et al. 2011, European Medicines Agency 2012). However, 5-year report 
concludes that the aims of the Paediatric Regulation are realistic and should be achieved in 
time, based on the experience gained so far.  
A part of the EU regulation required the marketing authorisation holders to submit all 
existing information on paediatric studies of established medicines to the competent national 
authority for assessment by the beginning of the year 2008 (Paediatric Regulation, European 
Commission 2013). This huge assessment work of more than 18 000 study reports has been 
shared between Member States (European Medicines Agency 2014a). The studies under as-
sessment have included: 167 studies on around 60 centrally authorised medicines and more 
than 17 500 studies on around 1 000 nationally authorised medicines. By the end of year 2011, 
the assessment had prepared recommendations to clarify of 51 SmPCs, to add safety infor-
mation in SmPCs of 11 active substances and, for 10 medicines granting of new paediatric 
indication (European Medicines Agency 2012). If the marketing authorisation holders would 
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not update the SmPCs according to the recommendations, the authorities are empowered to 
require this under the Paediatric Regulation. The assessment work has continued and ac-
cordingly new information have been included regularly in the SmPCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Rewards and incentives of the Paediatric Regulation granted by the end of 2011 in the 
European Union (European Medicines Agency 2012).  
 
Experiences obtained of the impact of the US legislation  
The experiences gained in the USA, where the similar paediatric legislation was issued a 
decade earlier (1997) than in the EU, supports the belief that it is possible to achieve improve-
ments in the availability of better medicines for children. There are two laws that encourage 
and require pharmaceutical companies to study their products in children, the Best Pharma-
ceuticals for Children Act (2002) and the Pediatric Research Equity Act (2003). These laws 
were revised but finally made permanent in 2012 (Appendix 3). 
After implementation of the legislation, some evaluation stated that the initiatives had 
proved the feasibility of conducting clinical trials involving children (Schreiner 2003). Subse-
quently, the number of paediatric clinical trials has increased and accordingly the infor-
mation about the use of medicines in children increased in labelling (Steinbrook 2002, Li et 
al. 2007, Benjamin et al. 2009, Hoppu et al. 2012). By the time the FDA Modernization Act of 
1997 had been in force for five years, there had been 333 Proposed Pediatric Study Requests 
(comparable with PIPs) and exclusivity had been granted to 75 products, and 58 changes 
were made to the labelling of 56 authorised medicines.  
It has been voluntary for the marketing authorisation holders of off-patent medicines to 
conduct paediatric safety and efficacy studies and to develop formulations for children in the 
USA, as is the case also in the EU. This has not been a sufficiently motivating incentive for 
companies in the USA (Milne and Bruss 2008). Paediatric formulations are far from straight-
forward and this has been claimed to be one of the reasons why medicines for the paediatric 
population has failed to be routinely included into the development of medicines (Steinbrook 
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2002, Schreiner 2003, Milne and Bruss 2008). According to the considerations of the Econom-
ics Working Group within the Pediatric Formulation Initiative of the Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, the following factors are typical 
for the paediatric pharmaceutical market: (i) relatively small market size, <10% of the overall 
pharmaceutical market; (ii) the high proportion of off-patent medicine use in the paediatric 
population; (iii) no paediatric incentives for generic products; (iv) fewer chronic diseases than 
adults and; (v) greater complexity of formulation development that must consider for exam-
ple physiologic changes occurring in growing children. The Economics Working Group sug-
gested that the incentives in the USA paediatric exclusivity program may have been sufficient 
for preclinical, clinical studies and formulation development, but not to cover the costs after 
the authorisation; e.g. continued manufacturing, distribution and marketing of products of 
paediatric use. However, they also proposed that in some areas, the development of a suita-
ble medicine for children may well be profitable and thus there ought to become more spe-
cialised paediatric delivery products on the market.  
A study quantifying the economic return to industry estimated that the Pediatrix Exclu-
sivity Program compensated the manufacturers the costs of conducted clinical trials in chil-
dren for blockbuster products in the USA (Li et al. 2007). However, for other types of prod-
ucts there were modest returns on investments and for one product it was estimated that the 
return was negative. In this study, nine medicines/products were chosen from a range of 
many therapeutic areas (e.g. allergy/immunology, cancer, central nervous system, cardiovas-
cular, psychiatry, endocrine, gastrointestinal and infectious disease). The authors suggest 
further modelling is needed to evaluate the economic benefits to industry in return for their 
expenses.   
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3 Aims of the Study 
There were three overall purposes for this study. The first aim was to investigate medicine 
use among children in a general population, and the second, to investigate drug-related prob-
lems in this population. The third aim was to study the prescribing of medicines for off-label 
use and unauthorised medicines in hospitalised children. 
 
The specific aims were: 
1. Publication I (chapter 5) 
a. To determine the prevalence of medicine use in a representative population sample 
of children in Finland in 2007. 
b. To identify the factors associated with medicine use. 
 
2. Publication II (chapter 6) 
a. To determine the prevalence and the types of drug-related problems in paediatric 
pharmacotherapy in a representative population sample of children in Finland in 
2007. 
b. To determine the medicines associated with drug-related problems. 
c. To determine the prevalence of serious and unexpected adverse drug events associ-
ated with paediatric pharmacotherapy. 
 
3. Publications III and IV (chapters 7 and 8) 
a. To determine the prevalence and frequency of prescribing medicines for off-label use 
and unauthorised medicines in hospitalised children (publications III and IV). 
b. To assess the possible change in prescribing medicines for off-label use and unau-
thorised medicines over 10-years’ time, between 2001 and 2011, and four years after 
the Paediatric Regulation came into force (publication IV). 
c. To review international studies on this kind of prescribing to compare the situation 
in Finland to that in other countries and if there have been changes with time (publi-
cation III and unpublished review in chapter 8). 
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4 Materials and Methods  
The data used for this thesis were from two different types of sources; (i) from a postal pop-
ulation survey and (ii) from hospital patient medical charts. Summary of data used in each 
of the four publications are presented in Table 6. The publications I, II, III and IV of this thesis 
are included as chapters 5, 6, 7 and 8; and follows after materials and methods. 
 
Table 6. Summary of the used data, study design, main outcome measures and statistical 
methods in publications of this thesis. 
 
Publication Design and data  Main outcome Statistical methods 
I 
 
Cross-sectional, representative 
population survey, postal 
questionnaire 2007 
 
N=4 032 
Age 0–11 years 
Response rate 67% 
Prevalence of medi-
cine use and factors 
associated with it 
Chi-squared test 
Categorical variables 
 
Logistic regression analyse 
Explicable variables: 
Rx medicine use 
OTC medicine use 
Rx and/or OTC medicine use 
Explanatory variables: 
Gender and age 
Health status 
No. of symptoms 
No. of diseases 
Rx use by the parent 
OTC use by the parent 
 
II 
 
Cross-sectional, representative 
population survey, postal 
questionnaire 2007 
 
N=4 032 
Age 0–11 years 
Response rate 67% 
 
Lifetime prevalence  
and type of drug-re-
lated problems 
 
Chi-squared test 
Categorical variables 
 
Confidence intervals  
Proportions 
 
 
III  
 
 
Prospective, information on 
patient medical charts in three 
Kuopio University Hospital 
paediatric wards  
16.4.–25.5.2001 
 
N=141  
Age 0–15 years 
 
Prevalence and fre-
quency of prescrib-
ing medicines for 
off-label use and 
unauthorised medi-
cines 
 
Chi-squared test 
Differences in proportions 
 
Kruskal-Walls test 
Continuous variables 
 
 
IV 
 
Prospective, information on 
patient medical charts in three 
Kuopio University Hospital 
paediatric wards  
11.4.–20.5.2011 
16.4.–25.5.2001 
 
N=123 
N=141  
Age 0–15 years 
 
Difference in preva-
lence and frequency 
of prescribing medi-
cines for off-label 
use and unauthor-
ised medicines be-
tween 2001 and 
2011 
 
Confidence intervals  
Proportions 
 
Two-sample test with continuity 
correction 
Equality of proportions 
 
Mann-Whitney U-Test 
Medians 
 
Cohen’s kappa  
Coefficient of agreement  
OTC, over-the-counter; Rx, prescription medicine  
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4.1 POPULATION SURVEY 
The cross-sectional population survey was planned and conducted by the Children and Med-
icines Research group in Social and Clinical Pharmacy at the University of Eastern Finland, 
former University of Kuopio. This data was used for two publications of this thesis, I and II. 
The same survey data has been used in eight other publications. The list of these is presented 
in the Appendix 4. 
4.1.1 Study population 
The target population for the survey was children aged less than 12 years living in Finland 
(n=702 320) at the end of the year 2006 (Statistics Finland). The coverage of the final sampling 
frame was 91.5% with 642 957 children. The children whose mother tongue was some lan-
guage other than Finnish or Swedish were excluded. 
 
The following children were not reached through the Finnish Population Register Centre: 
 children lacking permanent address; for example, those in institutional care or under cus-
tody (approx.  50 000 individuals in the entire population of Finland) 
 children with a parent with an opt out from marketing and other surveys (approx. 110 000 
individuals in the entire population) 
 children with a restraining order on the parent 
 children aged less than 6 weeks.  
 
The flow chart of the formation of the final study population is presented in Figure 7.  
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Figure 7. Flow chart of the population survey conducted in 2007 
 
A detailed description of the sample size estimation, power calculation and sampling is pro-
vided in chapter 5. The final response rate (67%) after two reminders was estimated as suffi-
cient, i.e. statistically representative sample from which statistical significance can be derived 
(Kelley et al. 2003, Tolonen 2006 s. 94, Tolonen et al. 2006). In addition, there were no signif-
icant statistical differences between the children of respondents and non-respondents with 
respect to age, gender, and the mother tongue (Table 7). The proportion of children from 
Eastern Finland was higher in the final study population than in the target population and 
conversely children from Western Finland were somewhat under-represented among re-
spondents (Table 8). Children whose mother tongue was Finnish were somewhat over-rep-
resented as were the oldest age group of children, 7−11 years of age.  
  
Non-respondents: 
Did not respond, n=1 871  
Not reached, n=8 
Target population 
Children aged 
<12 years living 
in Finland, end of 
year 2006 
n=702 320 
Not available 
n=59 363 
Sampling frame 
n=642 957 
Random sample 
n=6 000 
Not eligibles 
n=89 
Eligibles 
n=5 911 
Respondents 
n=4 032 
Respondents for 
questions of drug-
related problems 
n=3 979 
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Table 7. Number of respondents and non-respondents of the survey according to the child’s 
gender, age, residential area and native language, publications I and II of this thesis. 
 
Characteristics Respondents 
n=4 032 (%) 
Non-respondents  
n=1 885 (%) 
Gender   
 Girl 1 926 (48)  933 (49) 
 Boy 2 106 (52) 952 (51) 
Age group   
 0‒2 1 004 (25) 440 (23) 
 3‒6  1 287 (32) 643 (34) 
7‒11 1 741 (43) 802 (43) 
Region    
Southern Finland 1 648 (41) 781 (41) 
Western Finland 1 309 (32) 666 (35)* 
Eastern Finland   512 (13) 165 (9)*** 
Oulu Province 408 (10) 198 (11) 
      Lapland Province 137 (3) 66 (4) 
Åland Islands 18 (<1) 9 (<1) 
Native language   
Finnish 3785 (94) 1761 (93) 
Swedish 247 (6) 124 (7) 
*p<0.05, ***p<0.001, 2-sample test for equality of proportions with continuity correction. The proportion 
of Swedish speaking target population was 6 % and Finnish speaking 91%. 
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Table 8. Study and the target (reference) population of the survey in publications I and II of 
this thesis. 
 
Characteristics Respondents 
n=4 032 (%) 
Sample 
n=6 000 (%) 
Target populationa 
n=702 320 (%) 
Gender    
 Girl 1 926 (48)  2 898 (48) 343 642 (49) 
 Boy 2 106 (52) 3 102 (52) 358 678 (51) 
Average age 5.6 - 5.5 
Age group    
 0‒2 1 004 (25)* 1 470 (24)** 184 808 (26) 
 3‒6  1 287 (32)* 1 960 (33) 229 385 (33) 
7‒11 1 741 (43)** 2 570 (43)** 288 127 (41) 
Region    
Southern Finland 1 648 (41) 2 357 (39)** 288 840 (41) 
Western Finland 1 309 (32)** 2 147 (36) 244 945 (35) 
Eastern Finland   512 (13)*** 647 (11)* 69 426 (10) 
Oulu Province 408 (10) 615 (10) 72 688 (10) 
      Lapland  
      Province 
137 (3) 206 (3) 22 800 (3) 
Åland Islands 18 (<1) 28 (<1) 3 621 (<1) 
Native language    
Finnish 3 785 (94)*** 5 622 (94)*** 638 131 (91) 
Swedish 247 (6) 378 (6) 40 058 (6) 
Lappish - - 254 (<1) 
Other languages - - 23 877 (3) 
*p<0.05, ** p<0.01, ***p<0.001, 2-sample test for equality of proportions with continuity correction. 
aOfficial Statistics of Finland, population structure 
4.1.2 Data collection 
The data were collected with a six-page pilot-tested questionnaire, including closed (n=17) 
and open ended (n=13) questions (Appendix 5). The questionnaire was sent either in Finnish 
or Swedish according to the respondent’s mother tongue.  
The covering letter emphasised that the person who normally takes care of the child’s 
medication should fill in the questionnaire. The majority (95%) of the respondents were the 
mothers (n=3 808) and only in one case did someone other than a parent fill in the question-
naire. The name of the child was inserted into the questionnaire and removed after the return 
of the questionnaire.  
Most of the questions were designed to be comparable with questions used in previous 
medicine utilisation studies or health surveys in Finland (Klaukka et al. 1990, Arinen et al. 
1998, Vainio 2004, Turunen 2007, School Health Promotion Studies by the National Institute 
for Health and Welfare).  
In an initial test of the questionnaire, our research group recruited a pilot group; a conven-
ience sample of 61 mothers with children aged less than 12 years. In testing reliability, the 
pilot group was asked to fill in the questionnaire on two separate occasions. They gave iden-
tical answers on both times. The mothers were also interviewed to ask if they had encoun-
tered difficulties in understanding or answering any of the questions. All the mothers were 
able to understand and answer the questions; also the meaning of the questions was identi-
fied to be same for all of them. The questionnaire was modified according to some feedback 
from the pilot group.  
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4.2 STUDIES IN PAEDIATRIC WARDS 
The data were collected from patient medical charts in three Kuopio University Hospital 
(KUH) wards; NICU, general paediatric ward and paediatric surgical ward in 2001 and 2011. 
These types of wards were chosen on the basis of previous studies (Turner et al. 1998, Conroy 
et al. 1999, Turner 1999, Conroy et al. 2000, ‘t Jong et al. 2000). It was also assumed that new-
borns in the NICU will most likely be medicated with medicines not been tested in their age 
group. This data was used in two publications of this thesis, III and IV. A detailed description 
of the data collection is described in chapters 7 and 8 on these publications.   
4.2.1 Study population 
An estimate of what would be a sufficient number of patients was obtained by reviewing the 
information on the average hospital stays and the numbers of patients treated in each of the 
selected hospital wards. A comparison with earlier studies was also done where the study 
populations had varied from 70 to 624 children (Turner et al. 1998, Conroy et al. 1999, Turner 
1999, Conroy et al. 2000, ‘t Jong et al. 2000). It was calculated that information on 140 patients 
could be collected in a 6-week period. This duration was also considered as a convenient time 
for data collection.  
All children aged less than 18 years treated in the three paediatric wards during the study 
periods were eligible. The two separate study populations contained 141 in 2001 and 123 
children in 2011 (Table 9). The majority (53%) of them were below 2 years old and oldest 15 
years of age. Overall, there were no statistical differences between the study years according 
to gender and age group. 
In the age classification, five preterm neonates were mistakenly classified as infants in 
2001, publication III; later their ages were reclassified and corrected as shown in Table 9 and 
in publication IV.  
 
Table 9. Study populations in the three paediatric wards, publications III and IV of this thesis. 
 
Characteris-
tics 
NICU 
n (%) 
General ward 
n (%) 
Surgical ward 
n (%) 
Total 
n (%) 
 2001 2011 2001 2011 2001 2011 2001 2011 
 Girl 22 (60) 14 (50) 33 (51) 27 (40) 14 (36) 15 (56) 69 (49) 56 (46) 
  Boy 15 (40) 14 (50) 32 (49) 41 (60) 25 (64) 12 (44) 72 (51) 67 (54) 
Age group         
 0‒27 days 30 (81) 24 (86) 3 (5) 1 (2) - - 33 (23) 25 (20) 
 28 days‒23    
 months 
7 (19) 4 (14) 27 (41) 33 (48) 8 (20.5) 4 (15) 42 (30) 41 (33) 
 2‒11 years - - 30 (46) 27 (40) 23 (59) 16 (59) 53 (38) 43 (35) 
 12‒15 years - - 5 (8) 7 (10) 8 (20.5) 7 (26) 13 (9) 14 (11) 
Total 37 (26) 28 (23) 65 (46) 68 (55) 39 (28) 27 (22) 141 (100) 123 (100) 
NICU, neonatal intensive care unit 
4.2.2 Classifications 
All prescriptions were classified in terms of their authorising status, i.e. authorised (licensed), 
off-label (Table 10) and unauthorised (unlicensed) (Table 11), using the previously described 
classification system devised by Turner et al. (1997) with two additional off-label classes: ‘no 
information’ and ‘pharmaceutical form’. The classes of medicines without marketing author-
isation identified in the present study were in principle the same but fewer and with some 
national differences in the authorising system than those described by Turner et al. 
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Table 10. Classification of off-label prescriptions in this thesis 
 
Off-label class Description 
Dose  Dose deviates from the one recommended in the SmPC (deviates by weight, 
BSA, frequency or deviates from age-related dose recommendation).  
 
Indication Medicine prescribed for another indication than listed in the SmPC or indication 
only for adults. 
 
Age Medicine not recommended in the SmPC to be used in certain age or no direc-
tions for use in particular age. 
 
Route  Medicinal product administered by deviant route than that recommended in the 
SmPC. 
 
Contraindication Medicine should not be used in children according to the SmPC. 
 
No information  No information at all for use in children or statement that there is not enough ev-
idence on efficacy and safety on use in children in the SmPC. 
 
Pharmaceutical form The used formulation not recommended for use in children in the SmPC or no di-
rections how to use that particular pharmaceutical form in children. 
BSA, body surface area; SmPC, summary of product characteristics 
 
Table 11. Classification of unauthorised medicines in this thesis 
 
Unauthorised class Description 
Modification of an au-
thorised medicine  
 
Includes extemporaneous products done in advance of need and prepared in the 
hospital pharmacy, e.g. tablets crushed and powdered. 
Special licence 
(named as imported 
medicines by Turner 
et al. 1997) 
 
Medicinal product not authorised in Finland but may be authorised in other coun-
try. The licence applied from the national medicines authority in individual cases 
or the authorisation granted by the national authority for a limited period of time. 
Medicine prepared by 
the hospital pharmacy 
(resembles ‘specials’ 
manufacturing licence 
by Turner et al. 1997) 
 
Pharmaceutical products prepared by the hospital pharmacy. The pharmacy is 
obligated to inform the national medicine authority about the process of produc-
ing these products. 
Expired MA The medicinal product still in use although the MA had expired. 
MA, marketing authorisation; SmPC, summary of product characteristics 
4.3 DATA MANAGEMENT 
All data of this thesis were entered into and managed with the Statistical Package for Social 
Sciences (SPSS Inc., Chicago, IL, USA and IBM Corp., Armonk, NY, USA) versions 11.5 (pub-
lication III), 14.0 (publication I), 19.0.0.1 (publication II) and 19.0.0.2 (publication IV). Statisti-
cal analyses were performed using the SPSS and R©-software version 2.14.0 (The R Founda-
tion for Statistical Computing, Vienna, Austria). 
4.4 ETHICAL CONSIDERATIONS 
The ethical principles of respecting the autonomy of research persons, and privacy and data 
protection were taken into account in all studies in this thesis. The following information on 
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the covering letter of the postal questionnaire (population survey) was included: the topic 
and purpose of the study, the voluntary nature of answering the questions, the assurance to 
treat all information in confidence, and contact information of researchers. By responding 
and returning the questionnaire the person indicated that s/he had consented to participate 
in the study. The register was maintained according to the Finnish legislation (Personal Data 
Act 523/99, 10 §). The returned questionnaires were handled and filed also according to the 
law (Archives Act 831/94) and directions of the University of Kuopio. All the identifiers; 
names and addresses were destroyed in 2007.  
In the case of patient medical chart studies, the KUH’s medical administrator approved 
the entry to the patient records (no. 15/2001 and no. 14/2011). In addition, the 2011-study 
protocol was approved by the Research Ethics Committee of the Hospital District of North-
ern Savo, Kuopio, Finland (no. 23/2011).  
Only data without any identifiers were used to produce the results of this thesis. 
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5 Factors Associated with Medicine Use Among Children 
Aged Less Than 12 Years – A Population Survey in  
Finland1 
5.1 INTRODUCTION 
Children’s medication has increasingly gained attention in the European Union and in the 
United States, and new regulations have been enacted accordingly (Regulation (EC) No 
1901/2006, Food and Drug Administration). Besides accentuating the need for clinical trials 
with children, these regulations emphasise the need to gather all the available information 
on medicine use among children. Such information is also needed by health care profession-
als. However, few studies have investigated the prevalence of medicine use among children, 
especially before adolescence (Kogan et al. 1994, Eggen 1997, Arinen et al. 1998).  
The factors which have been found to be associated with higher prevalence of medicine 
use include poor health status (Kogan et al. 1994, Tobi et al. 2003), maternal medicine use 
(Maiman et al. 1986), and young age (Thrane and Sørensen 1999, Madsen et al. 2001). Previ-
ous studies have found that the association between medicine use and the gender of the child 
is twofold: in younger age groups, the use of medicines is more common among boys than 
girls, while in adolescence it is more common among girls (Straand et al. 1998, Thrane and 
Sørensen 1999, Holstein et al. 2003, Tobi et al. 2003). Based on studies conducted in the United 
States, the level of the mother’s education and household income seem to correlate with the 
child’s medicine use (Maiman et al. 1986, Kogan et al. 1994). Mothers with more education 
and higher household incomes are more likely to give OTC medicines to their children than 
those with less education and lower incomes. 
Previous studies on children’s medicine use have several limitations. Most of the studies 
have reported the use of prescribed medicines on the basis of physician records (Straand et 
al. 1998, Cazzato et al. 2001, Sanz et al. 2004) or national prescription registers (Thrane and 
Sørensen 1999, Madsen et al. 2001). Other studies have focused on the use of single but widely 
used and somehow problematic groups of medicines, e.g., antibiotics (Borgnolo et al. 2001, 
Melander et al. 2003, Gagliotti et al. 2005). Medicine use among children has also been studied 
as a part of larger health surveys, producing quite superficial knowledge about medicines 
(Arinen et al. 1998, Hansen et al. 2003, Holstein et al. 2003). Most of the studies have focused 
on adolescents, and children have often been recruited to the studies through their schools, 
which raises questions about the generalizability of the results (Dengler and Roberts 1996, 
Chambers et al. 1997, Stoelben et al. 2000, Tobi et al. 2003). Moreover, only a few studies 
describe OTC medicine use among children (Kogan et al. 1994, Wong et al. 2007).  
The aim of this study was to assess the prevalence of medicine use, including prescribed 
and OTC medicines, and to identify the factors associated with medicine use among children 
aged under 12 years in a Finnish general population. 
                                                          
1Adapted with kind permission of John Wiley and Sons from: Hämeen-Anttila K, Lindell-Osuagwu L, Sepponen K,  
Vainio K, Halonen P, Ahonen R. Factors associated with medicine use among children aged under 12 years - a population 
survey in Finland. Pharmacoepidemiol Drug Saf 19: 400–407, 2010. 
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5.2 METHODS 
Context: Finnish health care 
In Finland, health care is financed mainly by taxes, and primary health care is available to all 
citizens for ambulatory medical services in health centers, free of charge for children and for 
a small fee for adults. Outpatient visits can also be made to private health care clinics. All 
children are covered for health care in the public sector from birth, and also during the 
mother’s pregnancy. The maternity and child health care system includes prevention, health 
checkups, and health education until the child is of school age, after which the school health 
care system takes over these tasks.  
Medicines, both OTC and prescription, can only be bought from pharmacies. The Social 
Insurance Institution reimburses the patient for a part of the cost of prescribed medicines.  
 
Design and study population  
This cross-sectional population survey was conducted in Finland in spring 2007. A random 
sample (n=6000) of children under 12 years of age was taken. The sampling was conducted 
by the Finnish Population Register Center from its database, which contains constantly up-
dated information on everyone living permanently in Finland. A questionnaire was sent to 
one parent of each child, primarily to the mother. The person who usually takes care of the 
child’s medication was instructed to answer the questionnaire. The child’s name was printed 
on the questionnaire in order to specify the child in families with two or more children. Two 
reminders were sent. The questionnaire was available in Finnish and Swedish, both of which 
are official languages in Finland.  
The six-page questionnaire contained the following five sections: background information 
of the child, health status of the child, the child’s medicine use, sources of information about 
medicines, and background information of the responding parent, including the parent’s 
own medicine use. The questionnaire was pilot-tested with a convenience sample of mothers 
(n=61) selected by the research group, and modified on the basis of the pilot.  
The sample size was calculated on the basis of the information on medicine use among 
children from a previous population study in Finland (Klaukka et al. 1990). We used a de-
sired significance level of α<0.05 and the expected power of 80%. In order to gain statistically 
significant differences in medicine use between the age groups of 0–2, 3–6, and 7–11 years, 
the sample needed for each group was 1315, so altogether 3945 children were needed. A sam-
ple size of 6000 with a response rate of 70% was expected to be sufficient. 
Of the 6000 questionnaires sent, 4121 were returned, yielding a response rate of 69% (Fig-
ure 8). Although the name of the child was printed on the questionnaire, some parents (n=89) 
filled in the questionnaire for one of their other children. These 89 were not included in the 
study population, and the analysis was done with 4032 responses giving a final response rate 
of 67%. The final study population was representative in age and gender of children aged 
under 12 years and who were living in Finland. The analysis of the non-respondents showed 
no differences from the target population in age, gender, or regional distribution, and the 
response rate was considered sufficient to produce non-biased results (Tolonen 2006).  
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Figure 8. Formation of the final study population 
 
Questionnaires were completed by the mother (95%), father (4%), or both (1%). Of the re-
spondents, 67% were working or studying, and 28% were at home with children (Table 12). 
The mean age was 36 years (range 18–61). Children from all six regions of Finland were in-
cluded: Southern, 40.7% (the actual proportion of the children in that area is 41.1%); Western, 
32.6% (34.9%); Eastern, 12.8% (9.9%); Oulu region, 10.1% (10.4%); Lapland, 3.4% (3.3%); and 
Åland 0.5% (0.5%).  
National and local ethical guidelines for researchers were followed in carrying out the 
study. The anonymity of the respondents was assured by deleting the name of the child from 
the questionnaire as soon as it was returned. The data management and disposal of all per-
sonal data were conducted in accordance with national privacy protection laws.  
  
Definitions of medicine use 
The indicators for medicine use were taken from previous studies carried out in Finland to 
allow comparisons of the results (Klaukka et al. 1990, Arinen et al. 1998). The use of pre-
scribed medicines was determined by asking the parents to report the current use of any 
medicines prescribed by a physician, and write a list of all medicines. They were also asked 
to report the use of OTC medicines during the preceding 2 days. All listed medicines were 
coded according to the ATC classification system (World Health Organization). The reported 
use of vitamins was excluded in this study, since the main focus was on medicine use meant 
to relieve symptoms and treat illnesses.  
Final response rate 67% 
Initial response rate after 2 reminders 
Sampling frame: 642 957 children 
Random sample of 6 000 children 
5 992 children 
4 121 children 
4 032 children 
8 respondents 
were not reached 
89 children were ex-
cluded because they 
did not belong to the 
initial sample popula-
tion 
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Statistical methods 
Data were analysed with SPSS for Windows statistical software, Release 14.0 (SPSS Inc., Chi-
cago, IL, USA). The categorical variables were cross-tabulated and their potential dependen-
cies were estimated with χ2 tests.  P values less than 0.05 were considered significant. 
In order to determine the adjusted odds ratios (ORs) of various factors for medicine use 
by the child, logistic regression analyses were conducted for prescribed and OTC medicine 
use, and the total exposure to medicines (prescribed and/or OTC medicine use). Prior to the 
regression analyses, interdependencies (Spearman correlation coefficient or contingency co-
efficient) of the variables shown in Table 12 were calculated. Relatively low values (range 
ρ=0.002–0.423 Spearman; C=0.008–0.397 contingency coefficient) suggested that all variables 
were sufficiently independent to be included in the initial models. Next, variables were de-
leted from the models one by one on the basis of their statistical non-significance. Changes 
of the β values were assessed at each step, a 20% change being considered a threshold value. 
The dependence between health status and the number of symptoms experienced (Spearman 
ρ=0.370) was assessed by deleting the number of symptoms experienced from the models.  
This increased the β values of health status considerably, and suggested that the number of 
symptoms experienced might be a confounder. Therefore, the final models are adjusted for 
this variable. Furthermore, age and sex seemed to interact and this was explored by using 
the interaction variable in the model. The ORs in the presence of interaction were estimated 
and even though the likelihood ratio test showed no statistical significance, some of the ORs 
were found statistically significant in a detailed inspection within ages and genders (Hosmer 
and Lemeshow 1989). Thus, the interaction variable was included in the final models to dis-
cover this phenomenon in a more detailed way. The results are presented as ORs together 
with their 95% confidence intervals (CIs). 
5.3 RESULTS 
About one in six of the children (17%) were using prescribed medicines at the time of the 
study, and an equal proportion (17%) had used one or more OTC medicines (vitamins ex-
cluded) on the preceding 2 days. A total of 151 children (4%) used both prescribed and OTC 
medicines. Children had on average 1.3 symptoms reported by the parent from a list of symp-
toms (range 0–13), most commonly common cold (33% of the children), rash (24%), flatus 
(11%), and growing pains (9%). Altogether, 18% of the children had at least one illness diag-
nosed by a physician. The most common illnesses reported were allergy (4% of the children), 
asthma (4%), atopic eczema (3%), and ear infection (2%). A total of 169 children (4%) had two 
or three illnesses diagnosed by a physician. The majority of the parents (96%) rated their 
child’s health status as good or fairly good (Table 12).  
The most commonly used prescription medicines were medicines for obstructive airway 
diseases (6% of the children). Furthermore, corticosteroids for dermatological use (3%) and 
antibiotics for systemic use (3%) were commonly used. The analgesics including NSAIDs 
were the most commonly used OTC medicines (7% of the children), followed by cough and 
cold preparations (2%), and preparations for the treatment of wounds and ulcers (2%).  
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Factors associated with the use of prescribed medicines 
The use of prescribed medicines was commonest among younger boys and children who had 
symptoms, illnesses diagnosed by a physician, and health status rated by the parent as worse 
than good (Table 12). Furthermore, two characteristics of the respondents were associated 
with the child’s use of prescribed medicine: children with young mothers were more likely 
to use prescribed medicines than other children, and the mothers’ own use of prescribed and 
OTC medicines was associated with the children’s use of prescribed medicine.  
The results of the logistic regression analysis are presented in Table 13. The following var-
iables were significantly associated with the child’s use of prescribed medicines, when ad-
justed with other variables: young age among boys, health status assessed worse than good 
by the parent, number of illnesses diagnosed by a physician, and use of prescribed medicine 
by the parent.  
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Factors associated with the use of OTC medicines 
The child’s characteristics that associated univariably with OTC medicine use were age, birth 
order, health status, number of symptoms experienced, and illnesses diagnosed by a physi-
cian (Table 12). Children with worse than good health status, symptoms and diagnosed ill-
nesses were more likely to use OTC medicines than others. Furthermore, young children and 
second-borns were more likely to use OTC medicines than others. Several characteristics of 
the responding parent were associated with the child’s use of OTC medicine: parents who 
gave OTC medicines to their children tended to be young, used prescribed and OTC medi-
cines themselves, and were at home with their children (Table 12).  
According to the logistic regression analysis, the young age of the child, health status as-
sessed worse than good, and the use of OTC medicine by the parent were significantly asso-
ciated with the child’s use of OTC medicine, when adjusted with other variables (Table 13). 
However, children were less likely to use OTC medicines if they had some illness diagnosed 
by a physician. 
 
Factors associated with the total exposure to medicines (prescribed and/or OTC medicines) 
The characteristics that associated univariably with total exposure to medicines (prescribed 
and/or OTC medicines use) followed the same pattern as with the prescribed and OTC med-
icine use (Table 12). The use of any medicines was commonest among younger children and 
children with symptoms, children with illnesses diagnosed by a physician, with those health 
status rated by the parent as worse than good, young parent, and parent who also used pre-
scribed or OTC medicines herself. As with OTC medicine use, the birth order of the child was 
associated with the total exposure to medicines by the child: second-borns were more likely 
to use medicines than other children. 
The following variables were significantly associated with the child’s use of any medicines 
(prescribed and/or OTC medicines use), when adjusted with other variables: young age, 
health status assessed worse than good by the parent, number of illnesses diagnosed by a 
physician, and use of prescribed or OTC medicine by the parent (Table 13).  
5.4 DISCUSSION 
Our study supports earlier findings which suggest that poor health status (Kogan et al. 1994, 
Tobi et al. 2003) and young age of the child (Thrane and Sørensen 1999, Madsen et al. 2001) 
as well as maternal medicine use (Maiman et al. 1986) is associated with a child’s medicine 
use. According to our study, the association between medicine use and gender is not as 
straightforward as some earlier studies suggest when they claim that at young ages medicine 
use is more common among boys than girls (Straand et al. 1998, Thrane and Sørensen 1999, 
Holstein et al. 2003, Tobi et al. 2003). The estimation of ORs in the presence of interaction 
between age and gender revealed that age is a stronger predictor than gender in explaining 
the difference in medicine use. Among boys this association is clearer. The socio-economic 
characteristics of the responding parent, such as education, working status, or the monthly 
net income of the household, did not have an influence on children’s medicine use in this 
study, in contrast to previous findings that mothers with more education and higher house-
hold incomes tend to give more OTC medicines to their children (Maiman et al. 1986, Kogan 
et al. 1994). The differences between the results of our present study and those of previous 
studies conducted in the United States may be due to cultural differences, and to the health 
care system in Finland, where free access to primary health care is available for all children 
regardless of the socio-economic status of the family. 
This study shows that a considerable proportion of children aged under 12 years were 
using prescribed medicines and OTC medicines, the prevalence being 17% for both. Com-
parison of our result with the prevalence rates in other studies is difficult since the outcome 
measure of medicine use differs considerably in different studies, e.g., 2 days (Bush et al. 
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1985, Arinen et al. 1998), one or two weeks (Dengler and Roberts 1996, Stoelben et al. 2000), 
one month (Hansen et al. 2003, Holstein et al. 2003), or even three months (Chambers et al. 
1997) to one year (Straand et al. 1998, Thrane and Sørensen 1999, Madsen et al. 2001, Headley 
and Northstone 2007). Thus, there is a need to agree on the indicators for medicine use in 
order to be able to compare the results from different countries. We strongly suggest that the 
present use of medicine should be the outcome measure when prevalence rates of medicine 
use are studied, because of minimal recall bias. 
This study was based on a nationally representative sample of children aged under 12 
years with a response rate of 67%. The responses represent Finnish children in age and gen-
der, but their regional distribution differed from that of the target population. However, we 
did not find any significant differences in medicine use in different regions, so, the results 
may be generalised to represent medicine use among children aged under 12 years in Fin-
land. We report the use of both prescribed and OTC medicine by children, which is a strength 
of this study since, typically, studies on medicine use among children report only prescrip-
tion medicine use (Maiman et al. 1986, Eggen 1997, Thrane and Sørensen 1999, Tobi et al. 
2003) omitting OTC medication. Parents were asked to report the current use of prescribed 
medicine and the use of OTC medicine during the previous 2 days, which decreases the pos-
sibility of recall bias.  
5.5 CONCLUSIONS 
A considerable proportion of children aged under 12 years use prescription and OTC medi-
cines in Finland. Young age and health-related factors, morbidity and health status, and pa-
rental medicine use predicted children’s medicine use. However, our results do not support 
some previous findings about differences in medicine use according to the socioeconomic 
characteristics of the parent. The finding of the association between parents’ and children’s 
medicine use is interesting and needs further investigation.  
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6 Parental Reporting of Adverse Drug Events and Other 
Drug-Related Problems in Children2 
6.1 INTRODUCTION  
Medicines are commonly prescribed to children, and pharmacotherapy is most common in 
infants and toddlers less than 2 years of age (Sturkenboom et al. 2008, Carrasco-Garrido et al. 
2009, Ylinen et al. 2010). Previous studies have indicated that drug-related problems (DRPs) 
are of major clinical relevance and are a significant public health concern in paediatric pop-
ulations in terms of mortality, morbidity and healthcare costs (Impicciatore et al. 2001, Moore 
et al. 2002, Easton-Carter et al. 2003, Temple et al. 2004, Johann-Liang et al. 2009). Typical 
DRPs in children include adverse drug reactions (ADRs), incorrect medication, the child not 
receiving the prescribed medicine, and poisonings (Easton et al. 1998, Easton-Carter et al. 
2003, Easton et al. 2004, Kimland et al. 2007). If one considers paediatric hospital admissions 
due to ADRs, then up to 39% of the ADRs are assessed as being life threatening (Impicciatore 
et al. 2001). Most of the adverse drug events (ADEs) reported to the FDA in 1997–2000 con-
cerning infants were serious, with 61% resulting in death, disability or some other serious 
outcome (Moore et al. 2002).  
Under-reporting of ADRs to spontaneous reporting systems is widespread (Hazell and 
Shakir 2006). It has been estimated that rarely more than 20% of serious ADRs, and 10% of 
all reactions, are actually reported. In the UK, the Commission on Human Medicines (CHM) 
and the Medicines and Healthcare Products Regulatory Agency (MHRA) encourages 
healthcare professionals to report for newer medicines and vaccines all suspected reactions, 
but only serious reactions for established medicines (The Medicines and Healthcare Products 
Regulatory Agency 2012)*. In the USA, healthcare professionals and their patients are en-
couraged to report only serious adverse events to Med Watch, The FDA Safety Information 
and Adverse Event Reporting Program (Med Watch 2012). Thus, reports on children to the 
national adverse event reporting systems mostly concern serious ADEs (Moore et al. 2002, 
Johann-Liang et al. 2009, Aagaard et al. 2010b). However, it is important to obtain much more 
information about suspected ADRs in paediatric pharmacotherapy in order to detect any 
signals of ADRs as early as possible (Star 2011). Moreover, in children the processes of ongo-
ing growth and development may lead to medication effects which are not encountered in 
adults. 
Parents are the key individuals in the detection of ADEs and other DRPs in their children. 
Parental reporting of ADRs has been demonstrated to be feasible. For example, Tobaiqy et al. 
(2011) found that the ADR reports by parents were clear, concise, and relevant for paediatric 
pharmacovigilance. Unlike the situation in USA, Canada and Australia, at the time of the 
present study there was no system in most European countries, including Finland, for pa-
tients or parents themselves to report perceived events to the adverse event reporting sys-
tems (Health Canada 2012, Med Watch 2012, Therapeutic Goods Administration 2012). In 
this respect, the UK was an exception with the spontaneous reporting system, UK Yellow 
Card Scheme, run by the MHRA. A nationwide pilot scheme was launched for parents, carers 
                                                          
2Adapted with kind permission of Springer from: Lindell-Osuagwu L, Sepponen K, Farooqui S, Kokki H, Hämeen-Anttila 
K, Vainio K. Parental reporting of adverse drug events and other drug-related problems in children in Finland. Eur J Clin 
Pharmacol 69: 985–994, 2013.   
*Web page last modified: 09 May 2013: “All suspected adverse reactions in children are encouraged to report, even if they 
occurred with an established drug.” 
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and patients to report ADRs directly to the MHRA in 2005. The proportion of ADR reports 
on patients below 17 years received from parents and carers has increased over time, even 
though the numbers of reports are low compared with reports submitted by nurses and phy-
sicians (Hawcutt et al. 2012).  
Epidemiological information on drug-related problems in paediatric pharmacotherapy in-
cluding ADEs is limited. Most previous studies provide information on hospitalised children 
or information from outpatient clinics and national databases and therefore there is lack of 
population-based information on paediatric DRPs (Easton et al. 1998, Impicciatore et al. 2001, 
Easton-Carter et al. 2003, Easton et al. 2004, Le et al. 2006, Moore et al. 2007, Clavenna and 
Bonati 2009a, Johann-Liang et al. 2009, Aagaard et al. 2010a). No population-based reports in 
English of parental reporting of DRPs in children were found in our systematic searches from 
PubMed, Scopus and International Pharmaceutical Abstracts. In addition, to the best of our 
knowledge, only a few reports have been published on ADRs or ADEs from the parents’ 
perspective (Woods et al. 1987, Buajordet et al. 2002, Oshikoya et al. 2009, Knopf and Du 2010, 
Tobaiqy et al. 2011). The aim of this study was to survey the lifetime prevalence and type of 
DRPs in children below 12 years of age in Finland. The secondary aims were to evaluate the 
organ-systems affected by ADEs, serious and unexpected ADEs and the medicines associated 
with DRPs. 
6.2 METHODS 
Population and sample 
A population-based survey was performed in spring 2007, with a sample of 6 000 children 
aged below 12 years. The study sample was selected from the Finnish Population Register by 
random sampling at the end of 2006, excluding children in institutional care or under cus-
tody, or in situations with a restraining order on the parent. The International Conference on 
Harmonization (ICH) and Committee for Proprietary Medicinal Products (CPMP) guidelines 
define children as 0–11 years and adolescents as 12–17 years of age (ICH Guidelines 2012); 
hence, the age criterion below 12 years was selected. After the mailing of initial question-
naires, two reminders were sent to non-respondents at 4 and 8 weeks. The response rate after 
the initial mailing was 47%, after the first reminder 62%, and after the second reminder the 
final response rate was 67%, with a study population of 4032 children. Questionnaires were 
completed by the mother (95%), father (4%), or both (1%). A more detailed description of the 
study population and study design can be found in Ylinen et al. (2010) and Hämeen-Anttila 
et al. (2010). 
 
Survey design 
The data were collected through a six-page pilot-tested questionnaire, containing closed 
(n=17) and open-ended (n=13) questions. The questions were divided into the following sec-
tions: demographic information on both the child and respondent (parent), for the child the 
health status, medicine use including any DRPs experienced, and for the parent, medicine 
use and attitudes towards medicines, and the source of information about medicines. Most 
of the questions were designed to be comparable with those used in previous investigations 
into medicine use in Finland. The questionnaire was sent to either the parents or guardian of 
the child in the country’s two official languages, Finnish and Swedish. The parent who 
mainly takes care of the child’s medication issues was asked to answer the questions. The 
name of the child was printed on the questionnaire and erased after the questionnaire was 
returned in a prepaid envelope. In this report, the terms respondent and parent are used 
interchangeably, referring to the person who filled in the questionnaire. Answering the ques-
tionnaire after reading the covering letter describing the study was considered provision of 
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informed consent. Parents volunteered by returning the questionnaire and their privacy and 
that of their child were protected throughout the research process.  
 
Outcome measures  
The main outcome measure of this study was the proportion of children with a DRP. The 
number and type of DRPs and medicines were collected with the following two questions:  
 
1. Has any medicine ever caused harm to the child? If so, list the harmful effects and all 
the medicines that have caused them. 
2. Have there been any other problems with the child’s medication? If so, what kinds of 
problems? Also list the medicines that have caused these problems.  
 
A total of 3 964 parents answered the first and 3 926 responded to the second question. 
The reported problems with the child’s medication were classified into two main classes: 
ADEs and other DRPs. The ADEs were classified according to the MedDRA® (the Medical 
Dictionary for Regulatory Activities, version 10.0) terminology. The terms that the parents 
provided were matched for MedDRA®-terms in order to be as consistent as possible. The 
term ADE is used, since it was not possible to assess the causal relationship between a med-
icine and a drug-related harmful effect experienced (Uppsala Monitoring Centre 2013a). In 
addition, an ADE was classified as serious when the parent reported that the ADE had re-
quired hospital admission or the prolongation of a hospital stay, had resulted in persistent 
or significant disability or incapacity, or had threatened the child’s life. An ADE was classi-
fied as unexpected if it was not mentioned in the valid and approved summary of product 
characteristics (SmPC). Other DRPs were classified as problems in administration or dosing, 
delayed treatment or access to treatment, problems in counselling, and other problems. Med-
icines were classified according to the World Health Organization’s Anatomical Therapeutic 
Chemical (ATC) classification system.  
To ensure the validity of the study, a parallel classification of all DRPs was carried out. 
The classifications were completed independently by two pharmacists (ADEs: SF and LLO, 
other DRPs: J. Kuusamo and LLO). Any differences (12%) in classification were discussed 
between the authors and a consensus was reached. A clinician with pharmacovigilance ex-
perience (HK) was consulted as needed. The cross-check of classifying the ADEs as serious 
or unexpected was conducted by the same clinician. 
 
Statistical analysis 
The IBM SPSS Statistics 19.0.0.1 software was used for entering and analysing the data. De-
scriptive statistics were used, i.e. frequencies, percentages, and cross-tabulation. Associations 
of the ADEs with health-related and other characteristics of the child and parent were quan-
tified by using proportions (%) and their 95% confidence intervals (95% CIs), which were 
calculated by using the R© software version 2.14.0 (R Foundation for Statistical Computing). 
The associations between categorical variables were determined using the Chi-squared test. 
Group differences were considered statistically significant if a p value was <0.05 or if the 95% 
CIs for two rates did not overlap.  
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6.3 RESULTS  
At least one DRP was reported by 824 (21%, 95% CI 20–22) respondents. Out of all children 
of respondents, 688 (17%, 95% CI 16–19) had experienced at least one ADE, 203 (5.2%, 95% 
CI 4.5–5.9) had experienced other DRPs, and 67 (1.7%, 95% CI 1.3–2.1) children had experi-
enced both ADEs and other DRPs. Most of the children with a suspected ADE had experi-
enced either one (n=440; 64%) or two (n=155; 23%) ADEs. However, six children had experi-
enced six to eight ADEs, and a 2-year-old girl and an 8-year-old boy had experienced a total 
of 10 ADEs. The reporting of ADEs according to the characteristics of the child and parent 
are presented in Table 14.  
 
Table 14. Number and proportion of all children and children with an adverse drug event ac-
cording to the child’s and parent’s characteristics. 
 
Parameter  All children  
(n=3 964) 
 Children with an 
ADE (n=688) 
Pearson x2 
  n Percentage  n Percentage 
(95% CI) 
p-value 
Gender        0.055 
Girl  1 889 48  305 16 (15–18)  
Boy  2 075 52  383 19 (17–20)  
Age at the time of the 
study, years 
      0.298 
0‒2  993 25  179 18 (16–21)  
3‒6 
7‒11 
 1 264 
1 707 
32 
43 
 231 
278 
18 (16–21) 
16 (16–18) 
 
Birth order       <0.001 
First 
Second 
≥Third 
 1 639 
1 301 
1 008 
41 
33 
25 
 335 
226 
124 
20 (19–23) 
17 (15–20) 
12 (10–15) 
 
No. of children in the household      0.001 
1 
2 
3 
≥4 
 661 
1 630 
977 
673 
17 
41 
25 
17 
 127 
308 
166 
82 
19 (16–22) 
19 (17–21) 
17 (15–20) 
12 (10–15) 
 
Health status, rated by the parent      <0.001 
Good  3 194 81  468 15 (13–16)  
Fairly good  623 16  157 25 (22–29)  
Moderate or poor  132 3  55 42 (33–51)  
No. of illnesses diagnosed by a 
physician 
     <0.001 
0  3 232 82  487 15 (14–16)  
1  546 14  148 27 (23–31)  
≥2  164 4  49 30 (23–38)  
Present medicine use by the child      <0.001 
No medicine in use  2 764 70  393 14 (13–16)  
Rx and/or OTC 
medicine in use 
 1 158 29  280 24 (22–27)  
Parent’s age, years       0.001 
≤30  848 21  177 21 (18–24)  
31‒45  2 821 71  477 17 (16–18)  
≥46  251 6  28 11 (8–16)  
Parent’s level of education      0.015 
≤10   243 6  26 11 (7–15)  
11–13  2 407 61  420 17 (16–19)  
≥14 years  1 283 32  235 18 (16–21)  
Parent’s healthcare education      <0.001 
Yes  990 25  227 23 (20–26)  
No  2 949 74  456 16 (14–17)  
ADE, adverse drug event; CI, confidence interval; OTC, over-the-counter; Rx, prescription medicine 
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Adverse drug events 
The most common site for the reported ADEs (n=1106), was the gastrointestinal (GI) tract 
followed by the skin and subcutaneous tissue (Table 15). With respect to individual ADEs, 
the most common were drug rash (23%), antibiotic-associated diarrhoea (10%), urticaria 
(5.4%), allergic reaction to antibiotics (5.4%), drug ineffectiveness (5.3%), nausea and vomit-
ing (4.6%), stomach upset (4.6%), stomach pain (3.0%), loose bowel (2.8%), diarrhoea (1.9%), 
and restlessness (1.7%). 
 
Table 15. Adverse drug events (ADEs) in children (n=3 964) according to MedDRA® classifica-
tion 
 
 ADEs 
n (%) 
Children with an ADE 
n (%) 
System involved (SOC)   
Gastrointestinal 372 (34) 277 (7) 
Skin and subcutaneous tissue disorders 284 (26) 256 (6) 
General disorders and administration site  
conditions 
125 (11) 106 (3) 
Immune system 120 (11) 96 (2) 
Psychiatric disorders 97 (9) 56 (1) 
Nervous system disorders 28 (3) 20 (<1) 
Infections  16 (1) 15 (<1) 
Metabolism and nutrition disorders  13 (1) 10 (<1) 
Respiratory, thoracic and mediastinal disorders    12 (1) 11 (<1) 
Cardiac disorders 7 (1) 7 (<1) 
Musculoskeletal and connective tissue disorders 6 (<1) 5 (<1) 
Investigations 5 (<1) 5 (<1) 
Eye disorders 4 (<1) 4 (<1) 
The type of ADE not specified by the parent 17 (2) 17 (<1) 
   
Total 1 106 (100) 688 (17) 
SOC, System Organ Class in the MedDRA®, Medical Dictionary for Regulatory Activities® classification 
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Serious adverse events 
Fifteen of children (0.4%, 95% CI 0.2–0.6), experienced serious ADEs, requiring hospital ad-
mission or the prolongation of a hospital stay, or that were life threatening (Table 16). Anti-
biotics were associated with eight serious ADEs in 7 children. Vaccines and medicines affect-
ing the nervous system induced serious ADEs in 3 children. Insulin therapy induced insulin 
shock in a 10-year-old boy, and medicines used to treat otitis had induced intestinal villi at-
rophy in a 7-year-old girl. No persistent disabilities or incapacities were reported. 
 
Table 16. Serious adverse drug events in 15 children 
 
SOC ADE term in MedDRA® Medicine associated 
with ADE 
Gastrointestinal disorders Intestinal villi atrophya Medicines used to treat 
otitis  
 Antibiotic-associated diarrhoea Amoxicillin  
   
Infections Diarrhoea, Clostridium difficile Antibiotic  
 Intestinal infection due to Clostridium dif-
ficile 
Antibiotic  
 Abdominal infection Antibiotic  
 Tuberculosisa  Calmette's vaccine  
   
General disorders and ad-
ministration site conditions 
Malignant hyperthermia  Anaesthetics  
 Fever, injection site redness Vaccine  
   
Metabolism and nutrition 
disorders 
Hyponatremia Oxcarbazepine  
 Insulin shock, insulin hypoglycaemia Insulin  
   
Nervous system disorders Epilepsy Anaesthetics  
   
Several SOCs Melena, drug rash, stomach pain Antibiotic  
 Melena, mucous membrane disorder  Beta-lactamase-sensitive 
penicillins  
 
 
Growth retardationa, malabsorptiona, otitisa, 
drug rash 
PDT-vaccine  
 Dyspnoea, drug rash Beta-lactam antibacteri-
als, penicillins  
ADE, adverse drug event; PDT, pertussis-diphtheria-tetanus vaccine; SOC, System Organ Class in 
MedDRA®, the Medical Dictionary for Regulatory Activities  
aAlso an unexpected ADE 
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Unexpected adverse events 
In 31 children (0.8%, 95% CI 0.5–1.1), the reported ADEs were unexpected, i.e. they were not 
consistent with information in the approved SmPC (Table 17). Antibiotics were associated 
with eight unexpected ADEs in 6 children, and analgesics and antipyretics, including non-
steroidal anti-inflammatory drugs (NSAID), with six unexpected ADEs in 6 children. Selec-
tive beta-2-adrenoreceptor agonists were associated with eight unexpected ADEs in 4 chil-
dren, cough preparations with three unexpected ADEs in 3 children, and antiepileptics with 
five unexpected ADEs in 3 children. In 3 children, the unexpected ADEs were serious, re-
quiring hospital admission. 
 
Table 17. Unexpected adverse drug events in 31 children 
 
SOC ADE term in MedDRA®  
 
Medicines associated 
with ADE 
Gastrointestinal disorders Constipation (2) Cefalexin, salbutamol 
Intestinal villi atrophya (1) Medicines used to treat 
otitis  
Vomiting (3) Paracetamol   
Stomach pain (1) Paracetamol  
Diarrhoea (1) Hydroxyzine  
Rectal prolapse (1) Suppositories 
   
General disorders and ad-
ministration site conditions 
Sweating (1) Sotalol  
 Unspecified delay in development (1) Vigabatrin  
 Unable to walk (1) Diazepam  
   
Infections Tuberculosisa (1) Calmette's vaccine  
   
Musculoskeletal and con-
nective tissue disorders 
Joint swelling (1) Amoxicillin  
   
Nervous system disorders Convulsion (1) Penicillin  
 Consciousness disturbed (1) Opium derivatives and 
expectorants  
   
Psychiatric disorders Irritability, restlessness (1) Trimethoprim  
 Nightmare (2) Paracetamol, salbuta-
mol 
 Nightmare, crying, hallucination (1) Salbutamolb,  
terbutalineb   
 Insomnia (1) Valproic acid  
   
Respiratory, thoracic and 
mediastinal disorders 
Dyspnoea (1) Cefaclor  
 Runny nose (1) Ibuprofenb, ketoprofenb  
 Bleeding nose (1) Cetirizine  
   
Skin and subcutaneous tis-
sue disorders 
Drug rash (2) Ethylmorphine  
   
Several SOCs  Growth retardationa, malabsorptiona, otitisa (1) PDT-vaccine  
 House dust allergy, asthmatic attack (1) Antibiotic  
 Flaccidity, sleepy (1) Cisapride  
 Absence seizures, ocular deviation,  
constipation (1) 
Phenobarbitalc,  
valproic acidc  
 Drug-induced delirium, screaming, fumbling 
(1) 
Salbutamol  
ADE, adverse drug event; PDT, pertussis-diphtheria-tetanus vaccine; SOC, System Organ Class in 
MedDRA®, the Medical Dictionary for Regulatory Activities  
aAlso a serious ADE 
bTwo medicines used separately at two different times but reported to induce the same ADEs 
cTwo medicines in concomitant use 
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Other drug-related problems 
Of the reported other DRPs (n=240), the most common were problems with the administra-
tion and dosing of the medicine (86%, 95% CI 81–90). The reasons for these problems were 
difficulties in swallowing; the bad taste of the medicine; spurting or pouring out the dose; 
too large a dose volume, especially in oral liquids; the child could not or did not want to take 
the medicine; technical problems with the formulation, container or other equipment; and 
lack of dosing directions in patient information leaflets of prescribed medicines. Antibiotics 
were associated with 34% of the administration and dosing problems (n=207), and analgesics 
and antipyretics, including NSAIDs, with 14%. The second most common (6.6%) problem in 
other DRPs was delayed treatment or access to treatment, followed by problems in counsel-
ling (2.9%), and other unspecified problems (4.2%).  
 
Medicines associated with drug-related problems 
Parents named a total of 960 medicines that had been associated with a DRP. More than half 
of them (64%, 95% CI 61–67) were anti-infectives for systemic use, followed by medicines for 
the respiratory system (10%), and for the nervous system (8.4%). Amoxicillin was associated 
with DRPs more commonly (19%) than any other single medicine. Vaccines were associated 
with ADEs 13 times, but were not associated with other DRPs. The medicines suspected of 
causing ADEs are presented in Table 18. The number and type of DRPs in commonly re-
ported medicines are presented in Table 19. Most children with ADEs and other DRPs had 
had one (n=581; 84% and n=166; 82%, respectively) or two (n=91; 13% and n=36; 18%, respec-
tively) medicines, and only one had had five medicines associated with DRPs.  
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Table 18. Medicines associated with suspected adverse drug events in children (n=3 964) 
 
 Number of medicines 
associated with an ADE  
n (%) 
 
Anti-infectives for systemic use  
 
540 (66) 
 J01 antibacterials for systemic use  527 (65) 
   J01CA04 amoxicillin 175 (22) 
J07 vaccines 
 
13 (2) 
Respiratory system 74 (9) 
 R03 drugs for obstructive airway diseases 33 (4) 
   R03AC02/R03CC02 salbutamol 18 (2) 
 R05 cough and cold preparations  
 
27 (3) 
Nervous system 58 (7) 
   N02BE01 paracetamol 23 (3) 
   N05BB01 hydroxyzine 
 
9 (1) 
Alimentary tract and metabolism 46 (6) 
   A11CC01 ergocalciferol  
 
29 (4) 
Musculoskeletal system 32 (4) 
   M01AE01 ibuprofen 16 (2) 
   M01AE02 naproxen 
 
14 (2) 
Sensory organs 8 (1) 
   S01AA13 fusidic acid  
 
3 (<1) 
Dermatologicals 
 
8 (1) 
Antineoplastic and immunomodulating agents 9 (1) 
   L01BA01 methotrexate  
 
7 (1) 
Cardiovascular system 6 (1) 
   C07AA07 sotalol  
 
2 (<1) 
Blood and blood forming organs 6 (1) 
   B03AA07 ferrous sulphate  
 
4 (<1) 
Antiparasitic products, insecticides and repellents 2 (<1) 
   P01BA02 hydroxychloroquine  
 
2 (<1) 
Hormonal preparations for systemic use, excluding sex hormones  
and insulins 
3 (<1) 
   H02AB06 prednisolone  1 (<1) 
   H04AA01 glucagon  
 
1 (<1) 
N02/M01 unspecified pain and fever medicines 
 
3 (<1) 
Medicines used to treat otitis 
 
1 (<1) 
Unknown medicinesa 17 (2) 
  
Total 813 (100) 
ADE, adverse drug event 
aThe name of the medicine was not mentioned or was unclear  
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6.4 DISCUSSION 
In the present study, the lifetime prevalence of DRPs was 21%, which was clearly higher than 
the rates previously reported in other studies conducted with different methods and in dif-
ferent settings such as hospitals (Easton et al. 1998, Easton-Carter et al. 2003, Easton et al. 
2004) and a drug information centre (Kimland et al. 2007). Additionally, the proportion and 
type of DRPs reported by the parents in the present survey differ from those in previous 
studies where health professionals were responsible for detecting, assessing and reporting 
the DRPs. Since the parents are physically the closest persons to the child, not only at home, 
but also during any hospitalization, they are most likely to notice most common, minor, and 
also unexpected ADEs, and encounter other DRPs; therefore, the finding of a higher DRP 
prevalence in the present study is not unexpected. The health of the child is of paramount 
concern to parents and they will likely remember DRPs. The study undertaken in a Norwe-
gian University Hospital indicates that the reporting frequency of suspected ADEs by physi-
cians was as low as 6%, whereas parents reported 13% of ADEs, even though a specific study 
was in progress in the physicians’ department (Buajordet et al. 2002). Physicians recorded 
the most serious and complicated ADEs, while parents tended to detect central nervous sys-
tem reactions and GI reactions. Parents’ role in reporting seems to be important, especially if 
the health care professionals appear to pay little attention to DRPs.  
The present rate of ADEs (17%) is consistent with earlier findings from two studies where 
parents reported ADRs, even though the study periods and data collection approaches were 
different (Woods et al. 1987, Oshikoya et al. 2009). Woods et al. reported the prevalence of 
ADRs with a mean follow-up time of 11 weeks to be 17% in 1 590 children aged between 3 
and 11 years. In a study with a 3-month follow-up period conducted by Oshikoya et al., the 
prevalence of ADRs was 18% in 2 868 children aged below 12 years. A significantly lower 
prevalence was found in a large German study where physicians asked the parents about the 
child’s medication and possible ADRs within the 7 days prior to the interview (Knopf and 
Du 2010). The prevalence of perceived ADRs in children below 11 years of age was 1.2%. This 
setting, a physician’s interview, and a short study period, may explain the reason for the 
significantly lower prevalence of ADRs compared with that of ADEs found in the present 
study.  
In most previous studies concerning ADRs or ADEs in children, the study settings have 
been hospitals, outpatient clinics and/or national databases (Impicciatore et al. 2001, Le et al. 
2006, Moore et al. 2007, Clavenna and Bonati 2009a, Johann-Liang et al. 2009, Aagaard et al. 
2010a, Smyth et al. 2012). The incidence rates of ADRs, study periods, and the way in which 
the data were collected have varied greatly in these studies. In their review of 33 paediatric 
ADR studies, Aagaard et al. (2010a) reported that the average annual incidence of ADRs in 
paediatric outpatients was 14% and that in inpatients was 42%. In national ADR databases, 
the annual incidence of ADRs was <1%. The reported incidence rates of ADRs in general are 
lower in national databases and in outpatient settings than in hospitalised children. Under-
reporting is a characteristic feature of the national databases (Hazell and Shakir 2006). In the 
Finnish national register for ADRs in the years 1973–2006, there were 1 203 registered reports 
of ADRs in children below 16 years of age (Kalliokoski et al. 2007). Furthermore, most ADR 
reports were concerned with children aged 1–2 years. Since the 1990s, the annually reported 
number of paediatric ADR cases has been within the range 24 to 69, which are low numbers 
relative to the population of 967 664 Finnish children below 16 years of age in 2006 (Kallio-
koski et al. 2007, Official Statistics of Finland 2011).  
The number of reported serious and unexpected ADEs was relatively small in our study 
population. Parents were not asked to define the seriousness of ADEs or the interventions or 
activities that had been undertaken to resolve the problem. However, some parents reported 
these issues, such as hospitalisation, spontaneously. It was also not possible to assess the 
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relationship that might have existed between the medicine and the ADE. It is possible that 
an underlying disease might have caused some of the problems reported. However, physi-
cians and other healthcare professionals should be aware that medicines may act in unex-
pected ways in children, and furthermore not all the possible ADRs are described in SmPC 
texts.  
In the present study, as well as in previous studies, the two most commonly reported 
ADEs were GI, skin and subcutaneous tissue disorders (Bourgeois et al. 2009, Clavenna and 
Bonati 2009a, Oshikoya et al. 2009, Aagaard et al. 2010a, Smyth et al. 2012). Of the other DRPs, 
the most common were problems with the administration and dosing of the medicine. This 
might be partly due to medicine formulations that are not suitable for paediatric populations. 
For example, with oral medicines, the taste, odour and texture are important (Nunn 2003). 
The ability to take and use different dosage forms is influenced by the child’s age, state of 
physiological and psychological development, and health status (Nunn 2003, European Med-
icines Agency 2006, Costello et al. 2007). Consequently, different dosage forms should be 
available for those medicines intended for use in all age groups to ensure feasible, simple, 
accurate and safe dosing. Administration and dosing problems are also affected by the atti-
tudes, knowledge and skills of the parents (Sepponen et al. 1999, Sanz 2003, Costello et al. 
2004). Therefore, counselling the parents about administration is also important. 
The medicines that children most commonly use are those for obstructive airway diseases, 
anti-infectives, analgesics and antipyretics, cough and cold preparations and vitamins (Stur-
kenboom et al. 2008, Carrasco-Garrido et al. 2009, Ylinen et al. 2010). In the present study, 
over half of the medicines reported to be associated with ADEs and other DRPs were anti-
infectives, which probably reflect how commonly these medicines are used in children. This 
finding is also consistent with reports from other ADE or ADR studies in paediatric pharma-
cotherapy (Bourgeois et al. 2009, Clavenna and Bonati 2009a, Aagaard et al. 2010a, Smyth et 
al. 2012). 
The study population is a representative sample of Finnish children in terms of age and 
gender (Hämeen-Anttila et al. 2010, Ylinen et al. 2010). Hence, we may generalise the results 
to represent the lifetime prevalence of DRPs among Finnish non-institutionalised children 
below 12 years of age. However, there is the possibility of recall bias since the parents were 
asked to report the DRPs covering the child’s whole lifespan. No information on the age at 
which the child had the DRP was available. For the same reason, DRPs in different age groups 
could not be detected. The relatively high response rate (67%) may reflect the parents’ views 
about the importance of medicines and issues related to pharmacovigilance in their children. 
Patients can contribute significantly to successful pharmacovigilance, according to studies 
comparing ADR reporting by patients and healthcare professionals (Herxheimer et al. 2010). 
The added scientific value of patient reports has been also identified by the countries with 
existing patient reporting schemes (van Hunsel et al. 2012). In the European Union, the Eu-
ropean Medicines Agency implemented new legislation in July 2012, which provides patients 
with the possibility of reporting ADEs directly to their national medicine authority through 
an online reporting system (Directive 2010/84/EU). The Member States should openly en-
courage all stakeholders, including patients to report. Reporting of ADEs by parents will be 
valuable not only for the earlier signal detection of symptomatic reactions to new medicines, 
but also for the detection of unexpected ADRs in special populations such as children. Fur-
ther investigations are needed to reveal how patient reporting can affect signal detection in 
paediatric pharmacovigilance. 
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6.5 CONCLUSIONS 
One fifth of the children below 12 years of age had experienced DRPs in Finland. ADEs were 
the most frequent DRPs in children reported by the parents. Appropriate counselling, includ-
ing information on possible adverse effects and advice on dosing, is important for parents 
and children, both at the prescribing and dispensing of the medicine. Parents need to be en-
couraged to report suspected ADEs to healthcare professionals and other authorities. In or-
der to improve paediatric pharmacovigilance, any suspected ADRs that are not consistent 
with the approved marketing authorisation, or that are serious, should always be reported. 
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7 Off-label and Unlicensed Drug Prescribing in Three 
Paediatric Wards in 2001 and Review of the International 
Literature3 
7.1 INTRODUCTION 
The regulatory system for drug licensing and clinical trials generally ensure high quality, 
safety and efficacy of marketed medicinal products. Unfortunately, usually clinical drug tri-
als are conducted mainly in adults; hence physicians must often prescribe drugs for children 
to be given in ways and for conditions not approved in the marketing authorisation (MA), 
and for which clinical trial evidence of safety and efficacy is sparse. Of all the active sub-
stances licensed by the European Agency for the Evaluation of Medicinal Products (EMEA) 
during October 1995 to September 2005, only 33 % were licensed for use in children, 23% in 
infants and 9% in newborns (Ceci et al. 2006). As a consequence, the use of drugs outside the 
terms of the MA (off-label use) and the use of drugs with no MA (unlicensed use) is wide-
spread in paediatric pharmacotherapy (Turner et al. 1998, Conroy et al. 1999, Conroy et al. 
2000, ‘t Jong et al. 2000, Conroy and Peden 2001, McDonnell 2001, Pandolfini and Bonati 2005, 
Cuzzolin et al. 2006). This is a concern because adverse drug reactions in children may be 
more common with unlicensed and off-label treatment than with drugs licensed for paediat-
ric use, and the practice may result in either over- or underdosing of drugs in different age 
groups (Turner et al. 1999, Horen et al. 2002, Ufer et al. 2004). The new Regulation 
(1901/2006/EC) of the European Parliament and Council on medicinal products for paediatric 
use came into force in January 2007. This Regulation requires clinical trials to be done also in 
the paediatric population, especially, if children are likely to benefit from a new drug. The 
regulation also allows pharmaceutical companies to update the summary of the product 
characteristics (SPC) of authorised drugs used off-label on children by submitting, to the reg-
ulatory authorities, accumulated data on safety or efficacy in this age group, and undertaking 
new paediatric trials.  
Prescribing of drugs for off-label and unlicensed use has been described in studies from 
North and South America, Australia, the Middle East and Europe (Cuzzolin et al. 2006). 
These studies show that the situation varies across countries because of the differences in 
authorisation status of medicinal products and clinical practice. We initiated the present 
study to assess the prescribing of unlicensed drugs and of drugs off-label for children in Kuo-
pio University Hospital (KUH), Finland. The new Regulation (1901/2006/EC) of the European 
Parliament and Council on medicinal products for paediatric use obliges the Member States, 
including Finland, to collect available data on use of medicinal products in the paediatric 
population. Thus, this study provides valuable information on current practice in Finland 
and reviews international studies of such prescribing for hospitalised children. 
 
  
                                                          
3Adapted with kind permission of John Wiley and Sons from: Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen 
M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of 
the international literature. J Clin Pharm Ther 34: 277–287, 2009. 
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Review of the international literature 
Reports of prescribing of drugs off-label and of unlicensed drugs for hospitalised children 
were retrieved through electronic searches of Medline (PubMed) and International Pharma-
ceutical Abstracts (IPA), using list of keywords representing pharmaceutical preparations, 
paediatric population, different hospital departments, and off-label and unlicensed drug pre-
scribing (Appendix 2). The search included reports published in English between the years 
1990 and 2007.  
Twenty-four studies, from 12 different countries, mostly European (n=8), were identified 
for inclusion in this review. The study periods ranged from 4 weeks to 2 years. Most of the 
studies were prospective (n=19) and more than half included at least 100 children.  The stud-
ies report the frequency of prescribing off-label and unlicensed drugs for children in neonatal 
intensive care units (NICUs), paediatric intensive care units (PICUs), medium-care units 
(MCUs), surgical intensive care units (SICUs), paediatric general and acute care/emergency 
department, cardiology, gastroenterology, oncology, psychiatry, isolation and surgical 
wards. Some studies focused on neonates or infants (n=4) (Conroy et al. 1999, Barr et al. 2002, 
O’Donnell et al. 2002, Dell’Aera et al. 2007), paediatric pain management (Conroy and Peden 
2001) or adverse drug reactions associated with off-label and unlicensed drug use (Turner et 
al. 1999, Neubert et al. 2004).  
The number of patients studied ranged from 34 to 355 409 and their age from less than 1 
day to 18 years (Table 20). The number of prescriptions or prescription and drug episodes 
studied ranged from 176 to 4455. In two studies, the number of prescriptions was not indi-
cated. 
The definition of off-label drug use and unlicensed drug varied between different studies. 
Therefore, the results are not directly comparable but give an overall picture of the issue. The 
most common (15/24) definitions, as used by Turner et al. (1997, 1998, 1999), describe off-label 
use as the use of drugs outside the terms of the MA, with regard to dose, age group, route of 
administration, different indication or contraindication in children. Unlicensed drugs are de-
fined as modified formulations including extemporaneous preparations, drugs or formula-
tions with ‘specials’ manufacturing licence, and imported drugs and chemicals used as 
drugs. In addition, three reports used very similar classifications.   
The national medicine compendia (British Pharmaceutical Industry’s Data Sheet Compen-
dium, Physician’s Desk Reference, Australian Prescription Products Guide, Swedish Physi-
cian’s Desk reference, Rote Liste, Informatore Farmaceutico, Repertorium and Farmacother-
apeutisch Kompas, Israel Drug Compendium, National French compendium Vidal, Yugo-
slav National Formulary, Swiss Drug Compendium) were the primary sources of infor-
mation, followed by package inserts and manufacturers. Manufacturers were contacted 
mainly if the information was ambiguous or to confirm the licensing status. In seven studies, 
a secondary or additional source of information was the British National Formulary. 
The proportion of children with at least one prescription for off-label use or unlicensed 
drug ranged from 36 to 100% in 19 studies (Table 20). Four studies reported the proportion 
of children with a prescription for off-label use (range 43%−93%). In four studies, the propor-
tion of children receiving prescriptions for off-label use or unlicensed drug was not reported.  
 
 
 
 Ta
bl
e 
20
. 
S
um
m
ar
y 
of
 s
tu
di
es
 r
ep
or
ti
ng
 o
f 
pr
es
cr
ib
in
g 
of
 O
L 
an
d/
or
 U
L 
dr
ug
s 
fo
r 
ho
sp
it
al
is
ed
 c
hi
ld
re
n 
in
 c
hr
on
ol
og
ic
al
 o
rd
er
. 
 C
ou
n
tr
y 
(R
ef
er
en
ce
) 
M
et
h
od
 a
n
d
 
st
u
d
y 
p
er
io
d
 
S
tu
d
y 
w
ar
d
s 
or
 t
yp
e 
of
 
p
at
ie
n
ts
 
N
o.
 o
f 
p
at
ie
n
ts
 
A
g
e 
of
 p
a-
ti
en
ts
 
N
o.
 o
f 
p
re
-
sc
ri
p
ti
o
n
s 
O
L 
of
 a
ll 
p
re
-
sc
ri
p
-
ti
o n
s 
 
%
 
U
L 
of
 a
ll 
p
re
sc
ri
p
-
ti
on
s 
 
 %
 
P
at
ie
n
ts
 
re
ce
iv
in
g
 
O
L 
or
 U
L 
 
 %
 
U
S
a 
M
cK
in
zi
e 
et
 a
l. 
19
97
  
R
 
1 
m
on
th
 
Pa
ed
ia
tr
ic
 e
m
er
ge
nc
y 
de
-
pa
rt
m
en
t 
35
9 
<
18
 y
ea
rs
 
 
- 
- 
- 
43
 O
L 
U
K
 
Tu
rn
er
  
et
 a
l. 
19
98
  
P 13
 w
ee
ks
 
S
ur
gi
ca
l a
nd
 m
ed
ic
al
 
pa
ed
ia
tr
ic
 w
ar
ds
 
60
9 
 
 
4 
da
ys
 t
o 
20
 
ye
ar
s 
2 
01
3 
18
 
 
7 
36
 
U
K
 
C
on
ro
y 
et
 a
l. 
19
99
  
P 13
 w
ee
ks
 
N
IC
U
 
70
  
 
N
eo
na
te
s 
45
5 
 
 
55
 
 
10
  
 
90
 
U
K
 
Tu
rn
er
 e
t 
al
. 
19
99
  
P 13
 w
ee
ks
 
S
ur
gi
ca
l, 
m
ed
ic
al
, 
ne
on
a-
ta
l s
ur
gi
ca
l, 
ca
rd
ia
c 
IC
U
, 
PI
C
U
 
1 
04
6 
1 
da
y 
to
 1
8 
y e
ar
s 
 
4 
45
5 
35
 O
L 
or
 U
L 
48
 
A
us
tr
al
ia
 
Tu
rn
er
 1
99
9 
 
P 5 
w
ee
ks
 
S
ur
gi
ca
l a
nd
 g
en
er
al
 
pa
ed
ia
tr
ic
 w
ar
ds
 
20
0 
 
49
 d
ay
s 
to
18
 
ye
ar
s 
73
5 
dr
ug
 e
pi
-
so
de
s 
16
 O
L 
or
 U
L 
36
  
U
K
, 
S
w
ed
en
, 
It
al
y,
 G
er
m
an
y,
  
N
et
he
rl
an
ds
 
C
on
ro
y 
et
 a
l. 
20
00
  
P 4 
w
ee
ks
 
 
Pa
ed
ia
tr
ic
 w
ar
ds
 in
 5
 
ho
sp
it
al
s 
62
4 
 
  
4 
da
ys
 t
o 
16
 
ye
ar
s 
2 
26
2 
39
  
 
7 
 
 
67
 
 
Is
ra
el
 
G
av
ri
lo
v 
et
 a
l. 
20
00
  
R
 
2 
m
on
th
s 
Pa
ed
ia
tr
ic
 a
m
bu
la
to
ry
 
se
rv
ic
e 
13
2 
 
 
1 
m
on
th
 t
o 
18
 
ye
ar
s 
22
2 
 
26
 
 
8 
42
 
 
U
K
 
C
on
ro
y 
an
d 
Pe
de
n 
20
01
  
P 4 
w
ee
ks
 
A
cu
te
 m
ed
ic
al
 a
nd
 a
cu
te
 
su
rg
ic
al
 w
ar
d 
- 
- 
71
5 
pr
es
cr
ip
-
tio
n 
ep
is
od
es
 
33
 
0 
- 
N
et
he
rl
an
ds
 
‘t 
Jo
ng
 e
t 
al
. 
20
01
  
P 5 
w
ee
ks
 
M
C
U
, 
N
IC
U
, 
S
IC
U
, 
PI
C
U
 
23
7 
0−
17
 y
ea
rs
 
2 
13
9 
18
 
 
48
 
 
92
 
Is
ra
el
 
B
ar
r 
et
 a
l. 
20
02
  
P 4 
m
on
th
s 
N
IC
U
 
10
5 
N
eo
na
te
s 
52
5 
 
59
 
16
 
93
  
A
us
tr
al
ia
 
O
’D
on
ne
ll 
et
 a
l. 
20
02
  
P 10
 w
ee
ks
 
N
IC
U
 
97
 
 
In
fa
nt
s 
1 
44
2 
47
 
11
 
80
 
It
al
yb
 
Pa
nd
ol
fin
i e
t 
al
. 
20
02
  
P 12
 w
ee
ks
 
9 
ge
ne
ra
l p
ae
di
at
ri
c 
w
ar
ds
 in
 d
iff
er
en
t 
ho
sp
i-
ta
ls
 
1 
46
1 
1 
m
on
th
 t
o 
14
 
ye
ar
s 
4 
26
5 
60
 
0.
2 
89
 O
L 
O
L,
 o
ff
-l
ab
el
; 
U
L,
 u
nl
ic
en
se
d;
 N
IC
U
, 
ne
on
at
al
 in
te
ns
iv
e-
ca
re
 u
ni
t;
 I
C
U
, 
in
te
ns
iv
e 
ca
re
 u
ni
t;
 P
IC
U
 p
ae
di
at
ri
c 
in
te
ns
iv
e-
ca
re
 u
ni
t;
 M
C
U
, 
m
ed
iu
m
-c
ar
e 
un
it;
 S
IC
U
, 
su
rg
i-
ca
l i
nt
en
si
ve
-c
ar
e 
un
it;
 P
, 
pr
os
pe
ct
iv
e;
 R
, 
re
tr
os
pe
ct
iv
e.
 
Pr
es
cr
ip
tio
n 
ep
is
od
es
: 
ea
ch
 e
pi
so
de
 b
ei
ng
 a
 c
ou
rs
e 
of
 a
 d
ru
g 
or
 a
 s
in
gl
e 
on
e 
of
f 
do
se
. 
D
ru
g 
ep
is
od
es
: 
th
e 
su
m
 o
f 
th
e 
nu
m
be
r 
of
 d
iff
er
en
t 
dr
ug
s 
ad
m
in
is
te
re
d 
du
ri
ng
 e
ac
h 
pa
tie
nt
 a
dm
is
si
on
. 
a O
ff
-l
ab
el
 d
ru
g 
us
e 
w
as
 d
ef
in
ed
 a
s 
us
e 
of
 a
 s
pe
ci
fic
 d
ru
g 
in
 a
 p
at
ie
nt
 y
ou
ng
er
 t
ha
n 
th
e 
FD
A
-a
pp
ro
ve
d 
ag
e 
ra
ng
e 
fo
r 
an
y 
in
di
ca
tio
n 
of
 t
ha
t 
dr
ug
. 
b O
ff
-l
ab
el
 d
ef
in
iti
on
 d
iff
er
en
t,
 in
cl
ud
es
 f
or
m
ul
at
io
n 
th
at
 h
as
 b
ee
n 
m
od
ifi
ed
. 
 
Ta
bl
e 
20
. 
(c
on
ti
nu
es
)
60 
 
   Ta
bl
e 
20
. 
(c
on
ti
nu
es
) 
 
 
 
C
ou
n
tr
y 
(R
ef
er
en
ce
) 
M
et
h
od
 a
n
d
 
st
u
d
y 
p
er
io
d
 
S
tu
d
y 
w
ar
d
s 
or
 t
yp
e 
of
 
p
at
ie
n
ts
 
N
o.
 o
f 
p
at
ie
n
ts
 
A
g
e 
of
 p
a-
ti
en
ts
 
N
o.
 o
f 
p
re
-
sc
ri
p
ti
o
n
s  
O
L 
of
 a
ll 
p
re
-
sc
ri
p
-
ti
on
s 
 
%
 
U
L 
of
 a
ll 
p
re
sc
ri
p
-
ti
on
s 
 
 %
 
P
at
ie
n
ts
 
re
ce
iv
in
g
 
O
L 
or
 U
L 
 
 %
 
N
et
he
rl
an
ds
c 
‘t 
Jo
ng
 e
t 
al
. 
20
02
  
P 5 
m
on
th
s 
Pa
ed
ia
tr
ic
 w
ar
d 
an
d 
ne
o-
na
to
lo
gy
 u
ni
t 
29
3 
 
0 
da
y 
to
 1
6.
7 
ye
ar
s 
1 
01
7 
44
 
28
 
92
 
B
ra
zi
ld
 
C
ar
va
lh
o 
et
 a
l. 
20
03
  
P 6 
w
ee
ks
 
PI
C
U
 
51
 
1 
m
on
th
 t
o 
13
 
ye
ar
s 
74
7 
50
 
11
 
10
0 
O
L 
88
 U
L 
U
K
 
C
on
ro
y 
et
 a
l. 
20
03
  
P 4 
w
ee
ks
 
Pa
ed
ia
tr
ic
 o
nc
ol
og
y 
pa
-
tie
nt
s 
51
 
7 
m
on
th
s 
to
 
16
 y
ea
rs
 
56
9 
pr
es
cr
ip
-
tio
n 
ep
is
od
es
 
26
 
19
 
10
0 
U
K
 
D
ic
k 
et
 a
l. 
20
03
  
R
 
>
6 
m
on
th
s 
Pa
ed
ia
tr
ic
 g
as
tr
oe
nt
er
ol
-
og
y 
un
it
 
30
8 
20
 d
ay
s 
to
 1
7 
ye
ar
s 
77
7 
37
 
12
 
- 
Is
ra
el
 
G
av
ri
lo
v 
et
 a
l. 
20
03
  
R
 +
 P
 
3 
+
 4
 m
on
th
s 
2 
PI
C
U
s 
15
8 
6 
da
ys
 t
o 
18
 
ye
ar
s 
 
87
4 
40
 
41
 
83
 
G
er
m
an
y 
N
eu
be
rt
 e
t 
al
. 
20
04
  
P >
8 
m
on
th
s 
Pa
ed
ia
tr
ic
 is
ol
at
io
n 
w
ar
d 
17
8 
5 
da
ys
 t
o 
17
 
ye
ar
s 
74
0 
26
 
0.
4 
52
 
Fr
an
ce
e 
S
er
re
au
 e
t 
al
. 
20
04
  
P 6 
m
on
th
s 
C
hi
ld
 a
nd
 a
do
le
sc
en
t 
ps
yc
hi
at
ry
 d
ep
ar
tm
en
t 
16
2 
 
3−
15
 y
ea
rs
 
29
5 
25
 
23
 
- 
S
er
bi
a 
an
d 
M
on
te
ne
gr
o 
B
aj
ce
tic
 e
t 
al
. 
20
05
  
P >
2 
ye
ar
s 
Pa
ed
ia
tr
ic
 c
ar
di
ol
og
y 
de
-
pa
rt
m
en
t 
54
4 
4 
ho
ur
s 
to
 1
8 
ye
ar
s 
2 
03
7 
47
 
11
 
76
 
U
S
a 
Ei
la
nd
 a
nd
 K
ni
gh
t 
20
06
  
P 6 
m
on
th
s 
Pa
ed
ia
tr
ic
 g
en
er
al
 w
ar
d 
40
3 
 
3 
da
ys
 t
o 
18
 
ye
ar
s 
1 
38
3 
31
 
- 
- 
S
w
itz
er
la
nd
 
D
i P
ao
lo
 e
t 
al
. 
20
06
  
P >
6 
m
on
th
s 
N
eo
na
ta
l, 
PI
C
U
, 
in
te
rm
e-
di
at
e 
ca
re
, 
m
ed
ic
al
 a
nd
 
su
rg
ic
al
 w
ar
d 
60
 
0−
13
.7
 y
ea
rs
 
48
3 
25
 
24
 
10
0 
It
al
y 
D
el
l’A
er
a 
et
 a
l. 
20
07
  
P 2 
m
on
th
s 
N
IC
U
 
34
 
N
eo
na
te
s 
17
6 
51
 
12
 
88
 
U
S
f 
S
ha
h 
et
 a
l. 
20
07
  
R
 
1 
ye
ar
 
31
 h
os
pi
ta
ls
 
35
5 
40
9 
≤
18
 y
ea
rs
 
 
- 
- 
- 
79
 O
L 
O
L,
 o
ff
-l
ab
el
; 
U
L,
 u
nl
ic
en
se
d;
 N
IC
U
, 
ne
on
at
al
 in
te
ns
iv
e-
ca
re
 u
ni
t;
 I
C
U
, 
in
te
ns
iv
e 
ca
re
 u
ni
t;
 P
IC
U
 p
ae
di
at
ri
c 
in
te
ns
iv
e-
ca
re
 u
ni
t;
 M
C
U
, 
m
ed
iu
m
-c
ar
e 
un
it
; 
S
IC
U
, 
su
rg
i-
ca
l i
nt
en
si
ve
-c
ar
e 
un
it
; 
P,
 p
ro
sp
ec
tiv
e;
 R
, 
re
tr
os
pe
ct
iv
e.
 
Pr
es
cr
ip
tio
n 
ep
is
od
es
: 
ea
ch
 e
pi
so
de
 b
ei
ng
 a
 c
ou
rs
e 
of
 a
 d
ru
g 
or
 a
 s
in
gl
e 
on
e 
of
f 
do
se
. 
D
ru
g 
ep
is
od
es
: 
th
e 
su
m
 o
f 
th
e 
nu
m
be
r 
of
 d
iff
er
en
t 
dr
ug
s 
ad
m
in
is
te
re
d 
du
ri
ng
 e
ac
h 
pa
tie
nt
 a
dm
is
si
on
. 
c O
ff
-l
ab
el
 d
ef
in
iti
on
 in
cl
ud
es
 c
on
tr
ai
nd
ic
at
io
n 
fo
r 
ce
rt
ai
n 
pa
tie
nt
 (
b-
bl
oc
ke
rs
 in
 c
hi
ld
re
n 
w
ith
 a
st
hm
a)
, 
 
an
d 
de
fin
iti
on
 o
f 
un
lic
en
se
d 
dr
ug
s:
 n
o 
do
sa
ge
 in
fo
rm
at
io
n 
fo
r 
ch
ild
re
n 
or
 c
on
tr
ai
nd
ic
at
ed
 f
or
 c
hi
ld
re
n.
 
d T
he
 d
ef
in
iti
on
s 
of
 o
ff
-l
ab
el
 d
ru
g 
us
e 
an
d 
un
lic
en
se
d 
dr
ug
s 
de
vi
at
e 
si
gn
ifi
ca
nt
ly
 f
ro
m
 t
he
 d
ef
in
iti
on
s 
us
ed
 b
y 
Tu
rn
er
 e
t 
al
. 
 
e T
he
 d
ef
in
iti
on
 o
f 
un
lic
en
se
d 
dr
ug
 in
cl
ud
es
 d
ru
gs
 t
ha
t 
ar
e 
lic
en
se
d 
fo
r 
ad
ul
ts
 b
ut
 n
ot
 r
ec
om
m
en
de
d 
in
 c
hi
ld
re
n 
an
d 
dr
ug
s 
w
ith
 n
o 
in
fo
rm
at
io
n 
on
 u
se
 in
 c
hi
ld
re
n.
 
f O
ff
-l
ab
el
 d
ru
g 
us
e 
w
as
 d
ef
in
ed
 a
s 
us
e 
of
 a
 s
pe
ci
fic
 d
ru
g 
in
 a
 p
at
ie
nt
 y
ou
ng
er
 t
ha
n 
th
e 
FD
A
-a
pp
ro
ve
d 
ag
e 
ra
ng
e 
re
ga
rd
le
ss
 o
f 
in
di
ca
tio
n.
 
 
61 
62 
 
The proportion of prescriptions for off-label use ranged from 18 to 60% (20 studies) (Table 
20). The proportion of prescriptions for unlicensed drugs ranged from 0 to 48% (19 studies). 
Two studies reported the proportion of prescriptions for off label use combined with the 
proportion of prescriptions for unlicensed drugs (16% and 35%). 
The most frequent reason (in 12 studies) for off-label prescriptions was deviation from 
dosage recommendation followed by deviation from approved age range. The most frequent 
reason (in 15 studies) for prescriptions of unlicensed drugs was modification of licensed 
drugs.  
Thirteen studies, reported that the age-group most commonly receiving prescriptions for 
off-label use was adolescents (in two studies 66% and 69.7%) (Neubert et al. 2004, Pandolfini 
et al. 2002). Similarly, the age-groups most commonly receiving unlicensed drugs were neo-
nates, infants and children less than 2-year old (‘t Jong et al. 2002, Di Paolo et al. 2006). 
Eight studies included NICUs or other neonatal wards (Conroy et al. 1999, Turner et al. 
1999, ‘t Jong et al. 2001, Barr et al. 2002, O’Donnell et al. 2002, ‘t Jong et al. 2002, Di Paolo et 
al. 2006, Dell’Aera et al. 2007). The proportion of infants who received either prescription for 
off-label use or unlicensed drugs ranged from 80 to 93% in four NICUs (Conroy et al. 1999, 
Barr et al. 2002, O’Donnell et al. 2002, Dell’Aera 2007). In addition, ‘t Jong et al. (2001) reported 
that infants and newborns in NICU had high use of home-label prescriptions (41%). Simi-
larly, in year 2002, ‘t Jong et al. reported that the number of patients receiving one or more 
unlicensed or off-label drug prescriptions was higher in newborns and small infants (98% 
compared with 88% in all children).  Bajcetic et al. reported that in paediatric cardiology de-
partment the neonates received the largest proportion of off-label drugs, and Di Paolo et al. 
reported that infants and toddlers (1–23 months) received more unlicensed drugs (33%) than 
other groups. 
In studies mainly from intensive care units (n=9), the proportion of children receiving ei-
ther prescription for off-label use or unlicensed drugs is high (range 80–100%). Similarly, all 
children with malignancies and 76% of cardiologic patients received at least one prescription 
for off-label use or unlicensed drug (Conroy et al. 2003, Bajcetic et al. 2005).  
The most common single drug prescribed off-label was salbutamol (in seven studies). For 
unlicensed drugs, the variation among studies was wide. Caffeine was mentioned in three 
studies among the commonest unlicensed drugs. 
7.2 METHODS 
We reviewed prospectively the prescriptions for patients aged below 18 years admitted to 
three children’s wards; NICU, general paediatric ward and paediatric surgical ward of KUH. 
The data were collected during a 2-week period in each of the wards between 16 April and 
25 May 2001. KUH is one of the five University Hospitals in Finland. In 2001, KUH provided 
tertiary level treatment for a population of 860 000 inhabitants with 183 000 children aged 
below 18 years (Statistics Finland).  
From the patient records at the wards, we recorded each patient’s age, gender, date of 
birth, weight and diagnoses. For each drug prescribed, indication for use, dose, frequency, 
intended route of administration and dosage form were recorded.  We did not include cyto-
statics, standard intravenous replacement solutions, flushes of 0.9% sodium chloride or hep-
arin, blood products, oxygen, nutritional and technical products, basic creams and ointments, 
or drugs in clinical trials. Drugs were classified according to the World Health Organization’s 
Anatomical Therapeutic Chemical (ATC) classification system. We classified all drugs pre-
scribed in terms of their drug-licensing status, i.e. licensed, off-label and unlicensed, using a 
previously described classification system (Turner et al. 1997, 1998) and according to the ap-
proved SPC texts in the Finnish drug formulary, Pharmaca Fennica (2001).  
To ensure the validity of the study, we did a parallel classification of the drug-licensing 
status. Two different pharmacists completed the classification independently. There were no 
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differences in these two parallel classifications of off-label and unlicensed and licensed drug 
classes. Moreover, to test the reliability of the study parallel data with 15 patients, who re-
ceived 120 prescriptions, were collected. The differences between the two data collections 
were slight and not significant; i.e. two different persons were able to collect the same infor-
mation. 
A total of 141 children; 37 in the NICU, 65 in the general paediatric ward and 39 in the 
children’s surgical ward were treated in KUH during the 2-week study period (Table 21). 
The children’s median age was 1.6 years and 75 (53%) children were below 2 years of age.  
The study population was considered as a representative sample of the patients in the 
three paediatric wards of KUH. The diagnoses of children in the study population were typ-
ical illnesses and conditions treated in the three wards. The children in the NICU were mainly 
(23/37) ex-preterm or preterm infants who had problems because of their prematurity (74/91 
of recorded the diagnoses). In the NICU, many children had respiratory distress syndrome, 
which is typical for preterm infants. In the general ward, the most common diagnoses were 
respiratory diseases and infections (30/109 of the recorded diagnoses); and in the surgical 
ward, most of the children (25/39 of the patients) had surgical procedures under general or 
regional anaesthesia. The median of the follow-up-time per child was 3 days (range 0–12 
days).  
Data were analysed with the Statistical Package for Social Sciences (SPSS software version 
11.5 for Windows; SPSS Inc, Chicago, IL, USA). The differences in proportions between the 
three wards were compared with Pearson’s chi-square test and those in continuous variables 
with the Kruskal-Wallis test. A p-value of 0.05 or less was considered significant. This study 
was approved by the hospital’s medical administrator.  
7.3 RESULTS 
One hundred and eight of the 141 children, 28/37 in the NICU, 46/65 in the general and 34/39 
in the surgical ward received at least one prescription (Table 21). A total of 629 prescriptions, 
155 in the NICU, 152 in the general ward and 322 in the paediatric surgical ward were pro-
vided. The mean number of prescriptions per child was less, 4.2±4.4 (range 0–19) in the NICU 
and 2.3±2.5 (range 0–11) in the general, than in the surgical ward, 8.3±6.4 (range 0–23) pre-
scriptions (p=0.002 compared with NICU and p=0.001 compared with general ward). 
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Table 21. Number of children with different types of prescriptions in the three paediatric wards 
studied. 
 
Ward Study Popula-
tion 
 
 
Children with 
a prescription 
for licensed 
drug 
Children with 
an off-label 
prescription 
 
Children with 
a prescription 
for unlicensed 
drug 
Total number 
of  children 
with a pre-
scription 
 n (%) n (%) n (%) n (%) n (%) 
Neonatal inten-
sive care unit 37 (26) 6 (23) 20 (28) 15 (42) 28 (26) 
General ward 65 (46) 17 (65) 20 (28) 16 (44) 46 (43) 
Surgical ward 39 (28) 3 (12) 31 (44) 5 (14) 34 (31) 
           
Total 141 (100) 26 (100) 71 (100) 36 (100) 108 (100) 
 
Of the 108 children with a prescription, 82 (76%) children, 79% in the NICU, 63% in the gen-
eral ward and 91% in the surgical ward (p=0.014), were prescribed at least one drug for off-
label use or unlicensed drug. Seventy one (66%) children received prescriptions for off-label 
use, 36 (33%) for unlicensed drugs, and 25 (23%) got both types of prescriptions.  Of all pre-
scriptions (n=629), 51% were for licensed drugs, 36% for off-label use and 13% for unlicensed 
drugs (Table 22). 
 
Table 22. Off-label prescriptions and prescriptions for unlicensed drugs in the different paediat-
ric age groups. 
 
Age groups Study popula-
tion 
 
Prescriptions 
for licensed 
drugs 
Off-label pre-
scriptions 
 
Prescriptions 
for unlicensed 
drugs 
Total number 
of prescrip-
tions 
 n (%) n (%) n (%) n (%) n (%) 
Newborns  
(0–27 days) 28 (20) 30 (9) 15 (7) 9 (11) 54 (9) 
Infants and tod-
dlers 
(28 days to 23 
months) 
47 (33) 107 (33) 76 (34) 62 (76) 245 (40) 
Children 
(2–11 years) 53 (38) 128 (40) 103 (45) 10 (12) 241 (38) 
Adolescents  
(12–17 years) 13 (9) 56 (18) 32 (14) 1 (1) 89 (14) 
 
          
Total 141 (100) 321 (51) 226 (36) 82 (13) 629 (100) 
 
The number of off-label prescriptions per child with a prescription ranged from 0 to 17 (me-
dian 1). The number of unlicensed drug prescriptions per child with a prescription ranged 
from 0 to 6 (median 0). Of the children with an off-label prescription, 36 (51%) and of those 
with prescriptions for unlicensed drugs 26 (72%) were below 2 years (Table 22).  
The classification of off-label prescriptions (n= 226) are shown in Table 23. Most of the off-
label prescriptions, 161 (71%) were given in the surgical ward, while 36 (16%) of the prescrip-
tions were provided in the NICU and 29 (13%) in the general ward. The classes of prescribed 
unlicensed drugs are shown in Table 24. Most of the prescriptions for unlicensed drugs, 58 
(71%) were given in the NICU, 19 (23%) in the general and five (6%) in the surgical ward. 
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Table 23. Off-label classes 
 
Reason for prescription being off-label  Off-label pre-
scriptions        
 n=226 (%) 
No directions for use in children or mention of children in the SPC 87 (38) 
Administration by an alternative route 77 (34) 
Outside dosage recommendations (dose, frequency, weight) 50 (22) 
Prescribed for off-label indication 43 (19) 
Outside approved age range 28 (12) 
Formulation not approved for use in children 5 (2) 
Not recommended for use in children 1 (<1) 
SPC, summary of product characteristics. One prescription can be off-label in several ways. 
Table 24. Classes of unlicensed drugs 
 
Unlicensed class Prescriptions        
 n=82 (%) 
Special licence for non-licensed drug (includes products released for consumption 
in individual cases for special therapeutic reasons) 
51 (62) 
Drugs prepared by the hospital pharmacy 27 (33) 
Modification of licensed drug 3 (4) 
Marketing authorisation expired 1 (1) 
   
Total 82 (100) 
 
Of all prescriptions in the NICU, 23% were for licensed drugs prescribed off-label and 37% 
for unlicensed drugs, in the general ward 19% and 13%, and in the surgical ward 50% and 
2%, respectively (p<0.001). 
The twenty most commonly prescribed drugs include over half (56%) of all prescribed 
drugs (Table 25). Only five drugs among the top 20 were prescribed according to the SPC 
and formulation had not been modified for use in children. According the ATC classification, 
the most commonly prescribed drugs in the NICU were drugs for alimentary tract and met-
abolic diseases and anti-infective drugs for systemic use, in the general ward anti-infective 
drugs for systemic use and drugs for diseases of the respiratory system, and in the surgical 
ward, drugs that affect the nervous system and anti-infective drugs for systemic use were the 
most commonly prescribed drugs. 
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Table 25. Twenty most frequently prescribed drugs (% of total 629) in the three children’s 
wards. 
 
Drug Prescriptions 
n (%) 
% of prescriptions 
off- label 
% of prescriptions 
for unlicensed 
drug 
Midazolam (only in surgical ward) 32 (5) 56 - 
Paracetamol 29 (5) 52 - 
Fentanyla 24 (4) 67 - 
Oxycodone (only in surgical ward) 22 (4) 100 - 
Ergocalciferol (Vitamin D2 ) 20 (3) 20 - 
Sevoflurane 19 (3) 0 - 
Thiopental 19 (3) 100 - 
Ferrous sulfate 18 (3) 0 89 
Ketaminea (only in surgical ward) 18 (3) 100 - 
Ketoprofena 18 (3) 94 - 
Benzylpenicillin (Penicillin G) 15 (2) 20 - 
Budesonidea 15 (2) 47 - 
Salbutamola 15 (2) 0 - 
Cefuroxime 14 (2) 0 - 
Netilmicin 13 (2) 8 - 
Cisatracurium 13 (2) 0 - 
Neostigmine (combined preparation) 13 (2) 0 - 
Mineral substances (only in NICU) 12 (2) b 100 
Ascorbic acid 
(Vitamin C) (only in NICU) 
11 (2) b 100 
Combined vitamin preparations 
(only in NICU) 
11 (2) b 100 
NICU, neonatal intensive care unit.  
0, prescriptions given according to the summary of product characteristics. 
aIncluded on the EMEA priority list for studies into off-patent paediatric medicinal products. 
bPrescribed only unlicensed drugs.  
7.4 DISCUSSION 
Our findings show that prescribing unlicensed drugs for children is as common in Finland 
as in other countries. The proportion of children who received either an unlicensed or an off-
label prescription or both in KUH was 76%, which is somewhat smaller than that (80–90%) 
described, in previous studies (Conroy et al. 1999, ‘t Jong et al. 2000, O’Donnell et al. 2002, 
Gavrilov et al. 2003). This could be explained by the differences in the study populations, 
with the previous study populations being mainly from PICUs. This study indicates that 
there may be significant differences across different types of paediatric wards.  
Drugs used during the perioperative period explain why children in the surgical ward 
most commonly received off-label prescriptions. One example of a drug prescribed off-label 
and used for pain in children in the surgical ward was oxycodone, a substance which has 
been in clinical use for 90 years and which is the most commonly used opioid for acute pain 
in Finland both in adults and in children (El-Tahtawy et al. 2006, National Agency for Medi-
cines and Social Insurance Institution 2006). However, in the SPC of oxycodone there are no 
directions for use in children (Pharmaca Fennica 2001). Until the incentives of the Regulation 
(1901/2006/EC) of the European Parliament and Council came into force in January 2007, ex-
panding the MA for an old product or developing a new formulation solely for a small pop-
ulation, such as children, was not profitable for the manufacturers. Now, a paediatric use 
marketing authorisation entitles a manufacturer to 10-year data protection and exclusivity 
for a new paediatric formulation of an old drug. The lack of suitable paediatric formulation 
was the reason why oxycodone, ketamine and midazolam, were prescribed for administra-
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tion by the alternative buccal route. Published clinical studies provide information on paedi-
atric pharmacokinetics of oxycodone and midazolam administered by different routes, in-
cluding buccal and oral delivery (Kogan et al. 2002, Kokki et al. 2004, Kokki et al. 2006). By 
using these more child-friendly administration routes, intramuscular administration, which 
is one of the most frightening scenarios for hospitalised children, could be avoided.  
Children in the NICU received the largest number of prescriptions for unlicensed drugs, 
again reflecting lack of suitable formulations for neonates and infants. The overall proportion 
of prescriptions for unlicensed drugs (13%) in our study was similar to that described by 
others (10–12%) in PICUs in France, Australia, Brazil and Italy (Avenel et al. 2000, O’Donnell 
et al. 2002, Carvalho et al. 2003, Dell’Aera et al. 2007). Prescribing unlicensed drugs may be 
essential and does not necessarily imply poor medical practice. When there was no alterna-
tive, many prescriptions in this study were prepared by the hospital pharmacy or used a 
modification of a licensed product. The sales of such drugs may be insufficient for industrial 
production. In our study, an example was an ascorbic acid drop, which is no longer marketed 
by pharmaceutical companies in Finland.  
Similar to other studies (Conroy et al. 1999, Avenel et al. 2000, O’Donnell et al. 2002, 
Conroy and McIntyre 2005), the age-group of children with the greatest demand was lower 
than 2-year-old group.  If the SPC of a drug includes an age restriction, it is usually a state-
ment to the effect that information on appropriate use for the youngest potential users is 
lacking. An overdose increases the risk of adverse drug reactions, whereas an underdose may 
not be therapeutically useful, e.g. sub-optimal doses of antibiotics do not cure infections and 
may select out resistant microbes.   
Implementing paediatric clinical trials is time-consuming and expensive. To increase the 
availability of suitable, licensed drugs for children in Europe, some legislative measures have 
been taken. First, the EU directive (2001/20/EC) concerns clinical trials in children and defines 
how to protect them in trials. Second, in 1997, the EMEA published ‘Note for Guidance on 
Clinical Investigation of Medicinal Products in the Paediatric Population’. This gives direc-
tions for testing drugs in children and has been in force since January 2001. Third, a European 
legislative initiative called ‘Better Medicines for Children’ had been under way since the late 
1990s, and led to a legislative process that was finalised at the time the paper was written. 
The regulation includes, among other things, a 6-month extension for the SPC as an incentive 
to the pharmaceutical industry. The 6-month extension is the same as that provided in the 
USA since 1997 (Food and Drug Administration).  
In our study, among the top 20 prescribed drugs, five are listed in the EMEA priority list 
(European Medicines Agency 2007), which identifies off-patent products for which paediat-
ric studies are required.  
The results of this study, in support of those of earlier studies, indicate that prescribing of 
off-label and unlicensed drugs is common not only in high dependency units but also in nor-
mal inpatient care. In our population, it was most common in the treatment of paediatric 
surgical patients. Therefore, to avoid exposing children to unnecessary risks and to avoid 
depriving them of potentially effective pharmacotherapy, both enforcement of legislation 
and continued incentives are needed to encourage the development of paediatric medicines.  
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8 Prescribing for Off-label Use and Unauthorised Medi-
cines in Three Paediatric Wards in Finland, the Status 
Before and After the European Union Paediatric Regula-
tion4 
8.1 INTRODUCTION  
In paediatric inpatients, the off-label use of medicines and use of unauthorised medicines are 
common.5 The availability of authorised and commercially available medicines for children 
of all approved medicines varies between 48% and 54% according to the recent studies con-
ducted in the Europe, Oceania and the United States of America (USA) (Young et al. 2009, 
Ragupathy et al. 2010, van Riet-Nales et al. 2011). The availability decreases according to age, 
neonates have the least appropriate medicines with respect to information available (van 
Riet-Nales et al. 2011). In addition to active ingredients, preservatives and other excipients 
constitute problems in paediatric pharmacotherapy. In the Netherlands, half (52%) of the oral 
liquid preparations and 7% of the parenteral preparations contain potentially harmful excip-
ients (van Riet-Nales et al. 2011). Also, this results in the need to use unauthorised prepara-
tions in paediatric inpatients. 
Off-label use is defined as all uses of an authorised medicine not described in the approved 
summary of product characteristics (SmPC), for example prescribing for a different indica-
tion or age than what is approved by the regulatory authority (Turner et al. 1997, Turner et 
al. 1998, Neubert et al. 2008), whereas unauthorised (or unlicensed) medicine has not received 
a marketing authorisation as medicinal use in a particular country. When there is no other 
option, off-label use or unauthorised medicine is necessary. The lack of authorised medicinal 
products and sufficient information on medicines in children results in problems. Firstly, the 
off-label and unauthorised use of medicines is suggested to be associated with increased ad-
verse drug reaction risk (European Medicines Agency 2004, Mason et al. 2012). Secondly, 
inadequate dosage information may result in ineffective treatment through under-dosage 
and treatment failures and overdosing may carry a risk of adverse effects without any ther-
apeutic benefits (Mukattash et al. 2011). Moreover, unauthorised medicine use is associated 
with an increased risk of medication errors, especially in neonates (Conroy 2011). Authoris-
ing more medicines for children would decrease the risk of dosing errors according to health 
professionals (Mukattash et al. 2011).  
In the European Union (EU) the Paediatric Regulation [The Regulation (EC) No 1901/2006] 
aims to reduce the need for off-label use in paediatric pharmacotherapy and to improve the 
information available to prescribers and families. This regulation enforces companies (i) to 
report experimental research results, (ii) to study medicines in the paediatric population and 
                                                          
4Adapted with kind permission of John Wiley and Sons from: Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, 
Naaranlahti T, Kokki H. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the 
status before and after the European Union Paediatric Regulation. J Clin Pharm Ther 39: 144–153, 2014.  
5Jain et al. 2008, Hsien et al. 2008, European Medicines Agency 2009, Lindell-Osuagwu et al. 2009, Dessi et al. 2010, Doherty 
et al. 2010, Neubert et al. 2010, Khdour et al. 2011, Lass et al. 2011, Nguyen et al. 2011, Dos Santos et al. 2012, Kimland and 
Odlind 2012, Kimland et al. 2012, Oguz et al. 2012, Palčevski et al. 2012, Slažneva et al. 2012, Ballard et al. 2013  
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(iii) to develop age-appropriate formulations for all new medicines pursuing marketing au-
thorisation in the EU, including also line extensions for patent-protected medicines.  
In 2001, we found that prescribing for off-label use and unauthorised medicines is com-
mon in paediatric wards in the Kuopio University Hospital (KUH) (Lindell-Osuagwu et al. 
2009). Our interest in this study is to evaluate what impact the recent EU legislation would 
have had if any in every day clinical practice in KUH in 2011. We hypothesised a reduction 
in prescribing medicines for off-label use, because the Paediatric Regulation came into force 
in 2007 to improve the information available. Hence, we repeated the 2001 study 10 years 
later and evaluated the possible change in prescribing medicines for off-label use and unau-
thorised medicines in the same tertiary teaching hospital in Eastern Finland at the same three 
paediatric wards and at the same time of the year, in April and May 2011.  
 
Review of the international literature, unpublished 
The following section will focus on studies describing the situation of prescribing for off-
label use and unauthorised medicines in paediatric inpatients, published after the year 2007. 
A review of the situation prior to the year 2008 is given at the beginning of chapter 7. To be 
considered relevant for this review, the articles had to describe off-label use and/or use of 
unauthorised medicines or prescribing in hospitalised children. The reports describing only 
restricted therapeutic class of medicines or certain route of administration or only patients 
with a certain type of condition or with the main focus on ADRs related to off-label use and 
use of unauthorised medicines were excluded. Reports of emergency department visits were 
not included because patients were considered to be outpatients, not hospitalised. Reports 
published in language other than English were excluded with one exception; a report from 
Austria published in German (Prandstetter et al. 2009). This meant unfortunately that some 
interesting reports and a review from China had to be excluded. 
The searches were conducted with the following electronic databases; Scopus (incl. EM-
BASE) and PubMed. Scopus is a large abstract and citation database of peer-reviewed re-
search literature from more than 5 000 international publishers. The main component of Pub-
Med is Medline but it also contains other data. The search was limited to articles appearing 
from June 2007 (because the previous review went until the end of the year 2007) and to end 
at September 2013. Search terms (MeSH) and keywords represented pharmaceutical prepa-
rations, prescriptions, hospitalised paediatric patients, and off-label and unauthorised med-
icines use (Appendix 2). The references in the published study reports and reviews were also 
examined in order to identify additional studies.  
Several studies had investigated off-label use, there were fewer examining unauthorised 
medicine use in paediatric inpatients. Twenty-four studies were identified for inclusion for 
this review; 9 from EU countries (Table 26), 3 from the USA (Table 27), and 12 from other 
countries (Table 28). The study periods ranged from 4 days to one year. Most of the studies 
were prospective (n=18). The number of patients ranged from 38 to 2947 in prospective stud-
ies, and from 81 to 10 782 in the retrospective studies. The number of prescriptions studied 
ranged from 88 to 11 294. Half (n=12) of the studies included a neonatal unit; 6 in the EU, 7 
included paediatric intensive care unit (PICU), 6 included general wards, 4 studies included 
operating room and post anaesthetic care units or surgical wards, 3 studies included oncol-
ogy units. One paediatric pneumology and one cardiology unit and some other unspecified 
units were among wards. There were five studies conducted solely in neonatal units in the 
EU and two from other countries.  
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The classification of off-label use and the use of unauthorised medicines have varied between 
studies, similarly also there were variations in the pharmaceutical preparations included in 
the studies and their authorisation status across countries. Therefore, all the study results 
cannot be compared directly but give an overall picture of the situation. The disparities in 
the classifications are described in the footnote of the tables summarising the studies (Tables 
26, 28). In three studies from the USA, the medicines were classified into the following cate-
gories: authorised (labelled) for all ages, authorised with age restrictions and no authorised 
indications for children aged <18 years (Table 27). 
In the EU countries, the vast majority (70–98%) of children in hospital care, mainly in NI-
CUs had received at least one prescription for off-label use or unauthorised medicine. Out-
side the EU, the situation was rather similar; 48–99% of hospitalised children received pre-
scriptions for the use of these kinds of medicines. Five studies reported the proportion of 
children with off-label prescriptions (range 57–96%). Three studies did not report any prev-
alence of patients receiving prescriptions either for off-label use or for unauthorised medi-
cine. 
The proportion of prescriptions for off-label use varied from 18% to 65% in 8 European 
studies. The higher rates were reported in studies involving intensive care units and the low-
est rate was described in a Slovak study with off-label definition limited to indication and 
age only. Furthermore, the medicines included in the studies vary, for example blood prod-
ucts were not included in all studies (Lass et al. 2011, Slažneva et al. 2012). The inclusion or 
exclusion of different pharmacological groups of medicines limits the comparison of study 
results. 
The proportion of prescriptions for unauthorised medicines varied from 6% to 22% (6 
studies). Most of the reports involved neonates in six EU countries (Table 26). One reason to 
account for these differences may be the variations in authorising status of medicines be-
tween countries. Furthermore, the definition of authorising status was not the same in all 
studies; in German and Estonian study unauthorised medicines were either imported medi-
cines or pure chemicals prepared into a formulation in the hospital pharmacy (Neubert et al. 
2010, Lass et al. 2011). They did not report inclusion of modifications of adult pharmaceutical 
formulations into paediatric versions by the hospital pharmacy as in other studies. Outside 
the EU, the respective proportions were 12–71% for off-label use (11 studies) and 6–34% for 
unauthorised medicines (8 studies) (Table 28). Nine studies did not report the use of unau-
thorised medicines. 
In the EU countries, the most common reasons for off-label prescribing were the absence 
of paediatric information in the SmPCs (Neubert et al. 2010, Lass et al. 2011, Kimland et al. 
2012), especially in neonates, and deviation due to age (Hsien et al. 2008, Dessi et al. 2010, 
Nguyen et al. 2011, Slažneva et al. 2012). In the studies outside the EU, deviation from the 
dosage information was the most common or among commonest reasons for off-label pre-
scribing (Jain et al. 2008, Bavdekar et al. 2009, Khdour et al. 2011, Ballard et al. 2013). 
The risk to receive at least one prescription for off-label use or unauthorised medicine is 
higher among the youngest paediatric inpatients. Thus, two out of every three of neonate 
patients had received such prescriptions in Swedish hospitals, compared to one in three ad-
olescents (Kimland et al. 2012). Similarly, although investigated in smaller study populations, 
paediatric inpatients aged 0–1 year had a higher risk to receive prescription for off-label use 
or unauthorised medicine than other age groups in Palestine and India (Jain et al. 2008, 
Khdour et al. 2011).  
The variation in the most commonly prescribed medicines for off-label use was wide and 
depended on the type of unit and the age of children studied and type of medicines included 
in the studies. In Swedish hospitals, the most commonly prescribed medicines for off-label 
use were medicines for the blood and blood-forming organs (e.g. carbohydrates, electrolytes, 
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sodium chloride), nervous system (e.g. paracetamol, morphine, midazolam), and the alimen-
tary tract and metabolism; and some of the most commonly prescribed off-label individual 
substances were paracetamol, epinephrine, morphine and midazolam (Kimland et al. 2012).  
In the EU neonatal units, most of the prescriptions were for off-label use, e.g. 100 % of 
anaesthetics and analgesics used in neonates or preterm neonates in a German NICU (Neu-
bert et al. 2010); this was also the case for the alimentary, genitourinary, musculoskeletal and 
sensory system medicines used in Estonian neonatal units (Lass et al. 2011). Furthermore, a 
very high proportion of cardiovascular medicines was for off-label use or unauthorised in 
neonates in the same units. There were very few prescriptions written according to the ap-
proved SmPCs. In Estonian neonatal units, only a small proportion of medicines were pre-
scribed according to the SmPCs; less than 3% of all the prescriptions. The medicines used 
according to the marketing authorisation in preterm neonates were phospholipids, midazo-
lam, erythropoietin-beta, ibuprofen and amikacin.  
In the USA, in 2005 it was also found that neonates were the group for whom there were 
the fewest approved the Food and Drug Administration guidelines (Hsu and Brazelton 2009). 
Many widely used medicines were lacking FDA-approved prescribing guidelines for neo-
nates e.g. ranitidine, morphine, fentanyl, propofol, midazolam, furosemide, cefuroxime, at-
ropine, lorazepam and epinephrine. 
Caffeine was among the most commonly mentioned substances of the unauthorised med-
icines in Italy, Germany, Estonia and Sweden of the EU countries (Dessi et al. 2010, Neubert 
et al. 2010, Lass et al. 2011, Kimland et al. 2012). In Sweden, it was among the most common 
extemporaneously prepared medicines (Kimland et al. 2012). However, caffeine has been au-
thorised for neonates for example in France (Nguyen et al. 2011). Other unauthorised indi-
vidual substances in the EU studies mentioned were extemporaneously prepared morphine 
and midazolam (Kimland et al. 2012), furosemide, heparin and dobutamine for neonates 
(Lass et al. 2011), magnesium sulphate and ferrous sulphate also for neonates (Dessi et al. 
2010), and calcium gluconate, indometacin and ibuprofen for neonates (Neubert et al. 2010). 
Many studies highlight that neonates receive a very high number of off-label prescriptions 
while they are in hospital care. The prevalence of paediatric inpatients with a prescription 
for off-label use or unauthorised medicine is very high, especially in intensive care units. In 
addition, most of the medicines that were used either in off-label manner or were unauthor-
ised, were compounds that have been used in paediatric inpatients for numerous years.  
Furthermore, it would be crucial to devise a uniform classification of off-label medicine 
use as well as defining unauthorised medicines. Even in studies conducted in the EU coun-
tries, no consistent terminology has been used. There has been an attempt to verify consensus 
on definitions by a Delphi survey which was conducted among scientists, health profession-
als, industry and regulatory agencies (at the European and national level) (Neubert et al. 
2008). The authors suggested that terminology should be added to the European Medicines 
Agency’s glossary. However, no full consensus was reached, and no definitions of off-label 
use or of unauthorised medicines have been added to the website (European Medicines 
Agency 2014b). 
8.2 METHODS 
As in the 2001study, all patients below 18 years of age treated in three paediatric wards; ne-
onatal intensive care unit (NICU), general paediatric ward and paediatric surgical ward of 
KUH during a 2-week study period in each ward in April and May were eligible for the study 
in 2011 (Lindell-Osuagwu et al. 2009). KUH is one of the five university teaching hospitals in 
Finland. The hospital provides tertiary level treatment for a population of 843 000 inhabitants 
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with 160 000 children below 18 years of age (Statistics Finland). During the decade, there had 
not been any major functional or structural changes that could have had an impact on the 
comparison of the two study periods in these three paediatric wards. 
The prescriptions for the patients admitted to the three wards were reviewed daily during 
the 2-week study period. The following information was recorded: gender, gestation, age, 
weight and height, body surface area, diagnosis and medicines prescribed during patient’s 
hospitalisation, including patient’s possible regular medication. Details from each prescrip-
tion were recorded: name of medicine, indication for use, intended route of administration, 
dose, frequency, dosage form, and first and final date of use. The information on patients and 
prescriptions was reviewed from the electronic medical records and paper records. The fol-
lowing products were excluded from the analysis: standard intravenous replacement solu-
tions, sodium chloride 0.9% and heparin used to maintain patency of intravenous and arterial 
lines, blood products, oxygen, total parenteral nutrition and technical products, basic cream 
and ointments, and medicines in clinical trials.  
 
Classifications 
The patients were classified into four age groups: newborns 0–27 days, infants 28 days–23 
months, children 2–11 years, and adolescents 12–18 years according to the International Con-
ference on Harmonization guideline on Clinical Investigation of Medicinal Products in the 
Pediatric Population. The diagnoses were classified according to the World Health Organi-
zation’s International Classification of Diseases-10, version 2010, and medicines according to 
the Anatomical Therapeutic Chemical classification system. If more than one course of the 
same chemical substance was prescribed, but to be administered via different route or differ-
ent dose/formulation within the same hospitalisation, the courses were recorded as separate 
prescriptions. All prescriptions were classified in terms of the medicine’s authorising status, 
that is, authorised, for off-label use and unauthorised, using a previously described classification 
system and according to the approved SmPCs valid at the time of prescribing in Finland 
(Turner et al. 1997, Turner et al. 1998, Finnish Medicines Agency). The term off-label was 
defined as any use outside the terms of the SmPC. In case of prescribed pharmaceutical prep-
aration having generic alternatives, all SmPCs were cross-checked. In classifying the pre-
scription off-label according to a dose, ±10% deviation from the reference was tolerated. One 
prescription could be classified into more than one off-label class. The term unauthorised was 
applied to pharmaceutical preparations that were not currently authorised in Finland, in-
cluding all kinds of modifications to authorised preparations.  
To ensure the validity of the study, two pharmacists (MH, LLO) completed independently 
a parallel classification of the medicines’ authorising status in 10% of the study population. 
The coefficient of agreement, Cohen’s kappa was 0.66 and considered substantial. Any dif-
ferences in parallel classifications were discussed between the authors and a consensus was 
reached. Moreover, to test the reliability, parallel data were collected by the two pharmacists 
with 16 patients receiving 162 prescriptions. The differences between the two data collections 
were minor, that is, two pharmacists were able to collect consistent information from the 
patient records. 
 
Ethical considerations 
The study protocol was approved by the Research Ethics Committee of the Hospital District 
of Northern Savo, Kuopio, Finland (no. 23/2011). The hospital’s medical administrator ap-
proved the entry to the patient records (no. 14/2011). To protect confidentiality, the final data 
were analysed without any personal identifiers. 
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Statistical analysis 
The IBM SPSS Statistics 19.0.0.1 software (IBM Corp., Armonk, NY, USA) was used for en-
tering and analysing the data. Descriptive statistics were used, that is, frequencies and per-
centages. The 95% confidence intervals (95% CIs) for percentages were calculated by using 
the R© -software version 2.14.0 (The R Foundation for Statistical Computing, Vienna, Aus-
tria). The differences in proportions were considered statistically significant if the 95% CIs 
for two proportions did not overlap. The two-sample test for equality of proportions with 
continuity correction in R© software was used to compare proportions of patients and pre-
scriptions. The independent-samples Mann-Whitney U-Test in SPSS was used to compare 
medians. A p-value of 0.05 or less was considered significant. 
8.3 RESULTS  
A total of 123 patients were treated in the three paediatric wards of KUH during the 2-week 
study period in 2011 and 141 patients in the 2001-study (Table 29). The majority of the pa-
tients were below 2 years of age (median age 19 months) in both years. The median of the 
follow-up-time per child was 3 days (range 1–12) in 2011 as was the case in 2001. In the study 
population, the diagnoses and conditions were typical for patients usually treated in the three 
wards studied and without any major differences between the two study periods (Table 29).  
 
Table 29. Characteristics of the study population 
 
 2011 
N=123 
n (%) 
2001 
N=141 
n (%) 
Girls 56 (46) 69 (49) 
Age groupa   
 Newborns (0–27 days) 25 (20) 33 (23) 
  Of which preterm  14 (11) 17 (12) 
 Infants (28 days–23 months)  41 (33) 42 (30) 
Children (2–11 years) 43 (35) 53 (38) 
Adolescents (12–15 years)  14 (11) 13 (9) 
Children in wards   
NICU 28 (23) 37 (26) 
General  68 (55) 65 (46) 
Surgical   27 (22) 39 (28) 
Most common diagnosesb   
NICU:Certain conditions originating in the perinatal period (P00–
P96)c 
25 (89) 31 (84) 
General: Diseases of the respiratory system (J00–J99)c 37 (54) 26 (40) 
Surgical: Diseases of the respiratory system (J00-J99)c  
                   Injury, poisoning and certain other consequences of  
               external causes (S00–T98)c 
10 (37) 
 
6 (22) 
4 (10) 
 
12 (31) 
Patients in surgical procedures under general or regional anaesthesia in 
the surgical ward 
 
18 (67) 
 
25 (64) 
NICU, neonatal intensive care unit 
aMedian age in months in 2011: 19 (range 0–189), in 2001: 19 (range 0–187) 
bMedian number of diagnoses per patient in 2011: 2 (range 0–12), in 2001: 2 (range 0–8) 
cThe codes according to the WHO’s International Classification of Diseases-10 system 
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In 2011 during the 2-week study period, most of the patients (97%, n=119) received at least 
one prescription, compared to 77% (n=108) in 2001 (95% CIs: 91–99 vs. 69–83; p<0.001). The 
total number of prescriptions was 68% higher in 2011 (n=1054) than that in 2001 (n=629; Table 
30). In 2011 the median number of prescriptions per patient was higher than 10 years earlier 
(6 vs. 2; p<0.001). The most commonly prescribed were medicines affecting nervous system: 
448 prescriptions for 106 patients in 2011 and 242 for 51 patients in 2001, and anti-infectives 
for systemic use: 137 prescriptions for 69 patients in 2011 and 106 for 64 patients in 2001. The 
increased number of prescriptions of medicines affecting nervous system was mostly due to 
increase in analgesic prescriptions: paracetamol (133 in 2011 vs. 29 in 2001), fentanyl (60 vs. 
24) and oxycodone (33 vs. 22; Table 31). In the NICU and general ward in particular, there 
was a notable increase in the number of medicines affecting nervous system, mostly analgesic 
prescriptions, for more children in 2011 (Figure. 9).  
 
Table 30. Number of prescriptions and patients according to age groups. 
 
 2011  2001  
 No. of 
prescrip-
tions  
Median 
no. of 
prescrip-
tions per 
patient 
(range) 
Patients 
with a 
prescrip-
tion/total 
no. of pa-
tients 
 No. of 
prescrip-
tions 
Median 
no. of 
prescrip-
tions per 
patient 
(range) 
Patients 
with a pre-
scrip-
tion/total 
no. of pa-
tients  
Newborns  
(0–27 days) 
263  9 (0–29) 24/25  111 2 (0–19) 23/33 
 Preterm  205 15 (2–29) 14/14  97 5 (0–19) 16/17 
Infants  
(28 days–23 months) 
256 5 (0–33) 39/41  188 4 (0–19) 33/42 
Children (2–11 years) 390 9 (0–36) 42/43  241 2 (0–23) 42/53 
Adolescents  
(12–15 years) 
145 11 (1–20) 14/14  89 7 (0–15) 10/13 
        
Total  1 054 6 (0–36) 119/123  629 2 (0–23) 108/141 
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ATC system, World Health Organization’s Anatomical Therapeutic Chemical classification system 
A Alimentary tract and metabolism; B Blood and blood forming organs; C Cardiovascular system; D Dermatologicals; 
G Genitourinary system and sex hormones; H Systemic hormonal preparations, excl. sex hormones and insulins; J 
Anti-infectives for systemic use; L Antineoplastic and immunomodulating agents; M Musculoskeletal system; N Nerv-
ous system; P Antiparasitic products; R Respiratory system; S Sensory organs; V Various 
NICU, neonatal intensive care unit 
 
Figure 9. Number of patients and number of prescribed medicines according to the ATC system 
in the three paediatric study wards.  
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The proportion of patients with at least one prescription for off-label use or for unauthorised 
medicine was significantly higher in the 2011 study, 79% (n=97) compared to the 2001 study, 
58% (n=82; 95% CIs: 70–86 vs. 50–66; p<0.001) (Unpublished Figure 10). In 2011, all patients 
in the NICU with a prescription (n=27) received medicines either for off-label use or for un-
authorised medicine, that is, there was no patient who received prescriptions only for au-
thorised use. In the general ward 20/66 and in the surgical ward 2/26 patients with a prescrip-
tion received only authorised medicines and according to the SmPC. In 2011, newborns re-
ceived significantly more prescriptions for off-label use than in 2001 (51%, 95% CI 45–57 vs. 
22%, 95% CI 15–32; p<0.001; Figure 11). In both years, the proportion of prescriptions for 
unauthorised medicines was similarly higher in children below 2 years of age than in older 
children (21% vs. 5% in 2011 and 24% vs. 3% in 2001, p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Proportion of patients with different types of prescriptions in the three paediatric 
wards studied. Unpublished 
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Figure 11. Proportion of prescriptions for authorised, unauthorised medicines and for off-label 
use according to age. 
 
The proportion of patients receiving prescriptions for off-label use was significantly higher 
in the 2011 study than in the 2001 study: 71% (n=87) of the patients received at least one 
prescription for off-label use in 2011, compared to 50% (n=71) in 2001 (95% CIs: 62–78 vs. 42–
59; p=0.001). In 2011, the prescriptions were more likely to be off-label for the following rea-
sons: outside the dosage recommendations (n=182) and approved age range (n=104); and in 
2001: no directions for use in children (n=87) and administration by an alternative route 
(n=77; Figure 12). In 2011, the medicines most commonly prescribed for off-label use were 
fentanyl (n=50), paracetamol (n=41), salbutamol (n=35) and midazolam (n=31), and in 2001 
oxycodone (n=22), thiopental (n=19), midazolam (n=18) and ketamine (n=18; Table 31). 
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Figure 12. Proportion of prescriptions in off-label classes (one prescription can be off-label sev-
eral ways). Error bars indicate 95% CIs on independent proportions. BSA, body surface area. 
 
The proportion of patients receiving unauthorised medicines was significantly higher in 2011 
than in 2001: in the 2011 study, 53% (n=65) of patients received at least one prescription for 
unauthorised medicine, compared to 26% (n=36) in 2001 (95% CIs: 44–62 vs. 19–34; p<0.001). 
In both years, unauthorised medicines prescribed were most commonly those with a special 
license, that is, they were authorised in some other country and used with a special permis-
sion from the Finnish Medicines Agency. In 2011, prescriptions for medicines prepared by 
the hospital pharmacy were less common than in 2001 (10%, 95% CI 6–17 vs. 33%, 95% CI 23–
44; p<0.001; Table 31, Unpublished Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Proportion of prescriptions for unauthorised medicines in different classes. Error bars 
indicate 95% CIs on independent proportions. Unpublished 
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8.4 DISCUSSION 
Our study hypothesis was that the European Paediatric Regulation that had been in force for 
4 years should have reduced the proportion of prescriptions for off-label use. However, this 
was not the case as the proportion of prescriptions for off-label use had actually increased 
from the 2001 study to 42% in 2011 being among the highest level reported in Europe (13–34 
%) and other countries (32–39%) (Hsien et al. 2008, Neubert et al. 2010, Khdour et al. 2011, 
Dos Santos and Heineck 2012, Kimland et al. 2012, Palčevski et al. 2012, Slažneva et al. 2012, 
Ballard et al. 2013). A high rate of 51% for off-label prescriptions was reported also in India 
(Jain et al. 2008). The situation is most demanding among the youngest patients. The present 
study indicates that the rate of prescriptions for off-label use had increased especially in new-
borns. The rate of prescriptions for off-label use in neonates has been found to be high as well 
in some other European countries (Dessi et al. 2010, Neubert et al. 2010, Lass et al. 2011, Kim-
land et al. 2012). However, the results of the present study cannot be directly compared with 
the results of other recent studies, because there are variations in the methods and popula-
tions. First, the rigorous definitions of the terms off-label use and that of unauthorised medicines 
vary between studies. Secondly, there is also variation in the inclusion criteria of medicines, 
the paediatric wards included, duration of the study periods and number and age of patients.  
The proportion of patients receiving medication and the number of prescriptions per pa-
tient had increased in the period of 10 years, which could explain the increase in the preva-
lence of prescriptions for off-label use or for unauthorised medicines. In the NICU, in partic-
ular, pharmacotherapy had increased. In 2001, the median number of prescriptions for new-
borns was 2 and that for preterm 5 compared to 9 for newborns and 15 for preterm in 2011. 
The higher number of prescriptions for medicines affecting the nervous and cardiovascular 
systems in the 2011 study than in 2001 indicates more active treatment of pain and use of 
vasoactive preparations in the NICU. It seems that the increased use of pharmacotherapy has 
been a benefit for the younger patients in the NICU, and that it is now considered among the 
top institutions in the Vermont Oxford Neonatal Network comparison. However, all patients 
in the NICU with prescription received a prescription either for off-label use or for unauthor-
ised medicine. This is consistent with another EU country Estonia, where all preterm infants 
in neonatal units had prescriptions either for off-label use or for unauthorised medicines 
(Lass et al. 2011). Moreover, in the present study, as it was in the 2001 study, one-fifth of the 
prescriptions for infants were for unauthorised medicines. There is an unmet need for clinical 
trials in preterm and term neonates to investigate efficacy and safety of medicines commonly 
used in clinical practice. This need has also been identified by the European Medicines 
Agency (EMA) as a high priority (European Medicines Agency 2009, 2013c).  
The major reasons for off-label use of medicines, especially in newborns and infants have 
been the lack of suitable formulations and routes of administration (European Medicines 
Agency 2009, Kimland et al. 2012). In this regard, the present study indicates an improvement 
in the 10-years period. The rate of off-label use of medicines by an alternative route de-
creased, which might be due to an increase in approved appropriate formulations and routes. 
Two examples of medicines with new formulations were paracetamol (solution for infusion, 
dispersal tablets) and oxycodone (oral solution). These formulations were not available in 
2001. There was also improvement in terms of the decrease in the rate of prescriptions for 
medicines without any directions. However, a limitation of our study is that we did not com-
pare the changes in the SmPCs over time. Nevertheless, the changes found in the off-label 
status might be due to the Paediatric Regulation and the updated SmPCs of old products 
with existing experimental data. According to the EMA’s 5-year report on the experience of 
the Regulation, 77 recommendations to update SmPCs with new paediatric information were 
completed by the end of 2011 (European Medicines Agency 2012). The updating concerned 
34 active substances on the market in Finland. This is the result of updated information from 
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more than 18 000 paediatric studies on approximately 1000 active substances that was sub-
mitted by Marketing Authorisation Holders to authorities.  
In the present study the most commonly prescribed medicines for off-label use in 2011 
were two analgesics, paracetamol and fentanyl. The prescription of these medicines in-
creased in the 10-year period and especially in the NICU, as well as paracetamol prescrip-
tions in the general ward. This increase in use of analgesics in younger children is based on 
the fact that both the understanding of the harmful effects of severe pain in a growing body 
and mind, and the expertise to use analgesics in newborns and infants has improved sub-
stantially during the last decade (Kokki 2004, Kraemer 2010, Verghese and Hannallah 2010). 
However, most analgesics were already prescribed off-label in the 2001 study and are among 
the most commonly prescribed medicines for off-label use in two recent European and in one 
Australian study (Lass et al. 2011, Kimland et al. 2012, Ballard et al. 2013). For both medicines, 
paracetamol and fentanyl, there has been development, which is currently continuing, in the 
intravenous formulation for neonatal use (European Medicines Agency decision 2008, 2010). 
The completion of the paediatric investigation plan (PIP) for paracetamol was set on Septem-
ber 2011 and for fentanyl in June 2015. 
In the present study the proportion of prescriptions for unauthorised medicines had re-
mained similar (13%) compared to the 2001 study and that in the recent nationwide study in 
Sweden (Kimland et al. 2012). However, more children received prescriptions for unauthor-
ised medicines in 2011 than in the 2001 study. In addition, the youngest age group was still 
receiving most of the prescriptions for unauthorised medicines as it was already in the 2001 
study, and this was the case also in Sweden. Also, other studies conducted solely in neonatal 
units shows that unauthorised medicines are used with regularity in hospitalised neonates 
(Dessi et al. 2010, Neubert et al. 2010, Lass et al. 2011, Nguyen et al. 2011, Oguz et al. 2012). 
In the present study, the decreased proportion of prescriptions for medicines prepared by 
the hospital pharmacy may indicate the increase in availability of industrially manufactured 
products in 2011, even though still available only with special licences. One example of the 
unauthorised preparation with a special licence was tobramycin used in neonates in the pre-
sent study. The available authorised product contained potentially harmful excipient for ne-
onates, sodium metabisulphite (Finnish Medicines Agency, Lass et al. 2012).  
The study population in the present study was considered as a representative sample of 
the patients in the three paediatric wards of KUH. The loss of individuals from follow-up 
during the study period that could have caused bias was unlikely, because the researcher 
was present daily on the wards and the patient charts were reviewed daily. One strength of 
the present study is that the characteristics of the study population were similar to that in the 
2001 study; hence, the comparison of the differences in prescribing could be considered reli-
able. In addition, the follow-up-time per child and the study period in the present study were 
consistent with the ones in the 2001 study. The patient medical charts were electronic and 
paper-based in both study years. However, some new softwares were in use during the 2011 
study. The electronic medical records can be easily, quickly and continuously updated com-
pared to the paper-based records. It is possible that in the present study the information on 
prescriptions was more up-to-date compared to the 2001 study. The following limitations 
need to be considered when interpreting the results of the present study: the small size of the 
study population and the short study period in both years. However, they most likely de-
scribe the typical patients and medicine utilisation in the study wards. The medicine utilisa-
tion pattern was also close to those described in other similar paediatric units in Europe, 
Australia, and in the USA (Neubert et al. 2010, Lass et al. 2011, Smith et al. 2012, Ballard et al. 
2013).  
In comparing the prescribed medicines in the present study to The WHO Model List of 
Essential Medicines for Children, we noticed that half of the 20 most commonly prescribed 
medicines were listed by WHO, two of the essentials being unauthorised (caffeine and thio-
pental) and other eight prescribed off-label in varying extent. The WHO List of Essential 
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Medicines for Children is based on priorities in healthcare needs of the paediatric population, 
evidence-based efficacy and safety, and also comparative cost-effectiveness. The essential 
medicines ought to be available in the functioning health systems at all times, in the appro-
priate dosage forms with evidence based quality and information. Therefore, the lack of in-
structions in approved SmPCs and lack of marketing authorisation of essential medicines are 
of paramount concern. The medicines listed by WHO could also be recognised while priori-
tising the medicinal products to be developed and studied for paediatric pharmacotherapy 
in the EMA. 
8.5 CONCLUSIONS  
The EU Paediatric Regulation that came into force in January 2007 has had only minor or no 
impact on the authorising status of medicines commonly used in specialised paediatric health 
care. In 2011, prescribing medicines for off-label use and unauthorised medicines was still 
prevalent as it was in the 2001 study. However, the change in the reasons for prescriptions 
being off-label during a decade may indicate that the paediatric population is more often 
mentioned in the SmPCs than before but they are still often lacking dosage recommenda-
tions. There were also some new formulations feasible for paediatric use.  
The 4-year period that the Regulation had been in force may be too short for significant 
changes. Nevertheless, our finding supports the notion in the EMA’s 5-year report: the Reg-
ulation may be too weak to meet the clinical needs to improve the information and the de-
velopment of the off-patent medicines that are commonly used in paediatric pharmacother-
apy. It is also possible that the Regulation may affect more on new medicines than the me-
dicinal products with existing marketing authorisation.  
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9 General Discussion 
9.1 PREVALENCE OF MEDICINE USE IN CHILDREN AND FACTORS RE-
LATED TO USE OF MEDICINES 
A common outcome measure in paediatric medicine utilisation studies has been one-year 
prevalence and the prescription rate in children treated (Clavenna and Bonati 2009b). There 
have been few cross-sectional studies especially at a population level using the outcome 
measure of point prevalence. Two of them conducted in Finland in 1987 and 1995–1996 found 
that the prevalence of prescription medicine use was 13% and 17%, respectively, in children 
aged 0–14 years (Klaukka et al. 1990, Arinen et al. 1998). In the present study, the point prev-
alence of prescription medicine use was similar (17%) to that found in the years 1995–1996, 
though in a younger age group of children (0–11 years), whereas, the prevalence of OTC 
medicine use had increased in the decade from 10% in 1996 up to 17% in 2007. 
The overall increase in medicine use since 1987 may be related to several factors i.e. the 
increased number of new medicines which were introduced in that period and the increased 
incidence especially of allergies and asthma or improved diagnostics, which subsequently is 
reflected in the need of medicines for obstructive airway diseases, antihistamines, cortico-
steroids and anti-infectives (Klaukka et al. 1990, Arinen et al. 1998, Takala et al. 2001). In the 
present population-based study, allergy, asthma and atopic eczema were the most common 
diseases diagnosed by a physician. Therefore, not surprisingly, the most common groups of 
prescribed medicines were medicines for obstructive airway diseases and corticosteroids for 
dermatological use. The use of antibiotics was at the same level as with the corticosteroids 
for dermatological use. The increase in the use of the OTC medicines over the decade may 
reflect the increased awareness among the parents in treating minor childhood illnesses and 
the importance of relieving symptoms such as pain (Sepponen et al. 1999, Ecklund and Ross 
2001, Kankkunen et al. 2008). 
 
Factors related to medicine use in children  
Children in poor health more probably use medicines than children in good health (Carrasco-
Garrido et al. 2009, Du and Knopf 2009, Knopf et al. 2013). This logical finding in several 
other studies supports similar result of the present study.  
Gender and age are also known to be related to medicine use among children. In the pre-
sent study, the use of prescription medicines was most prevalent among boys in the youngest 
age group (<3 years of age). This is in line with the proportion of male child recipients of 
reimbursements in the Finnish statistics on medicines (1987–2012). Similar findings have 
been reported also from other European countries and Western Canada (Sturkenboom et al. 
2008, Zhang et al. 2013). In addition, young age alone is also associated with higher medicine 
use in children. In the present study, children aged 0–2 years received prescriptions more 
frequently than 7–11 year old children, which is also in line with the Finnish statistics on 
medicines. Studies from other European countries support also this finding (Thrane and 
Sørensen 1999, Madsen et al. 2001, Knopf et al. 2013). This is most likely because the burden 
of infectious diseases in children is highest during the first years of life (Sanz et al. 2004, von 
Linstow et al. 2008, Hatakka et al. 2010, Stam et al. 2012).  
The Finnish health care system provides all families with an equal opportunity to receive 
health care and preventive services regardless of their socio-economic status. The visits to a 
physician and to other health professionals working in public primary care are free for chil-
dren and the Social Insurance Institution reimburses part of the cost of prescribed medicines. 
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In the present study, socioeconomical differences did not seem to influence the ability to ob-
tain medicines among Finnish children in 2007 in the way they may be important in other 
countries with less generous health care systems. The welfare state ensures the ease of access 
to health care and availability of medicines for children which are important to sustain equal-
ity in health of children. However, conversely the ease of access to health care can lead to an 
increase in visits to see physicians, sometimes these may be unnecessary visits due to minor 
problems that could be taken care at home by parents (Gill et al. 2013).  
The economical situation of many families has probably changed since the study year 
2007. More up to date and more focused studies on socioeconomical factors related to medi-
cine use would be needed in order to draw firm conclusions.   
9.2 LIFETIME PREVALENCE AND TYPES OF DRUG-RELATED PROBLEMS 
IN CHILDREN 
To the best of one’s knowledge, this is the first study to explore DRPs in children as assessed 
by parents in a large child population. We observed that every fifth child aged 0–11 years 
had experienced a DRP during his or her lifetime in Finland, and most often, it was an ADE.  
Some studies have shown that DRPs are a reason for hospitalisation. In these cases the 
most frequent DRPs have been; the child does not receive the medication, ADRs and poison-
ings (Easton et al. 1998, Easton-Carter et al. 2003, Easton et al. 2004, Rashed et al. 2013).  In 
the present study, in addition to the ADEs, one major reason for other DRPs were difficulties 
in administration and dosing, which can mean that the child did not receive the intended 
dose. Children encountered difficulties in swallowing or they refused to take the medicine, 
also technical issues in administration had caused problems. This indicates that while pre-
scribing or dispensing it is very important to advise both the parents and if possible also the 
child on how and why the medicine needs to be administered. These problems may also 
reflect the lack of appropriate formulations for children (Nunn 2003). 
In the present study, ADEs were most often associated with anti-infectives for systemic 
use, medicines for respiratory system and those for nervous system disorders. This may re-
flect the common use of these medicines. There are few other studies at the population level 
but that conducted in Germany had similar finding (Knopf and Du 2010).  In Germany, most 
ADEs were mild and affected the gastrointestinal system and skin, which is in line with the 
results of present study.  
The assessments of parents have been utilised in detecting the possible ADEs in their chil-
dren in a few studies; this procedure has been described as being feasible (Buajordet et al. 
2002, Stewart et al. 2005, Oshikoya et al. 2009, Knopf and Du 2010, Tobaiqy et al. 2011). In 
addition, very young children are unable to communicate their experiences of pharmacother-
apy. Especially in outpatients, the parents or other caretakers are often the closest persons to 
appreciate if the child’s condition or behaviour has changed. Thus in pharmacovigilance, 
parents could be utilised to help in detecting of new and unexpected harmful reactions in 
their children. This is especially important when new medicines are being used because of 
the fact that the safety profiles of new medicines may deviate significantly when these med-
icines are given to a child population. In addition, ADEs are often poorly reported in clinical 
trials (Choonara 2013).  
Parents need relevant information about medicine use in their children; theoretical infor-
mation on the effect and possible adverse consequences, but also practical advice on how the 
medicine should be administered, and on the actions which need to be taken if a harmful 
effect is suspected (Costello et al. 2004). The results of the present study lend support to this 
proposal; parents with higher education and with health care education tend to report ADEs 
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in their children more frequently than parents with less schooling and those without 
healthcare education. By empowering parents and providing information and knowledge, 
many DRPs could be reduced, even prevented. If parents appreciate and receive sufficient 
information from health professionals, they could also participate efficiently in pharmacovig-
ilance in paediatrics, especially in detecting new adverse events. Nonetheless, some problems 
have been encountered in patient reporting e.g. limited resources in the national agencies to 
establish patient reporting schemes and to handle reports, and the possibility of duplicate 
reports (van Hunsel et al. 2012). Furthermore, it has been also found that the advantage of 
using patient reports is the description of reactions in more details than in reports of health 
care professionals (Avery et al. 2011).  
9.3 PREVALENCE AND FREQUENCY OF PRESCRIBING MEDICINES FOR 
OFF-LABEL USE AND UNAUTHORISED MEDICINES IN HOSPITALISED 
CHILDREN  
In Europe, the prevalence of off-label use and use of unauthorised medicines have remained 
as high in hospitalised children in 2008–2013 as in the time period between 1990 and 2007. 
No decreasing trend in this kind of use could be seen in the prevalence according to reviewed 
studies from the EU countries. In two thirds of the studies, the prevalence was more than 
75%. The high prevalence in the EU countries is probably due to the units being studied; 
predominantly NICUs. 
The first review in this thesis examined 24 studies from a 17-year period prior to 2008 and 
the second similar review located the same number of studies from a much shorter, 5-year 
period, published after 2007. In the European countries, the number of studies per year had 
doubled; 15 identified studies in 1990–2007 and 11 in 2008–2013. The increase in numbers of 
studies is at least partly due to the demands of the Paediatric Regulation i.e. member states 
were expected to collect data on paediatric medicine use.  
There had been no change in the proportion of off-label prescriptions over the reviewed 
periods. The average proportion of off-label prescriptions was 37% in studies published prior 
to and after 2008. The proportion of prescribed unauthorised medicines varied, which is most 
likely due to differences in the definition of unauthorised medicine use, differences in au-
thorised products in different countries and the hospital units in the studies. In European 
countries, the average of proportions of prescriptions for unauthorised medicines was 14% 
prior to 2008 and thereafter it was 19%. A meta-analysis would be needed if one wished to 
obtain more accurate estimates. Furthermore, it is necessary to unify the definitions for un-
authorised medicines and for off-label use of medicines in order to gain comparable results.  
The variation in proportions of prescribed unauthorised medicinal products between dif-
ferent European countries is partly due to a product authorised in one or more countries but 
not in all member states. Regulatory actions would be needed (through Co-ordination Group 
for Mutual Recognition and Decentralised Procedures) to make these products available in 
all member states. There are also products that have received authorisation for the whole EU 
(e.g. caffeine citrate, European Medicines Agency 2014c) but they are still not marketed in all 
member states.  
Both the reviews and the present results show that the treatment of paediatric patients in 
tertiary level hospitals is highly dependent on off-label use and the treatment with unauthor-
ised medicines. Paediatricians and other specialists experience these conflicts in their every-
day work. Patients need to be treated, but almost always the only possibility is to use off-
label medication with the uncertainty of the consequences regarding effectiveness and safety.  
In the present study, another group of paediatric patients in addition to neonates who 
received a very high number of prescriptions for off-label use and unauthorised medicines 
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were surgical patients and this was the case in both 2011 and 2001. Nine out of ten patients 
received either off-label or unauthorised medication in 2011.  
Analgesics, anaesthestics and sedatives have been found to be widely and commonly used 
in hospitalised children (Lasky et al. 2011). In a nationwide study from Sweden, among pae-
diatric inpatients the most common treatment indication on prescriptions was pain, and thus 
paracetamol and morphine were among the most commonly prescribed individual sub-
stances for off-label use (Kimland et al. 2012). In the present study, paracetamol, fentanyl, 
oxycodone and ibuprofen were among the top six most commonly used medicines, and also 
frequently prescribed off-label. The understanding of the effects of pain and the expertise to 
use analgesics in children has improved (Kokki 2004, Kraemer 2010, Verghese and Hannallah 
2010). There was a notable increase in the number of prescriptions for analgesics which oc-
curred between 2001 and 2011 in particular in the NICU and general ward. The analgesics 
were those marketed for a lengthy period and not protected with basic patent or supplemen-
tary protection certificate anymore. The frequent off-label prescribing combined with the reg-
ular and common use of analgesics highlights the clear need to devise children-friendly dos-
age forms and dosing schedules, especially for this group of medicines. This conclusion, es-
pecially with regard to fentanyl, confirms the finding of Bellis and colleagues (2013b); almost 
half (48%) of the fentanyl regimens used in an off-label manner or that were for unauthorised 
medicines in paediatric inpatients were associated with ADRs.  
It is known that the polypharmacotherapy increases the risk for adverse events (Smyth et 
al. 2012, Bellis et al. 2013a, b). Children with five or more medicines have a higher risk for 
experiencing ADRs than children with fewer medicines (Rashed et al. 2012a). In the present 
study, the incidence of pharmacotherapy had increased in all paediatric age groups in the 
studied decade, and the median number of prescriptions per patient was 6 in the whole study 
population in 2011, compared to 2 in 2001. Especially, preterm newborns tended to receive 
high numbers of prescriptions for medicines and this number had increased significantly in 
the studied decade. The immaturity of drug metabolising pathways in neonates makes them 
more prone to ADRs (Knight 1994). While increased pharmacotherapy has benefitted neo-
nates, in contrast, polypharmacotherapy combined with the high number of unapproved 
medicines can increase morbidity resulting in either in short- or long-term adverse conse-
quences (Moore et al. 2002).  
The neonatal intensive care unit of the present study is an example of high quality and 
advanced treatment (Vermont Oxford Network 2013). The knowledge and practice have 
moved on but the regulation has not kept pace with these advances. The results of the present 
study suggest that there were more directions for use in children in the SmPCs than a decade 
ago but the youngest age groups were still lacking dosing directions. The emphasis of the 
Paediatric Regulation is more on developing of new medicines even though there would also 
be a need to increase information on the posology of medicine administration and on the 
safety of older established therapies. Another important area is to develop child-friendly for-
mulations. However, there is no demand to study the effect of already established medicines. 
Furthermore, the incentives of the Paediatric Regulation may be too insignificant to encour-
age developing new formulations. In addition, if evidence exists about off-label treatment for 
example in neonates (Laitinen et al. 2000) and surgical patients, all of this data should be 
continuously collected for scrutiny by the regulatory authorities and SmPCs updated accord-
ingly as has been done to some extent after the introduction of Paediatric Regulation. 
As the 5-year report of the European Commission (2013) has indicated, the numbers of clin-
ical trials in children increased by about 10% but not all approved PIPs have been or will be 
completed. Only one PUMA with the 10 years market exclusivity was granted in five years 
since the regulation came into force. The present study lends support to the fact that the Eu-
ropean Medicines agency’s vision of ‘Better Medicines for Children’ is not yet a reality, even 
though the information in the SmPCs had increased.  
91 
 
 
The low market potential for medicinal products may be still unattractive to the pharmaceu-
tical companies and they do not appreciate the costs of conducting clinical trials in children. 
The slow development of paediatric medicinal products, the current delays in PIPs and the 
habit of physicians to rely on off-label prescribing (Lindkvist et al. 2011) all indicate that the 
present situation of using medicines off-label to treat paediatric patients will continue into 
the foreseeable future. More studies on off-label use of medicines and changes in paediatric 
information in SmPCs will be needed in addition to the next evaluation of the situation by 
European Commission/ European Medicines Agency to be conducted in 2017. These studies 
are needed to address the needs of different paediatric age and patient groups. 
 
In summary, the literature and results of this thesis have shown that there are drug-related 
problems in paediatric pharmacotherapy. One could hope that the obligations and incentives 
in the present legislations will improve the official information about medicines being given 
to children and to encourage the development of child-friendly formulations. On the other 
hand, it is important to increase awareness of the causes and consequences of the problems 
by improving education of health professionals and parents. The development of paediatric 
pharmacotherapy has to become a priority for pharmaceutical industry, regulatory agencies 
and for health professionals. In particular much more attention should be paid to the phar-
macotherapy of neonates, because nowadays medicines are playing an increasingly im-
portant role in the treatment of these children. Drug-related problems in paediatric pharma-
cotherapy are also an ethical concern. Paediatric patients should have the same access as 
adults to safe and thoroughly evaluated medicines; they have the same rights as adults to 
receive effective and safe pharmacotherapy. 
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10 Conclusions 
Firstly, this study aimed to assess the use of medicines and secondly to assess the drug-re-
lated problems in children living in Finland. The third aim was to study the prevalence and 
frequency of off-label prescribing and that of unauthorised medicines in paediatric hospital 
wards, with a special focus on assessing any possible change occurring in a decade, before 
and four years after the Paediatric Regulation came into force in 2007. Based on the described 
findings, the following conclusions can be drawn: 
 
1. Every sixth child aged 0–11 years was using a medicine at the time this study was con-
ducted in Finland in 2007, that is, about 120 000 children in this population were taking a 
medicine, a similar frequency as reported a decade previously. The study lends support 
to the evidence that morbidity, health status, young age and parental medicine use are 
associated with the extent of medicine use by the child. The socioeconomic characteristics 
of the parent(s) do not appear to have any influence on the use of medicines in Finnish 
children. 
 
2. One in every fifth child aged 0–11 years had experienced drug-related problems during 
his/her lifetime, predominantly adverse drug events. Drug-related problems were most 
often associated with anti-infectives for systemic use, medicines for the respiratory system 
and for nervous system. However, fewer than one out of a hundred children had experi-
enced serious or unexpected adverse events; antibiotics were most often involved.  
 
3. The frequency of off-label prescriptions had increased over a ten year period and that of 
unauthorised medicines had remained at the same level. Six out of ten children received a 
medicine for off-label use or an unauthorised medicine in three paediatric wards of the 
Kuopio University Hospital in 2001, compared to eight children out of ten in 2011. Accord-
ing to the reviewed studies, in the European Union countries the frequency of off-label use 
of medicines in hospitalised children has remained high at least from 1990 to the current 
date, and the values are rather similar in Finland as in other countries. No decrease seemed 
to have occurred in off-label use of medicines in paediatric inpatients in tertiary care in the 
four year period since the Paediatric Regulation came into force. 
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11 Implications for the Future  
According to the present findings of this thesis together with the existing literature, the fol-
lowing implications for practice and further research can be proposed. 
 
 
1. The extent of drug-related problems in hospitalised children or leading to a hospitalisa-
tion is not known in Finland. New studies need to be conducted to clarify these problems. 
Furthermore, the possible association between drug-related problems and off-label use of 
medicines and use of unauthorised medicines could be investigated in order to determine 
if there is a true cause-effect relationship. 
 
2. In the present study, half of the reported serious adverse drug events were related to 
antibiotics, which raise the question about the rationality of their prescribing and use. It 
would be worthwhile to conduct a review or a new study into the rational use of antibi-
otics in children in Finland. 
 
3. Internationally, there is a need for studies on caretakers’ role in early detection of new 
adverse drug reactions in paediatric population. 
 
4. There is a need to monitor the extent of off-label prescribing and of unauthorised medi-
cines in paediatric pharmacotherapy to be able to evaluate any future concrete impact of 
the Paediatric Regulation on the information and medicines available for children.  
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Appendix 1. Literature search profiles for drug-related problems 
 
 
Search PubMed 24.9.2013 Query 
Items 
found 
#12 Search (#10 NOT (clinical trial OR trial*)) Filters: Full text available; Free full 
text available; published in the last 10 years; English 
150 
#10 Search (#2 OR #3 OR #4 OR #5 OR #6) Filters: Full text available; published in 
the last 10 years; English 
776 
#11 Search (#2 OR #3 OR #4 OR #5 OR #6) Filters: Full text available; Free full text 
available; published in the last 10 years; English 
189 
#9 Search (#2 OR #3 OR #4 OR #5 OR #6) Filters: published in the last 10 years; 
English 
821 
#7 Search (#2 OR #3 OR #4 OR #5 OR #6) 1783 
#6 Search (#1 AND (survey* OR questionnaire*)) 228 
#5 Search ((pharmaceutical preparations/adverse effects OR drug therapy/ad-
verse effects) AND (parent* OR father* OR mother* OR legal guardians OR 
guardian*) AND (infant* OR toddler* OR child* OR schoolchild* OR pediatr* 
OR paediatr*)) 
1237 
#4 Search (medication errors AND (parent* OR father* OR mother* OR legal 
guardian* OR guardian*) AND (infant* OR toddler* OR child* OR schoolchild* 
OR pediatr* OR paediatr*)) 
192 
#3 Search (("drug-related problem" OR "drug-related problems" OR "drug related 
problem" OR "drug related problems") AND (infant* OR toddler* OR child* OR 
schoolchild* OR pediatr* OR paediatr*)) 
87 
#2 Search (#1 AND (parent* OR father* OR mother* OR legal guardians OR guard-
ian*)) 
158 
#1 Search (("adverse drug reaction" OR "adverse drug reactions" OR "adverse 
drug event" OR "adverse drug events") AND (infant* OR toddler* OR child* OR 
schoolchild* OR pediatr* OR paediatr*)) 
2035 
 
Scopus 25.9.2013, 1269 results 
(((TITLE-ABS-KEY((infant* OR toddler* OR child* OR schoolchild* OR pediatr* OR paedi-
atr*) AND (parent* OR guardian* OR father* OR mother*)) AND TITLE-ABS-KEY("side ef-
fect*" OR "adverse effect*") AND TITLE-ABS-KEY(drug* OR medicat* OR medicines OR 
"pharmaceutical preparation*") AND TITLE-ABS-KEY(prevalence OR incidence OR sur-
vey* OR questionnaire*) AND LANGUAGE(english))) AND NOT ((TITLE-ABS-KEY((in-
fant* OR toddler* OR child* OR schoolchild* OR pediatr* OR paediatr*) AND (parent* OR 
guardian* OR father* OR mother*)) AND TITLE-ABS-KEY("adverse drug reaction" OR "ad-
verse drug reactions" OR "adverse drug event" OR "adverse drug events" OR "drug-related 
problem" OR "drug-related problems" OR "drug related problem" OR "drug related prob-
lems") AND LANGUAGE(english)))) AND NOT (TITLE-ABS-KEY(trial OR trials)) 
  
 
 
 
Appendix 2. Literature search profiles for off-label use and unauthorised medicines in hospital-
ised children. Search profiles were updated in September 2013.   
   
 
2007/06:2013/02[dp] AND eng[la] AND (infant[mesh] OR child[mesh] OR adolescent[mesh] OR 
pediatr* OR paediatr* OR child* OR infant* OR newborn* OR neonate* OR adolesc*) 
 
 
Search PubMed  Query 
Items 
found 
#7 Search #5 AND #6 718 
#8 Search #5 NOT #7 (not hospitals, etc.) 351 
#6 Search "Hospitals"[Mesh] OR "Hospitalization"[Mesh] OR hospital OR 
hospitals OR hospitali* OR "Hospital Departments"[Mesh] OR ward* OR 
"Patient Care"[Mesh] OR clinic OR clinics OR clinical* OR "Hospital 
Units"[Mesh] OR "Inpatients"[Mesh] OR inpatient* 
5465411 
#5 Search #4 AND 2007/06:2013/02[dp] AND eng[la] AND (infant[Mesh] 
OR child[Mesh] OR adolescent[Mesh] OR pediatr* OR paediatr* OR 
child* OR infant* OR newborn* OR neonate* OR adolesc*) 
1069 
#4 Search #1 AND #2 10737 
#3 Search offlabel OR "off label" OR off-label OR unlicen* OR un-licen* OR 
nonlicen* OR non-licen* OR unregister* OR un-register* OR nonregis-
ter* OR non-register* OR unauthori* OR un-authori* OR nonauthor* 
OR non-author* OR (outside AND (authori* OR label* OR licen*)) 
9172 
#2 Search offlabel OR "off label" OR off-label OR unlicen* OR un-licen* OR 
nonlicen* OR non-licen* OR unregister* OR un-register* OR nonregis-
ter* OR non-register* OR unauthori* OR un-authori* OR nonauthor* 
OR non-author* OR (outside AND (authori* OR label* OR licen*)) OR 
"not licenced" OR "not licensed" OR "not authorized" OR "not author-
ised" OR "not approved" OR "not labeled" OR "not labelled" 
38792 
#1 Search "Pharmaceutical Preparations"[Mesh] OR drug OR drugs OR 
medicines OR medicat* OR prescriptions 
4600405 
 
Scopus (including Embase) 
 
1 (TITLE-ABS-KEY((pharmaceutical* W/1 preparation*) OR drug OR drugs OR medicines OR 
medicat* OR prescriptions) AND TITLE-ABS-KEY(offlabel OR "off label" OR off-label OR 
unlicen* OR un-licen* OR nonlicen* OR non-licen* OR unregister* OR un-register* OR non-
register* OR non-register* OR unauthori* OR un-authori* OR nonauthor* OR non-author* 
OR (outs* AND (authori* OR label* OR licen*))) AND TITLE-ABS-KEY(infant* OR child* OR 
adolesc* OR pediatr* OR paediatr* OR newborn* OR neonate* OR toddler*) AND TITLE-
ABS-KEY(hospital* OR ward* OR (patient W/2 care) OR clinic OR clinics OR clinical* OR in-
patient*) AND LANGUAGE(english)) AND PUBYEAR > 2006 747 refs 
 
2 (TITLE-ABS-KEY((pharmaceutical* W/1 preparation*) OR drug OR drugs OR medicines OR 
medicat* OR prescriptions) AND TITLE-ABS-KEY(offlabel OR "off label" OR off-label OR 
unlicen* OR un-licen* OR nonlicen* OR non-licen* OR unregister* OR un-register* OR non-
register* OR non-register* OR unauthori* OR un-authori* OR nonauthor* OR non-author* 
OR (outs* AND (authori* OR label* OR licen*))) AND TITLE-ABS-KEY(infant* OR child* OR 
adolesc* OR pediatr* OR paediatr* OR newborn* OR neonate* OR toddler*) AND LAN-
GUAGE(english)) AND PUBYEAR > 2006 1001 refs 
 
3 (2 NOT 1) (excl. hospitals) 
 
 
 
 
((TITLE-ABS-KEY((pharmaceutical* W/1 preparation*) OR drug OR drugs OR medicines OR 
medicat* OR prescriptions) AND TITLE-ABS-KEY(offlabel OR "off label" OR off-label OR 
unlicen* OR un-licen* OR nonlicen* OR non-licen* OR unregister* OR un-register* OR non-
register* OR non-register* OR unauthori* OR un-authori* OR nonauthor* OR non-author* 
OR (outs* AND (authori* OR label* OR licen*))) AND TITLE-ABS-KEY(infant* OR child* OR 
adolesc* OR pediatr* OR paediatr* OR newborn* OR neonate* OR toddler*) AND LAN-
GUAGE(english)) AND PUBYEAR > 2006) AND NOT ((TITLE-ABS-KEY((pharmaceutical* 
W/1 preparation*) OR drug OR drugs OR medicines OR medicat* OR prescriptions) AND TI-
TLE-ABS-KEY(offlabel OR "off label" OR off-label OR unlicen* OR un-licen* OR nonlicen* 
OR non-licen* OR unregister* OR un-register* OR nonregister* OR non-register* OR unau-
thori* OR un-authori* OR nonauthor* OR non-author* OR (outs* AND (authori* OR label* 
OR licen*))) AND TITLE-ABS-KEY(infant* OR child* OR adolesc* OR pediatr* OR paediatr* 
OR newborn* OR neonate* OR toddler*) AND TITLE-ABS-KEY(hospital* OR ward* OR (pa-
tient W/2 care) OR clinic OR clinics OR clinical* OR inpatient*) AND LANGUAGE(english)) 
AND PUBYEAR > 2006) 254 refs 
 
 Ap
pe
nd
ix
 3
. 
A
 t
im
el
in
e 
fo
r 
ob
lig
at
io
ns
, 
re
w
ar
ds
 a
nd
 in
ce
nt
iv
es
 o
f 
ru
le
s 
an
d 
ac
ts
 f
or
 t
he
 p
ae
di
at
ri
c 
m
ar
ke
ti
ng
 a
ut
ho
ri
sa
tio
n 
ap
pl
ic
an
ts
 in
 t
he
 U
S
A
 
(F
D
A
; 
U
.S
. 
Fo
od
 a
nd
 D
ru
g 
A
dm
in
is
tr
at
io
n)
. 
              
 
20
03
 
 P
ed
ia
tr
ic
  
Re
se
ar
ch
 E
qu
ity
 
Ac
t 
 
19
94
 
Fi
na
l R
ul
e 
19
97
 
FD
A
 M
od
er
ni
za
-
ti
on
 A
ct
 
 
19
98
 
Fi
na
l P
ed
ia
tr
ic
 
Ru
le
 
 
20
02
 
Be
st
 P
ha
rm
ac
eu
-
tic
al
s f
or
 C
hi
l-
dr
en
 A
ct
 
 
20
07
 
Fo
od
 a
nd
 D
ru
g 
A
dm
in
is
tr
at
io
n 
A
m
en
dm
en
ts
 A
ct
 
20
12
 
 F
D
A
  
S
af
et
y 
an
d 
In
no
-
va
ti
on
 A
ct
 
M
ar
ke
tin
g 
au
th
or
is
at
io
n 
ho
ld
-
er
s 
w
er
e 
re
qu
ir
ed
 t
o 
as
se
ss
 e
x-
is
tin
g 
pa
ed
ia
tr
ic
 s
tu
di
es
 a
nd
 
da
ta
 a
nd
 a
cc
or
di
ng
ly
 s
ug
ge
st
 
ch
an
ge
s 
to
 t
he
ir
 p
ro
du
ct
 la
be
ls
 
to
 t
he
 F
D
A
 
•
6 
m
on
th
 e
xt
en
si
on
 o
f 
pa
te
nt
 o
r 
ex
cl
u-
si
vi
ty
 p
ro
te
ct
io
n 
if 
pa
ed
ia
tr
ic
 t
ri
al
s 
w
er
e 
co
nd
uc
te
d 
re
sp
on
si
ve
 t
o 
th
e 
FD
A
 
•
Fo
r 
m
ed
ic
in
es
 w
ith
 m
ar
ke
tin
g 
au
th
or
i-
sa
tio
n 
(b
io
lo
gi
c 
pr
od
uc
ts
 a
nd
 a
nt
ib
io
t-
ic
s 
ex
cl
ud
ed
)  
•
R
eq
ui
re
m
en
t 
to
 a
ss
es
s 
sa
fe
ty
 a
nd
 e
f-
fe
ct
iv
en
es
s 
in
 t
he
 p
ae
di
at
ri
c 
 p
op
ul
a-
ti
on
 
•
Fo
r 
al
l n
ew
 m
ed
ic
in
es
, 
bi
ol
og
ic
al
 
pr
od
uc
ts
, 
an
d 
su
pp
le
m
en
ta
l i
nd
ic
a-
tio
ns
, 
fo
rm
ul
at
io
ns
 o
r 
po
so
lo
gy
 f
or
 
au
th
or
is
ed
 m
ed
ic
in
es
 •
C
on
tin
ua
tio
n 
of
 t
he
 6
 
m
on
th
 e
xt
en
si
on
 o
f 
pa
te
nt
 
or
 e
xc
lu
si
vi
ty
 p
ro
te
ct
io
n 
•
Fo
r 
m
ed
ic
in
es
 w
ith
 m
ar
-
ke
tin
g 
au
th
or
is
at
io
n 
(b
io
-
lo
gi
c 
pr
od
uc
ts
 a
nd
 a
nt
ib
i-
ot
ic
s 
ex
cl
ud
ed
) 
R
eq
ui
re
s 
st
ud
ie
s 
in
 p
ae
di
at
ri
c 
pa
-
tie
nt
s 
w
he
n 
th
e 
pr
op
os
ed
 o
r 
ap
-
pr
ov
ed
 u
se
 in
 a
du
lts
 r
ep
re
se
nt
 a
 
m
ea
ni
ng
fu
l t
he
ra
pe
ut
ic
 b
en
ef
it 
ov
er
 
ex
is
tin
g 
th
er
ap
ie
s,
 is
 li
ke
ly
 t
o 
be
 
us
ed
 in
 a
 s
ub
st
an
tia
l n
um
be
r 
of
 
pa
ed
ia
tr
ic
 p
at
ie
nt
s,
 a
nd
 is
 a
nt
ic
i-
pa
te
d 
to
 b
e 
sa
fe
 a
nd
 e
ff
ec
tiv
e 
in
 t
he
 
pa
ed
ia
tr
ic
 p
op
ul
at
io
n.
 
R
ea
ut
ho
ri
sa
tio
n 
of
 la
w
s:
 
B
es
t 
Ph
ar
m
ac
eu
tic
al
s 
fo
r 
C
hi
ld
re
n 
A
ct
 a
nd
 P
ed
ia
tr
ic
 
R
es
ea
rc
h 
Eq
ui
ty
 A
ct
 
Pe
rm
an
en
t 
re
au
th
or
is
a-
tio
n 
of
 la
w
s:
 B
es
t 
Ph
ar
-
m
ac
eu
tic
al
s 
fo
r 
C
hi
ld
re
n 
A
ct
 a
nd
 P
ed
ia
tr
ic
 R
e-
se
ar
ch
 E
qu
ity
 A
ct
 
 
 
Appendix 4. List of publications on population based medicine utilisation study in children aged 
less than 12 years living in Finland 2007. 
Siponen S, Ahonen R, Kiviniemi V, Hämeen-Anttila K (2013) Association between parental 
attitudes and self-medication of their children. Int J Clin Pharm 35: 113–120. 
Lindell-Osuagwu L, Sepponen K, Farooqui S, Kokki H, Hämeen-Anttila K, Vainio K (2013) 
Parental reporting of adverse drug events and other drug-related problems in children in 
Finland. Eur J Clin Pharmacol 69: 985–994.  
Holappa M, Ahonen R, Vainio K, Hämeen-Anttila K (2012) Information sources used by 
parents to learn about medications they are giving their children. Res Soc Adm Pharm 8: 
579–584. 
Siponen SM, Ahonen RS, Kettis Å, Hämeen-Anttila K (2012) Complementary or alternative? 
Patterns of complementary and alternative medicine (CAM) use among Finnish children. 
Eur J Clin Pharmacol 68: 1639–1645. 
 
Hämeen-Anttila K, Halonen P, Siponen S, Holappa M, Ahonen R (2011) Parental attitudes 
toward medicine use in children in Finland. Int J Clin Pharm 33: 849–858.  
 
Siponen SM, Ahonen RS, Savolainen PH, Hämeen-Anttila KP (2011) Children's health and 
parental socioeconomic factors: a population-based survey in Finland. BMC Public Health 
11: 457.  
 
Hämeen-Anttila KP, Niskala UR, Siponen SM, Ahonen RS (2011) The use of complementary 
and alternative medicine products in preceding two days among Finnish parents - a popu-
lation survey. BMC Complementary and alternative medicine 11: 107.  
 
Hämeen-Anttila K, Lindell-Osuagwu L, Sepponen K, Vainio K, Halonen P, Ahonen R 
(2010) Factors associated with medicine use among children aged under 12 years - a popu-
lation survey in Finland. Pharmacoepidemiol Drug Saf 19: 400–407. 
Ylinen S, Hämeen-Anttila K, Sepponen K, Lindblad AK, Ahonen R (2010) The use of pre-
scription medicines and self-medication among children - a population-based study in Fin-
land. Pharmacoepidemiol Drug Saf 19(10): 1000–1008. 
Rajala L, Sepponen K, Hämeen-Anttila K (2010) Lasten infektio-oireiden esiintyvyys: onko 
päivähoitomuodolla merkitystä? (with English summary: Prevalence of infectious symp-
toms in children - does the type of day care matter?). Dosis 26(4): 240–245. 
 
 
 
 
 
University of Kuopio 
Department of Social Pharmacy 
CHILDREN’S MEDICINE USE 
 
Answer the questions by circling the best fitting alternative or writing down in the blank space. Your answers are 
important even if the child is not using any medicines.  
 
 
 
 
1. The child is a 
1 Girl 
2 Boy 
 
2. Date of birth 
 day     month  year 
 
3. Is the child  
1 The firstborn 
2 The second born 
3 The third born 
4 Other. Which one? ______________ 
 
4. Which answer best describes the child’s usual care during 
the day? (choose the one which they spend the most hours at 
per week) 
1 Goes to school or preschool  
2 Is taken care of by a child minder outside home  
3 Is in the day-care-centre 
4 Is taken care of at home alone or with brothers and sisters 
5 Some other way. How? ____________________________ 
 
 
 
 
5. What is your opinion about the health status of the child at 
the moment?  
1 Good 
2 Fairly good 
3 Moderate 
4 Fairly poor 
5 Poor 
 
6. Does the child have any illness or injury that has been 
diagnosed by a doctor? 
1 No 
2 Yes. What illness / illnesses? 
 _____________________________________________
 _____________________________________________  
 
 
 
 
 
7. Below is a list of symptoms. Circle for each symptom if the child is suffering it at the moment. 
 
Symptoms No Yes Don’t know 
    
Constipation 1 2 3 
Diarrhoea 1 2 3 
Stomach bug 1 2 3 
Flatulence/Wind 1 2 3 
Other stomach disorders, describe?___________________ 1 2 3 
Headache 1 2 3 
Pain in the neck or shoulders 1 2 3 
Pain in the lower back 1 2 3 
Earache  1 2 3 
Sore throat 1 2 3 
Growing pains 1 2 3 
Other pain, describe? _____________________________ 1 2 3 
High temperature/Fever 1 2 3 
Symptoms of cold/flu (e.g. runny nose,  cough) 1 2 3 
Allergic symptoms (e.g. runny nose, eye symptoms) 1 2 3 
Eczema or skin symptoms 1 2 3 
Fatigue or feeling faint 1 2 3 
Sleep disturbance 1 2 3 
Tension or nervousness 1 2 3 
Low spirit or depression 1 2 3 
Some other symptom, describe? _____________________ 1 2 3 
    
 
BACKGROUND INFORMATION OF THE CHILD  HEALTH STATUS OF THE CHILD 
Appendix 5. Questionnaire for population-based medicine utilisation study in children aged less than 12 
years living in Finland 2007, in English.
 
 
 
 
 
8. Is the child using any prescription medicines at the moment? 
1 No (move to the question number 9) 
2 Yes. List every medicine and its purpose of use. List also 
 those medicines that are used as needed. You can 
 continue on the last page. 
 
Name of the medicine 
(e.g. Beclomet Easyhaler®) 
 Purpose of use  
(e.g. asthma) 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
9. Has your child taken yesterday or the day before yesterday 
any Over the counter (OTC)  medicines, including vitamins? 
1 No (move to the question number 10) 
2 Yes. List every medicine and its purpose of use. 
 
Name of the medicine 
(e.g. Pantyson®) 
 Purpose of use  
(e.g. skin rash) 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
10. Is the child using any OTC medicines or vitamins daily or 
almost daily? 
1 No (move to the question number 11) 
2 Yes. List all the medicines that are used daily or almost 
daily, and also how long the child has been using them. 
 
Name of the product 
 
 How long has (s)he been  
using it? /Length of use 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
  
 
 
 
 
 
 
 
 
11. Has the child taken yesterday or the day before yesterday 
any medicinal herbs, botanicals, or homeopathic products? 
1 No (move to the question number 12) 
2 Yes. List all products and their purpose of use. 
 
Product  Purpose of use 
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
12. Has any medicine caused the child harm? 
1 No (move to the question number 13) 
2 Yes. List all the harms and medicines that have caused 
them. You can continue on the last page. 
 
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________ 
 
13. Have there been any other problems with the child’s 
medication? 
1 No (move to the question number 14) 
2 Yes. What kind of problems? List also which medicines 
have caused them. You can continue on the last page. 
 
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________ 
 
14. At what age, on your opinion, can the child decide on 
taking a medicine for little ailments, e.g., headache, 
independently without any control or guidance of a parent?
  
1 < 4 
2 4–5 
3 6–7 
4 8–9 
5 10–11 
6 12–13 
7 14–15 
8 16–17 
9 18 or older 
10 No opinion 
 
 
 
THE CHILD’S MEDICINE USE 
 
 
 
 
 
15. Below is a list of information sources. Circle for every source how much you have used it when searching information  
concerning children's medication.  
 
Source of information Much To some extent Little Not at all 
     
Doctor/Physician 3 2 1 0 
Nurse 3 2 1 0 
Public health nurse / School health nurse 3 2 1 0 
Relative or friend who is a health care professional 3 2 1 0 
Pharmacist 3 2 1 0 
Helpline, which one?___________________________ 3 2 1 0 
Patient information leaflet 3 2 1 0 
Brochures concerning medicines 3 2 1 0 
Medical books 3 2 1 0 
Some other book, which one? ____________________ 3 2 1 0 
Health journals 3 2 1 0 
Ordinary newspapers or magazines 3 2 1 0 
Radio, television 3 2 1 0 
The internet, which websites?_____________________ 3 2 1 0 
Family, friends 3 2 1 0 
Health food shop /Natural product store 3 2 1 0 
Other, what?__________________________________ 3 2 1 0 
     
 
 
16. How reliable do you find the following information sources when searching information concerning children's medication?  
 
 
Source of information 
Very  
reliable 
 
Reliable 
Quite  
reliable 
Not  
reliable 
No 
opinion or 
haven’t used 
      
Doctor/Physician 4 3 2 1 0 
Nurse 4 3 2 1 0 
Public health nurse / School health nurse 4 3 2 1 0 
Relative or friend who is a health care professional 4 3 2 1 0 
Pharmacist 4 3 2 1 0 
Helpline, which one?___________________________ 4 3 2 1 0 
Patient information leaflet 4 3 2 1 0 
Brochures concerning medicines 4 3 2 1 0 
Medical books 4 3 2 1 0 
Some other book, which one? ____________________ 4 3 2 1 0 
Health journals 4 3 2 1 0 
Ordinary newspapers or magazines 4 3 2 1 0 
Radio, television 4 3 2 1 0 
The internet, which website?_____________________ 4 3 2 1 0 
Family, friends 4 3 2 1 0 
Health food shop /Natural product store 4 3 2 1 0 
Other, what?_________________________________ 4 3 2 1 0 
      
INFORMATION SOURCES OF MEDICINES 
 
 
 
17. Who is the person that filled in this questionnaire? 
1 Mother 
2 Father 
3 Other. Who?__________________________________ 
 
 
18. What is your own mother tongue? 
1 Finnish 
2 Swedish 
3 Other. What?_________________________________ 
 
19. Number of children in the family _____________________ 
 
 
20. Your year of birth ___________ 
 
 
21. Did the child take part in filling in this questionnaire? 
1 No 
2 Yes 
 
 
22. Have you taken any degree in health care? 
1 No 
2 Yes. Which one? 
_____________________________________________ 
 
23. Which province do you live in? 
1 Lapland  
2 Oulu 
3 Eastern Finland  
4 Western Finland  
5 Southern Finland  
6 Åland 
 
 
24. What is your level of education? Circle the highest degree 
you have taken. 
1 Primary school  
2 School certificate (equivalent to year ten) 
3 Higher School Certificate (leaving certificate/year 12) 
4 Non University Diploma 
5 Bachelors Degree (University)  
6 Postgraduate University Degree 
 
 
25. What is your current employment status? (Choose the one 
best option that describes your situation) 
1 I’m working part-time/full time 
2 I study or go to school  
3 I’m a housewife/-husband  
4 I’m temporarily absent from work (for example on 
maternity leave) 
5 I’m on sick leave  
6 I have been laid off or I’m unemployed  
7 I’m retired 
 
26. How much is your household’s net income (the income 
after taxes) in its entirety? If you don´t know it exactly you can 
mark your estimate of it. 
1 Below 500 e 
2 500–999 e 
3 1000–1499 e 
4 1500–1999 e 
5 2000–2499 e 
6 2500–2999 e 
7 3000–3999 e 
8 4000–4999 e 
9 5000–7499 e 
10 7500–10000 e 
11 Over 10 000 e 
 
 
27. Are you yourself using any prescription medicines at the 
moment? 
1 No (move to the question no 28) 
2 Yes. List all the medicines that you are using and their 
purpose of use. 
 
Medicine 
(e.g. Femoden®) 
 Purpose of use 
(e.g. contraception) 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
   
 
 
28. Have you taken yesterday or the day before yesterday any 
Over the counter (OTC) medicines, including vitamins? 
1 No (move to the question no 29) 
2 Yes. List the name of the medicine and what you used it 
for. 
 
Medicine  
(e.g. Burana®) 
 Purpose of use 
(e.g. headache) 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
   
 
 
BACKGROUND INFORMATION  
29. Have you taken yesterday or the day before yesterday any medicinal herbs, botanicals, or homeopathics?  
1 No (move to the question no 30) 
2 Yes. List the name of the product and what you used it for. 
 
Product  Purpose of use 
 
 
 
  
 
 
  
 
 
  
 
 
30. Below is a list of statements. Circle the option nearest to your own opinion.  
 
Statement I agree 
completely 
I agree I don’t agree 
or disagree 
I disagree I disagree 
completely 
No 
opinion 
       
Medicines are necessary in treating illnesses. 5 4 3 2 1 0 
Side-effects of children’s medicines worry me. 5 4 3 2 1 0 
I try to avoid giving medicines to my child. 5 4 3 2 1 0 
Over the counter (OTC) medicines are safe. 5 4 3 2 1 0 
Fever, a natural means of defense of the child’s body, 
should not be lowered artificially with medicines. 
5 4 3 2 1 0 
The child needs to learn how to bear the pain. 5 4 3 2 1 0 
Prescription medicines are effective. 5 4 3 2 1 0 
I usually give less analgesic to the child than is 
recommended in the instructions. 
5 4 3 2 1 0 
Prescription medicines are safe. 5 4 3 2 1 0 
Medicines can disturb the body’s own capability to heal 
illnesses. 
5 4 3 2 1 0 
Medicines that a doctor has prescribed for the child are 
necessary. 
5 4 3 2 1 0 
Medicines are unnatural to the human body. 5 4 3 2 1 0 
I try to take care of my child’s ailments by some other means 
than using medicines. 
5 4 3 2 1 0 
The more you need to use analgesics the less effective they 
are for pain. 
5 4 3 2 1 0 
I take care of my child’s minor ailments by using OTC 
medicines. 
5 4 3 2 1 0 
Medicines are dangerous, even when used according to the 
instructions. 
5 4 3 2 1 0 
I take my child to see a doctor only when other ways of 
treatment do not help. 
5 4 3 2 1 0 
Long-term use of analgesics reduces the pain threshold. 5 4 3 2 1 0 
OTC medicines are effective. 5 4 3 2 1 0 
Doctors prescribe antibiotics to children too easily. 5 4 3 2 1 0 
Interactions of medicines worry me. 5 4 3 2 1 0 
       
 
 
 
THANK YOU! 
 
 
 
Kuopion yliopisto   
Sosiaalifarmasian laitos 
Maaliskuu 2007 
LAPSEN LÄÄKKEIDEN KÄYTTÖ  
 
Vastaa kysymyksiin rengastamalla sopivat vastausvaihtoehdot tai kirjoittamalla vastauksesi sitä varten varattuun tilaan. 
Vastauksesi antaa arvokasta tietoa, vaikka lapsella ei olisikaan käytössään mitään lääkettä.  
 
 
 
 
1. Onko lapsi 
1 Tyttö 
2 Poika 
 
3. Onko lapsi 
1 Esikoinen 
2 Toinen lapsi 
3 Kolmas lapsi 
4 Muu. Kuinka mones? _____________________________ 
 
2. Lapsen syntymäaika    
 päivä         kuukausi  vuosi 
 
 
4. Miten lapsen päivähoito on järjestetty, vai käykö hän koulua? 
1 Käy koulua tai esikoulua 
2 Perhepäivähoidossa tai kolmiperhehoidossa 
3 Päiväkodissa 
4 Hoidetaan kotona yksin, sisarusten tai hoitolasten kanssa 
5 Muulla tavalla. Miten? ____________________________ 
 ______________________________________________ 
 
 
 
 
 
5. Millainen on mielestäsi lapsen tämänhetkinen terveydentila? 
1 Hyvä 
2 Melko hyvä 
3 Keskitasoinen 
4 Melko huono 
5 Huono 
 
6. Onko lapsella tällä hetkellä jokin lääkärin toteama sairaus tai 
vamma? 
1 Ei 
2 Kyllä. Mikä / mitkä? ______________________________ 
 ______________________________________________ 
 
 
 7. Alla on lueteltu joukko oireita. Merkitse jokaisen oireen kohdalle, onko lapsella niitä tällä hetkellä. 
  
 
Oireet Ei Kyllä En osaa  sanoa 
    
Ummetus 1 2 3 
Ripuli 1 2 3 
Oksennustauti 1 2 3 
Ilmavaivat 1 2 3 
Muut vatsaoireet, mitkä? __________________________ 1 2 3 
Päänsärky 1 2 3 
Niska- tai hartiakipu 1 2 3 
Selän alaosan kipu 1 2 3 
Korvakipu tai korvatulehdus 1 2 3 
Kurkkukipu 1 2 3 
Kasvukipu 1 2 3 
Muu kipu, mikä? ________________________________ 1 2 3 
Kuume 1 2 3 
Flunssan oireet (esim. nuha, yskä) 1 2 3 
Allergiaoireet (esim. nuha, silmäoireet) 1 2 3 
Ihottuma tai iho-oireet 1 2 3 
Väsymys tai heikotus 1 2 3 
Univaikeudet 1 2 3 
Jännittyneisyys tai hermostuneisuus 1 2 3 
Alakuloisuus tai masentuneisuus 1 2 3 
Muu oire, mikä? ________________________________ 1 2 3 
   
 
LAPSEN TAUSTATIEDOT 
LAPSEN TERVEYDENTILA 
Appendix 6. Questionnaire for population-based medicine utilisation study in children aged less than 
12 years living in Finland 2007, in Finnish.
 
 
 
 
 
 
8. Onko lapsella tällä hetkellä käytössä mitään lääkärin määrää-
mää lääkettä?  
1 Ei (siirry kysymykseen numero 9) 
2 Kyllä. Kirjaa kaikki käytössä olevat lääkkeet ja niiden 
käyttötarkoitus, myös tarvittaessa otettavat lääkkeet. Voit 
tarvittaessa jatkaa kyselylomakkeen viimeiselle sivulle. 
 
Lääkkeen nimi 
(esim. Beclomet Easyhaler) 
 Käyttötarkoitus 
(esim. astma) 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
   
 
 
10. Käyttääkö lapsi jotain ilman reseptiä saatavaa lääkettä tai 
vitamiinia päivittäin tai lähes päivittäin? 
1 Ei (siirry kysymykseen numero 11) 
2 Kyllä. Kirjaa kaikki käytössä olevat lääkkeet ja/tai vitamiinit ja 
kuinka kauan käyttö on jatkunut. 
 
 
Valmisteen nimi 
 
 Kuinka kauan käyttänyt? 
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
12. Onko jokin lääke joskus aiheuttanut lapselle haittaa? 
1 Ei (siirry kysymykseen numero 13) 
2 Kyllä. Kirjaa kaikki haitat. Luettele, mitkä lääkkeet ovat niitä 
aiheuttaneet. Voit tarvittaessa jatkaa kyselylomakkeen 
viimeiselle sivulle. 
________________________________________________________ 
________________________________________________________ 
________________________________________________________ 
________________________________________________________ 
________________________________________________________ 
 
9. Onko lapsi käyttänyt eilen tai toissapäivänä mitään apteekis-
ta ilman reseptiä saatavaa lääkettä, mukaan lukien vitamiinit?  
1 Ei (siirry kysymykseen numero 10) 
2 Kyllä. Kirjaa kaikki käytössä olevat lääkkeet ja/tai vitamiinit 
ja niiden käyttötarkoitus. 
 
Lääkkeen nimi 
(esim. Pantyson) 
 Käyttötarkoitus 
(esim. ihottuma) 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
   
 
 
11. Onko lapsi käyttänyt eilen tai toissapäivänä ilman reseptiä 
saatavaa luontaistuotetta, rohdosvalmistetta ja/tai homeo-
paattista valmistetta?  
1 Ei (siirry kysymykseen numero 12) 
2 Kyllä. Kirjaa kaikki käytössä olevat valmisteet ja niiden 
käyttötarkoitus. 
 
Valmisteen nimi 
 
 Käyttötarkoitus 
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
13. Onko lapsen lääkehoidossa joskus ollut muita ongelmia? 
1 Ei (siirry kysymykseen numero 14) 
2 Kyllä. Kirjaa kaikki ongelmat. Luettele, mitkä lääkkeet ovat 
niitä aiheuttaneet. Voit tarvittaessa jatkaa kyselylomak-
keen viimeiselle sivulle. 
______________________________________________________ 
______________________________________________________ 
______________________________________________________ 
______________________________________________________ 
______________________________________________________ 
 
14. Minkä ikäisenä lapsi voi mielestäsi itsenäisesti ilman vanhemman neuvoja ja valvontaa päättää lääkkeen käytöstä pieneen vaivaan, 
esimerkiksi päänsärkyyn tai muuhun vastaavaan?  
  1 Alle 4-vuotiaana  4  8–9-vuotiaana  7  14–15-vuotiaana 
  2  4–5-vuotiaana  5 10–11-vuotiaana  8  16–17-vuotiaana 
  3  6–7-vuotiaana  6 12–13-vuotiaana  9  18-vuotiaana tai vanhempana 
           10  En osaa sanoa 
LAPSEN LÄÄKKEIDEN KÄYTTÖ 
  
15. Alla on lueteltu joukko tietolähteitä. Ympyröi jokaisen tietolähteen kohdalle, kuinka paljon olet käyttänyt kyseistä lähdettä lapsen 
lääkitykseen liittyvissä asioissa.  
 
Tietolähde Paljon Jonkin verran Vähän En lainkaan 
     
Lääkäri 3 2 1 0 
Sairaanhoitaja 3 2 1 0 
Terveydenhoitaja (neuvolassa, koulussa) 3 2 1 0 
Sukulainen tai ystävä, jolla on terveydenhuoltoalan koulutus 3 2 1 0 
Apteekin henkilökunta 3 2 1 0 
Puhelinpalvelu, mikä? ______________________________________ 3 2 1 0 
Lääkepakkauksen sisällä oleva pakkausseloste  3 2 1 0 
Lääkkeisiin liittyvät esitteet 3 2 1 0 
Lääkärikirja 3 2 1 0 
Muu kirja, mikä? ___________________________________________ 3 2 1 0 
Terveysalan lehdet 3 2 1 0 
Tavalliset sanoma- ja aikakausilehdet 3 2 1 0 
Radio, TV 3 2 1 0 
Internet, mikä/mitkä sivu(t)?__________________________________ 3 2 1 0 
Sukulaiset, ystävät ja tuttavat 3 2 1 0 
Luontaistuotekauppa 3 2 1 0 
Muu, mikä? _______________________________________________ 3 2 1 0 
 
   
16. Miten luotettavina pidät seuraavia tietolähteitä lapsen lääkitykseen liittyvissä asioissa? 
 
Tietolähde Erittäin 
luotettava Luotettava 
Melko 
luotettava 
Ei  
luotettava 
En osaa 
sanoa tai en 
ole käyttänyt 
      
Lääkäri 4 3 2 1 0 
Sairaanhoitaja 4 3 2 1 0 
Terveydenhoitaja (neuvolassa, koulussa) 4 3 2 1 0 
Sukulainen tai ystävä, jolla on terveydenhuoltoalan koulutus 4 3 2 1 0 
Apteekin henkilökunta 4 3 2 1 0 
Puhelinpalvelu, mikä? ______________________________ 4 3 2 1 0 
Lääkepakkauksen sisällä oleva pakkausseloste  4 3 2 1 0 
Lääkkeisiin liittyvät esitteet 4 3 2 1 0 
Lääkärikirja 4 3 2 1 0 
Muu kirja, mikä? __________________________________ 4 3 2 1 0 
Terveysalan lehdet 4 3 2 1 0 
Tavalliset sanoma- ja aikakausilehdet 4 3 2 1 0 
Radio, TV 4 3 2 1 0 
Internet, mikä sivu?________________________________ 4 3 2 1 0 
Sukulaiset, ystävät ja tuttavat 4 3 2 1 0 
Luontaistuotekauppa 4 3 2 1 0 
Muu, mikä? ______________________________________ 4 3 2 1 0 
      
TIETOLÄHTEIDEN KÄYTTÖ 
 
 
 
 
17. Tämän lomakkeen kysymyksiin vastasi 
1 Äiti 
2 Isä 
3 Joku muu. Kuka? _________________________________ 
 
 
19. Koko perheen lasten lukumäärä ________________________ 
 
 
21. Osallistuiko lapsi kyselylomakkeen täyttämiseen? 
1 Ei 
2 Kyllä 
 
 
23. Missä läänissä asut? 
1 Lapin läänissä 
2 Oulun läänissä 
3 Itä-Suomen läänissä 
4 Länsi-Suomen läänissä 
5 Etelä-Suomen läänissä 
6 Ahvenanmaalla 
 
 
 
 
25. Mikä on tämänhetkinen työtilanteesi? 
1 Olen työssä 
2 Opiskelen päätoimisesti 
3 Olen kotiäiti tai koti-isä 
4 Olen tilapäisesti poissa työelämästä (esim. äitiyslomalla, 
hoito- tai vuorotteluvapaalla) 
5 Olen sairauslomalla tai sairauspäivärahalla 
6 Olen lomautettuna tai työttömänä 
7 Olen eläkkeellä tai osa-aikaeläkkeellä 
 
 
27. Onko sinulla itselläsi tällä hetkellä käytössä mitään lääkärin 
määräämää lääkettä? 
1 Ei (siirry kysymykseen numero 28) 
2 Kyllä. Kirjaa kaikki käytössäsi olevat lääkkeet ja niiden 
käyttötarkoitus. 
 
 
Lääkkeen nimi 
(esim. Femoden) 
 Käyttötarkoitus 
(esim. raskauden ehkäisy) 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
   
   
   
   
 
 
18. Mikä on oma äidinkielesi? 
1 Suomi 
2 Ruotsi 
3 Muu. Mikä? ___________________________________ 
 
 
20. Syntymävuotesi _______________ 
 
 
22. Onko sinulla jokin terveydenhuoltoalan koulutus? 
1 Ei 
2 Kyllä. Mikä? ___________________________________  
 
24. Mikä on koulutuksesi? Merkitse ylin suorittamasi koulutus tai 
tutkinto. 
1 Kansakoulu, osa peruskoulua tai keskikoulua  
2 Peruskoulu tai keskikoulu 
3 Ammattikoulu tai vastaava 
4 Lukio 
5 Opistotutkinto 
6 Ammattikorkeakoulututkinto 
7 Yliopistotutkinto 
 
 
26. Mitkä ovat taloutenne yhteenlasketut nettotulot (tulot 
verojen jälkeen) kuukaudessa? Jos et tiedä tarkkaa lukua, voit 
merkitä arviosi. 
1 Alle 500 e 7 3000–4999 e 
2 500–999 e 8 5000–7499 e 
3 1000–1499 e 9 750010000 e 
4 1500–1999 e 10 Yli 10000 e 
5 2000–2499 e  
6 2500–2999 e  
 
 
28. Oletko itse käyttänyt eilen tai toissapäivänä mitään 
apteekista ilman reseptiä saatavaa lääkettä, mukaan lukien 
vitamiinit? 
1 En (siirry kysymykseen numero 29) 
2 Kyllä. Kirjaa kaikki käyttämäsi lääkkeet ja/tai vitamiinit ja 
niiden käyttötarkoitus. 
 
Lääkkeen nimi 
(esim. Burana) 
 Käyttötarkoitus 
(esim. päänsärky) 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
   
   
   
   
 
TAUSTATIEDOT 
 29. Oletko itse käyttänyt eilen tai toissapäivänä ilman reseptiä saatavaa  
 luontaistuotetta, rohdosvalmistetta ja/tai homeopaattista valmistetta?  
1 En (siirry kysymykseen numero 30) 
2 Kyllä. Kirjaa kaikki käyttämäsi valmisteet ja niiden käyttötarkoitus. 
 
 
 
30. Seuraavassa on joukko lääkkeitä koskevia väittämiä. Ympyröi mielipidettäsi lähinnä oleva vaihtoehto. 
 
Väittämä 
Täysin 
samaa 
mieltä 
Jokseenkin 
samaa 
mieltä 
En samaa 
enkä eri 
mieltä 
Jokseenkin 
eri 
 mieltä 
Täysin  
eri  
mieltä 
En 
 osaa  
sanoa 
       
Lääkkeet ovat välttämättömiä sairauksien hoidossa. 5 4 3 2 1 0 
Lapselle annettavien lääkkeiden haittavaikutukset 
huolestuttavat minua. 5 4 3 2 1 0 
Pyrin välttämään lääkkeiden käyttöä lapselle.  5 4 3 2 1 0 
Ilman reseptiä saatavat lääkkeet, eli itsehoitolääkkeet, ovat 
turvallisia. 5 4 3 2 1 0 
Lapsen elimistön luonnollista puolustuskeinoa, kuumetta, ei 
pidä alentaa lääkkeillä keinotekoisesti. 5 4 3 2 1 0 
Lapsen pitää oppia kestämään kipua.  5 4 3 2 1 0 
Reseptilääkkeet ovat tehokkaita. 5 4 3 2 1 0 
Annan lapselle yleensä särkylääkettä vähemmän kuin 
ohjeessa suositellaan. 5 4 3 2 1 0 
Reseptilääkkeet ovat turvallisia. 5 4 3 2 1 0 
Lääkkeet saattavat häiritä elimistön omaa paranemiskykyä. 5 4 3 2 1 0 
Lääkärin lapselle määräämät lääkkeet ovat tarpeellisia. 5 4 3 2 1 0 
Lääkkeet ovat epäluonnollisia ihmisen elimistölle. 5 4 3 2 1 0 
Pyrin hoitamaan lapsen vaivan muuten kuin lääkkeillä. 5 4 3 2 1 0 
Mitä enemmän särkylääkkeitä joutuu käyttämään, sitä 
huonommin ne tehoavat kipuun. 5 4 3 2 1 0 
Hoidan lapsen pienet vaivat itsehoitolääkkeillä. 5 4 3 2 1 0 
Lääkkeet ovat ohjeen mukaan käytettynäkin vaarallisia. 5 4 3 2 1 0 
Vien lapsen lääkäriin vasta, kun muut hoitokeinot eivät riitä. 5 4 3 2 1 0 
Särkylääkkeiden pitkäaikainen käyttö alentaa kipukynnystä. 5 4 3 2 1 0 
Itsehoitolääkkeet ovat tehokkaita. 5 4 3 2 1 0 
Lääkärit määräävät antibiootteja lapsille liian helposti.  5 4 3 2 1 0 
Lääkkeiden yhteisvaikutukset huolestuttavat minua. 5 4 3 2 1 0 
Valmisteen nimi  Käyttötarkoitus 
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